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1 ABBREVIATIONS 
 
ALT   alanine transaminase 
APC   antigen presenting cell 
ASH   alcoholic steato-hepatitis 
AST   aspartate transaminase 
BSA   bovine serum albumin 
BM   bone marrow 
CaP   prostate cancer 
CRaP   castration-resistant prostate cancer 
CCL2/MCP-1  CC chemokine 2/ monocyte chemoattractant protein 1 
CCR2   CC chemokine receptor 2 
cDNA   copy DNA 
CFP   cyan fluorescent protein 
CH   cholestasis 
CIR   end stage liver cirrhosis due to alcoholic liver disease 
dpi   days post injection 
DNA   deoxyribonucleic acid 
DT   diphtheria toxin 
EC   endothelial cell 
ERK   extracellular signal regulated kinase 
FACS   fluorescence activated cell sorter 
FCS   fetal calf serum 
FDC   follicular dendritic cell 
FNH   focal nodular hyperplasia 
FSC   fibrosarcoma 
GFP   green fluorescent protein 
GP73/GOLPH2 golgi protein 73 
GRK   G-protein coupled receptor kinase 
HBV   hepatitis B virus 
HBsAg   hepatitis B virus surface antigen 
HCC   hepatocellular carcinoma 
HCV   hepatitis C virus 
H&E   hematoxylin-eosin staining 
HGF   hepatic growth factor 
HMEC   human dermal microvascular endothelial cells 
hr   hour 
HRP   horse-radish peroxidase 
HUVEC  human umbilical vein endothelial cells 
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HVEM   herpes virus entry mediator 
IFN   interferon 
IB   inhibitor of B 
IKK   IB kinase complex 
IL   interleukin 
i.p.   intraperitoneal 
i.v.   intravenous 
JAK2   Janus kinase 2 
JNK   c-Jun N-terminal kinase 
kDa    kilo Dalton 
LPS   lipopolysaccharide 
LT   lymphotoxin 
LT   lymphotoxin alpha 
LT   lymphotoxin beta 
LTR   lymphotoxin beta receptor 
MAPK   mitogen-activated protein kinase 
mdr2   multidrug resistance gene 2 
min   minute 
mRNA   messenger ribonucleic acid 
NFB   nuclear factor kappa B 
NIK   NFB inducing kinase 
NK cells  natural killer cells 
NPC   non-parenchymal cells 
NPC   nasopharyngal carcinoma (exclusively in chapter 6.5.3) 
NVH   non-viral hepatitis 
OLD   other liver diseases 
PBC   primary bilary cirrhosis/ autoimmune cholangitis 
PBS   phosphate-buffered saline 
PBST   phosphate-buffered saline (with) Tween-20 
PCR   polymerase chain reaction 
p.i.   post injection 
PI3K   phosphoinositol 3 kinase 
PLC   phospholipase C 
qPCR   quantitative PCR (real-time PCR) 
Rag1   recombination activating gene 1 
RIN   RNA integrity index 
RNA ribonucleic acid 
ROS   reactive oxygen species 
RT   reverse transcriptase 
ABBREVIATIONS 
 
7
SDS-PAGE  sodium dodecyl sulphate polyacrylamide gel electrophoresis 
siRNA   silencing RNA 
ST   steatosis 
STAT   signal transducers and activator of transcription 
TAK1   TGF activated kinase 
TAM   tumor associated macrophages 
TBS   tris-buffered saline 
TGF   transforming growth factor 
TLR   toll like receptor 
TNF   tumor necrosis factor alpha 
TNFR   tumor necrosis factor receptor 
TNFSF  TNF super family 
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2 SUMMARY 
It is conveyed that Hippocrates was most likely the first person to use the term “cancer” as he 
had observed similarities to the legs of crustacean when he treated a patient with an abscess 
within breast tissue. Cancer is one of the leading causes of death worldwide and accounted for 
7.6 million deaths in 2008. This indicates that approximately 13% of all deaths were due to 
cancer. The incidence of cancer is rising worldwide and estimations expect over 11 million 
deaths from cancer in 2030. Most deaths from cancer occur in low- and middle-income 
countries, but also in industrialized countries a rising cancer incidence is found 1. 
The term cancer comprises a lot of different diseases summarizing tumors that can arise in 
almost any organ – however, depending on the type of tissue affected survival rates can vary 
drastically. Most patients die due to tumors within lungs (1.4 million deaths/ year) followed by 
stomach (740,000 deaths), liver (700,000 deaths), colon (610,000 deaths) and breast (460,000 
deaths) 1. However, primary tumors rarely are the main cause of death (10% of patients), in 
most cases metastases lead to the majority of deaths in cancer-affected individuals (90% of 
patients) 2. 
Despite a lot of effort in research in the past, we are only beginning to understand the cellular 
and molecular mechanisms that lead to the transformation of normal cells into malignant ones. 
In my thesis I am focusing on two different projects – both dealing with the role of inflammatory 
mediators (cytokines and chemokines) in cancer development and metastasis – however in 
different experimental models and settings. 
 
CCR2 in Tumor Cell Extravasation and Lung Metastasis 
Metastasis is a multistage process comprising tumor cell dissemination, survival in the 
circulation, extravasation and ultimately colonization of distant organs 3, 4. Increased expression 
of the chemokine CCL2 correlates with poor prognosis and increased tumor burden in 
metastatic breast, prostate and colon cancer 5-9. Recent results suggest that tumor cell-derived 
CCL2 attracts Ly6Chi monocytes to facilitate tumor metastasis 5. However, the exact 
mechanisms how CCL2 expression by tumor cells can enable the independent steps of 
metastasis upon the attraction of inflammatory monocytes remain elusive. Furthermore, the role 
of the corresponding chemokine receptor CCR2, which is found to be expressed on various cell 
types, is only poorly characterized in metastasis.  
Together with Alexandra Hoos, I could show in a model of experimental metastasis how tumor 
cell-derived CCL2 activates the endothelium through activation of its receptor CCR2 and 
thereby inducing vascular permeability sufficient for driving tumor cell extravasation. In the 
absence of CCR2 (in Ccr2-/- mice), we could observe attenuation of metastasis with ablated 
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vascular permeability and decreased interaction of tumor and myeloid cells, indicating an 
involvement of CCR2 signaling in metastasis.  
In order to identify the role of CCR2 expression in the hematopoietic and stromal compartment, 
I performed reciprocal bone marrow reconstitutions experiments which suggested a critical role 
of endothelial CCR2 expression as mice expressing CCR2 only in the hematopoietic 
compartment had significantly fewer tumors within their lungs compared to mice with stromal 
expression of CCR2. With a genetic approach, using mice that express CCR2 exclusively on 
endothelial cells (Tie2CCR2/Ccr2-/- mice), metastasis could be restored confirming an essential 
role of endothelial CCR2 expression for tumor cell extravasation. Additionally, using mice with 
specific depletion of myeloid-derived CCR2 (LysMCreCcr2loxP/loxP mice) we could show that lack 
of CCR2 expression on monocytes did reduce but could not prevent metastasis, further 
corroborating the involvement of CCR2 expression on both compartments.  
In a simplified approach focusing on the step of tumor cell extravasation using primary 
pulmonary endothelial cells we could confirm the essential role of CCR2 expression on 
endothelial cells for tumor cell transmigration but also show the importance of monocytes again. 
By using the above mentioned in vitro model we elucidated that tumor cell extravasation was 
induced by activation of JAK2-Stat5 and p38MAPK pathways, which turned out to be integrated 
through CCR2. Stat3, Rac1 or PI3K activation did not turn out to play an important role in CCL2-
driven tumor cell extravasation.  
Our study identifies two yet undescribed molecular pathways in CCL2 driven tumor cell 
extravasation that go beyond the role of immune cell attraction by tumor cell-derived 
chemokines opening new targets for treating CCL2-dependent metastases. 
 
Lymphotoxin’s Role in Inflammation-Induced Carcinogenesis 
Hepatitis B and C viruses (HBV and HCV) cause chronic hepatitis and hepatocellular carcinoma 
(HCC) by poorly understood mechanisms. Worldwide, approximately 500 million people are 
chronically infected with HBV or HCV, leading to a rising incidence of HCC 10. Involvement of 
cytokines in chronic hepatitis and HCC was described in the past but no causal link found. 
Together with Johannes Haybäck, I could show that cytokines lymphotoxin (LT)  and  and 
their receptor LTR are up-regulated in HBV- or HCV-induced hepatitis and HCC. However, 
other non-viral induced forms of hepatitis seemed to depend on TNF rather than on LTR- 
signaling with strong up-regulation of TNF. Interestingly, up-regulation of LT was not only 
seen on immune cells, but also on hepatocytes of HCV and HBV-infected patients. 
Furthermore, I could show that HCV replication can be triggered by stimulation of LTR 
signaling in a non-infectious and an infectious setting in vitro and that silencing of LTR 
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decreases HCV replication, suggesting a positive feedback loop between LTR signaling and 
HCV replication identifying a potential target for therapeutical interventions.  
We characterized a mouse model with liver-specific LT over-expression (tg1223 mice) and 
found liver inflammation and HCC linking hepatic LT over-expression to hepatitis and HCC.  
Detailed analysis of this mouse model on mRNA and protein level revealed alternative 
expression of various genes at time points at which the liver still lacked any histopathology. At 
later time points tg1223 mice develop chronic hepatitis, modest liver damage and liver cancer. 
Various tumor markers such as gp73, glutamine synthetase and alpha-fetoprotein were 
expressed in the HCC of tg1223 mice and besides sustained oval cell proliferation was found.  
By intercrossing these mice with Ikkhep mice (mice lacking classical NFB signaling in 
hepatocytes) and Rag1-/- mice (mice lacking B- and T-cells), we could show the importance of 
inflammation and of NFB signaling in hepatitis-induced HCC development in this mouse 
model. Intercrossing tg1223 mice with Tnfr1-/- mice showed that TNF signaling is not important 
in this context. By applying LTR-Ig – an inhibitor of LTR signaling – we could completely 
suppress HCC formation and moreover reduced the incidence of hepatitis in LT-transgenic 
mice.  
In this study, we were able to show that sustained LT signaling in mice can be injurious, causing 
chronic hepatitis and HCC. Enhanced hepatic LTR signaling might be of potential clinical 
relevance because LTR and its ligands are drastically increased in human HBV- and HCV-
induced hepatitis and HCC, compared with normal livers or nonviral, benign liver diseases.  
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3 ZUSAMMENFASSUNG 
Überlieferungen zufolge war Hippokrates mit großer Wahrscheinlichkeit der Erste, der den 
Begriff „Krebs“ verwendet hat, da ihm, als er einen Abszess innerhalb des Brustraumes 
behandeltet, Ähnlichkeiten zu den Beinen von Krustentieren auffielen. Heute gelten Krebs-
erkrankungen als eine der meistverbreiteten Todesursachen und als Auslöser für 7,6 Millionen 
Todesfälle im Jahr 2008 (13% aller Todesfälle waren auf Krebserkrankungen zurückzuführen). 
Die Krebshäufigkeit steigt weltweit an und Prognosen zufolge werden 2030 über 11 Millionen 
Todesfälle aufgrund von Krebserkrankungen zu erwarten sein. Die meisten Todesfälle, die auf 
Krebserkrankungen zurückzuführen sind, wurden in Entwicklungs- und Schwellenländern 
verzeichnet, jedoch steigt die Zahl auch in den Industrienationen stetig an 1.  
Der Begriff Krebs umfasst viele verschiedene Krankheitsbilder die alle die Bildung eines Tumors 
gemeinsam haben, der sich in fast jedem Organ formen kann. Die Überlebenschancen variieren 
jedoch in Abhängigkeit von dem befallenen Gewebe beträchtlich. Die meisten Patienten sterben 
aufgrund von Tumoren in der Lunge (1,4 Millionen Todesfälle), gefolgt von Magen- (740000 
Todesfälle), Leber- (700000 Todesfälle), Kolon- (610000) und Brustkarzinomen (460000 
Todesfälle) 1. Der Primärtumor ist nur für eine Minderheit der Todesfälle verantwortlich (10% der 
Patienten), die Mehrheit der Patienten stirbt an Metastasen (90% der Patienten) 4.  
Trotz zunehmender Forschungsaktivität auf dem Gebiet der Krebserkrankungen stehen wir erst 
am Anfang die zellulären und molekularen Mechanismen zu verstehen, die zur Umwandlung 
normaler Zellen in maligne Zellen führen können.  
In meiner Doktorarbeit beschreibe ich zwei Projekte, die sich mit der Rolle von Entzündungs-
mediatoren (Zytokine und Chemokine) in der Krebsentstehung und Metastasierung befassen.  
 
CCR2 in Tumorzellextravasierung und Metastasierung in der Lunge 
Die Metastasierung ist ein vielstufiger Prozess der Tumorzellstreuung, Überleben im 
Blutkreislauf, Extravasierung und schließlich die Besiedlung entfernter Organe umfasst 3, 4. 
Erhöhte Expression des Chemokins CCL2 wurde im Zusammenhang mit einer schlechten 
Prognose und erhöhtem Tumorwachstum in metastasierendem Brust- Prostata- und Kolon-
karzinom beschrieben 5-9. Vor kurzem publizierte Forschungsarbeiten legen nahe, dass das von 
der Tumorzelle produziertes CCL2 Ly6Chi Monozyten anlockt und somit die Metastasierung 
begünstigen kann 5. 
Die genauen Mechanismen, wie CCL2-Produktion von Tumorzellen die verschiedenen Schritte 
der Metastasierung durch Anlocken von entzündungsfördernden Monozyten begünstigen kann, 
sind weiterhin unbekannt. Außerdem ist die Rolle des zugehörigen Chemokinrezeptors CCR2, 
der auf einer Vielzahl unterschiedlicher Zelltypen zu finden ist, im Zusammenhang mit 
Metastasierung nur wenig beschrieben. 
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Gemeinsam mit Alexandra Hoos konnte ich in einem experimentellen Metastasierungsmodell 
zeigen, wie CCL2, das von Tumorzellen produziert wird, das Endothel über CCR2 aktiviert und 
Permeabilität der Blutgefässe hervorruft, die ausreicht um Extravasierung von Tumorzellen 
auszulösen. In Abwesenheit von CCR2 (in Ccr2-/- Mäusen) beobachteten wir eine Verminderung 
der Metastasierung mit abgeschwächter Permeabilität der Blutgefäße und weniger Interaktion 
zwischen Tumorzellen und Monozyten, was auf eine Beteiligung der CCR2 Expression in der 
Metastasierung schließen lässt.  
Um die Rolle der CCR2 Expression auf hämatopoetischen und stromalen Zellen zu 
untersuchen, habe ich Experimente mit Knochenmarksrekonstitutionen durchgeführt, die der 
endothelialen CCR2 Expression einen wesentlichen Anteil an der Metastasierung zuschreiben. 
Mäuse, die CCR2 nur auf hämatopoetischen Zellen exprimieren, hatten wesentlich weniger 
Metastasen in der Lunge als Mäuse, die nur auf stromalen Zellen CCR2 exprimierten. In einem 
Versuch mit Mäusen, die CCR2 spezifisch auf Endothelzellen exprimieren (Tie2CCR2/Ccr2-/- 
Mäuse), wurde die Metastasierung zum Teil wiederhergestellt, was auf eine wesentliche Rolle 
der endothelialen CCR2 Expression bei der Tumorzellextravasierung schließen lässt. In 
zusätzlichen Experimenten mit Mäusen, denen CCR2 auf Zellen myeloischen Ursprungs fehlt 
(LysMCreCcr2loxP/loxP Mäuse), konnten wir eine verminderte Metastasierung beobachten, was 
die wesentliche Rolle der CCR2 Expression in hämatopoetischen und stromalen Zellen weiter 
untermauert.  
Mit einem vereinfachten Versuchsaufbau, der der Tumorzellextravasierung gleichen soll, 
konnten wir unter Verwendung primärer Endothelzellen die wesentliche Rolle der endothelialen 
CCR2 Expression für Tumorzelltransmigration bestätigen und erneut die Wichtigkeit von 
Monozyten zeigen.  
Mit Hilfe des zuvor erwähnten in vitro Modells konnten wir nachweisen, dass die Tumorzell-
extravasierung durch Aktivierung von JAK2-Stat5 und p38MAPK Signaltransduktionswegen 
induziert wird. Stat3-, Rac1- oder PI3K-Aktivierung hingegen spielt bei der CCL2-vermittelten 
Tumorzellextravasierung keine Rolle. 
Unsere Studie identifiziert zwei bisher nicht beschriebene Signaltransduktionswege in der 
CCL2-vermittelten Tumorzellextravasierung, was über die Funktion der Chemokine 
Immunzellen anzulocken hinaus geht und damit neue therapeutische Angriffsziele gegen CCL2-
abhängige Metastasierung bilden.  
 
Die Funktion von Lymphotoxin in entzündungsinduzierter Krebsentstehung 
Hepatitis B und C Viren (HBV und HCV) verursachen chronische Leberentzündung (Hepatitis) 
und hepatozelluläres Karzinom (HCC) durch bisher unverstandene Mechanismen. Weltweit sind 
ca. 500 Millionen Menschen chronisch mit HBV oder HCV infiziert, was zu einer steigenden 
Inzidenz von HCC führt 10. Eine Beteiligung von Zytokinen an der chronischen Leberentzündung 
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und der Entstehung von HCC wurde bereits beschrieben, aber bisher konnte kein ursächlicher 
Zusammenhang gefunden werden. 
Gemeinsam mit Johannes Haybäck konnte ich zeigen, dass die Zytokine Lymphotoxin (LT)  
und und ihr Rezeptor (LTR) in HBV- und HCV-induzierter Hepatitis und HCC hochreguliert 
sind. Hochregulierung von LT wurde nicht nur auf Immunzellen beobachtet, sondern auch auf 
Hepatozyten in HBV- oder HCV-infizierten Patienten. 
Zusätzlich konnte ich mit einem nicht-infektiösen und einem infektiösen Versuchsaufbau zeigen, 
dass die Replikation von HCV durch Aktivierung des LTR Signaltransduktionsweges verstärkt 
werden kann und das Abschalten der Signaltransduktion durch LTR die Replikation von HCV 
vermindert. Diese Daten legen nahe, dass eine positive Rückkopplung zwischen der 
Signaltransduktion durch LTR und der HCV Replikation besteht, was ein neues Ziel für einen 
therapeutischen Ansatz bedeuten kann. 
Wir haben ein Mausmodell charakterisiert, in dem LT spezifisch in der Leber überexprimiert 
wird (tg1223 Mäuse) und beobachteten die Entstehung von Hepatitis und HCC in diesen 
Mäusen. Diese Ergebnisse deuten auf einen ursächlichen Zusammenhang zwischen LT 
Überexpression und der Entstehung von Hepatitis und HCC hin. 
Die detaillierte Analyse dieses Mausmodells auf RNA und Proteinniveau ergab, dass 
verschiedenste Gene bereits an Zeitpunkten, an denen noch keine histopathologische 
Veränderung der Leber erkennbar war, verändert waren. 
Zu späteren Zeitpunkten entwickelten die tg1223 Mäuse chronische Hepatitis, Leberschaden 
und schliesslich HCC. Die Tumore von tg1223 Mäusen waren positiv für verschiedene 
Tumormarker wie gp73, Glutaminsynthetase und Alpha-Fetoprotein. Außerdem beobachteten 
wir anhaltende Proliferation von Ovalzellen. Durch Rückkreuzung dieser Mäuse mit Ikkhep 
Mäusen (keine klassische NFB Signaltransduktion in Hepatozyten vorhanden) und mit Rag1-/- 
Mäusen (keine Ausbildung von B- und T-Zellen) konnte die Entstehung von chronischer 
Hepatitis und HCC verhindert werden. Rückkreuzung von tg1223 Mäusen mit Tnfr1-/- Mäusen 
zeigte, dass die Signaltransduktion über TNF in diesem Zusammenhang keine wichtige Rolle 
spielt. Durch die Anwendung von LTR-Ig - einem Inhibitor der Signaltransduktion über LTR – 
konnten wir die Entstehung von HCC vollständig unterdrücken und außerdem die 
Hepatitisinzidenz in den LT-transgenen Mäusen verringern.  
Mit dieser Studie können wir zeigen, dass anhaltende Signaltransduktion über LTR schädlich 
sein kann und zur Entstehung von chronischer Hepatitis und HCC beiträgt. Verstärkte 
Signaltransduktion über LTR kann von klinischer Relevanz sein, da LTR und seine Liganden 
in HBV und HCV-induzierter Hepatitis und HCC im Patienten verstärkt vorliegen, verglichen mit 
normalen Lebern und nicht-viraler, gutartiger Lebererkrankung. 
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4 DEFINITIONS 
Cytokines & chemokines 
Cytokines are small signaling proteins that regulate immune-mediated signaling through 
interactions with specific receptors mainly for intracellular communication. This term comprises 
a large group of immuno-modulating substances, which can be produced by almost every cell 
type and can be found in either secreted or membrane bound forms. Chemokines are a small 
family of cytokines, which are usually secreted. They are able to induce chemotaxis, so their 
name is an abbreviation of “chemotactic cytokines”. 
 
Endothelial cells 
A cell type at the interior surface of the blood vessel forming a thin layer between the circulating 
blood in the lumen and the vessel wall.  
 
Extravasation 
One of the rate limiting steps in the metastatic process: The time frame in the dissemination 
phase of a malignant tumor when tumor cells leave the endothelial vasculature and enter the 
surrounding tissue and consequently colonize new organs.  
 
Inflammation 
A complex biological response of the immune system and vascular tissue to potentially 
dangerous stimuli like damaged cells, pathogens or other irritants. It means “to set on fire” and 
is characterized by its basic symptoms such as heat, swelling and redness. Inflammation is a 
mechanism of the innate immunity, a protective attempt to remove the stimuli and to initiate 
healing and is therefore non-specific. Inflammation can be either acute or chronic – the acute 
inflammation is the initial response to the stimuli and in general short and self-limiting. If the 
inflammatory state is prolonged, it is called chronic inflammation and sustained infiltration of 
immune cells can lead to tissue destruction and loss of proper function. 
 
Monocytes 
A bone marrow-derived cell type of myeloid origin with a relatively short half-life. Monocytes are 
non-dividing cells. In mice, bone marrow-resident and circulating blood monocytes are defined 
by their expression of CD115, F4/80, CD11b and CX3CR1. Two subsets of blood monocytes 
have been described according to their expression of Ly6C and CX3CR1 being 
Ly6ChiCX3CR1loCCR2+ and Ly6CloCX3CR1hiCCR2- blood monocyte subsets. Upon infection, 
Ly6Chi monocytes migrate from the bone marrow to the peripheral circulation in a CCR2-
dependent fashion. Challenged mice therefore often have increased numbers of circulating 
Ly6Chi monocytes 11.  
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5 CCR2 IN TUMOR CELL EXTRAVASATION AND LUNG METASTASIS 
 
‘Introduction’ (in parts), ‘Material and Methods’, ‘Results’ and parts of the ‘Discussion’ are taken 
from the following manuscript (in preparation): 
 
“Endothelial CCR2 signaling induced by colon carcinoma cells licenses extravasation via 
the JAK2-Stat5 and p38MAPK pathway“ 
Monika Julia Wolf1*, Alexandra Hoos2*, Judith Bauer3, Steffen Böttcher4, Markus Knust5, Achim 
Weber6, Nicole Simonavicius3, Holger Moch6, Markus Manz4, Michael Stürzl7, Roland Croner7, 
Manfred Kopf8, Adriano Aguzzi1, Manolis Pasparakis9, Marco Prinz5, Lubor Borsig2*, Mathias 
Heikenwalder1,3* 
1 Institute of Neuropathology, University Hospital Zurich, Switzerland 
2 Institute of Physiology, University of Zurich, Switzerland 
3 Institute of Virology, Technische Universität München/Helmholtz Zentrum München, Munich, Germany 
4 Division of Hematology, University Hospital Zurich, Switzerland 
5 Department of Neuropathology, University of Freiburg, Germany 
6 Insitute of Surgical Pathology, University Hospital Zurich, Switzerland 
7 Division of Molecular and Experimental Surgery, University Hospital Erlangen, Germany 
8 Institute for Integrative Biology, ETH Zurich, Switzerland 
9 Institute of Genetics, Centre for Molecular Medicine (CMMC), University of Cologne, Germany 
* These authors contributed equally to this work 
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5.1 Introduction 
5.1.1 Chemokines and the CCL2-CCR2 axis 
Chemokines are chemotactic cytokines, being small proteins with a molecular weight of 
approximately 8-14 kDa. To date, 4 different groups of chemokines are known – the CC, CXC, 
C and CX3C families 12, which all differ in the position of the two highly conserved cysteine 
residues at their N-terminus. Monocytes and T-cells are primarily targeted by CC chemokines, 
whereas neutrophils are targeted by members of the CXC family 13. In general, two main 
functions of chemokines are described – mediation of inflammation and maintenance of 
homeostasis – both act via similar mechanisms, namely controlling leukocyte migration into and 
within the tissue 14. However, the outcome strongly depends on the involved chemokines and is 
some cases beneficial for and in other cases detrimental to the organism. In the last few years, 
chemokines have caught the attention of researchers as they were shown to be involved in the 
pathogenesis of several diseases, such as autoimmune diseases, infectious diseases (e.g. HIV, 
HCV) and cancer (e.g. in metastasis) 15. In 1983, CCL2 was the first human CC chemokine to 
be discovered 16, which is now the most prominent member of the monocyte chemoattractant 
protein subfamily within the CC chemokines. Five members of this subfamily are known: MCP-1 
(CCL2), MCP-2 (CCL8), MCP-3 (CCL7); MCP-4 (CCL13) and MCP-5 (CCL12) 13, 17. All of them 
serve as ligands for CC chemokine receptor 2 (CCR2), a G-protein coupled receptor. Binding of 
one of these ligands to the receptor induces conformational changes which lead to its 
dimerization 18. As a consequence, Janus kinase 2 (JAK2) association and activation 
(phosphorylation) are triggered, necessary for effective G protein coupling to CCR2 19. Besides, 
the JAK/Stat pathway becomes activated. Signal transduction through GRK and arrestins lead 
to desensitization and internalization. Effector pathways downstream of CCR2 are JAK2, PI3K 
(phosphoinositol 3-kinase; p85/p110 and C2), phospholipase C (PLC) and mitogen-activated 
protein kinase (MAPK) via ERK1, ERK2 and p38, as well as the stress-activated kinase JNK1 
being involved in up-regulation of adhesion molecules and chemotaxis 20-24. Figure 1 
summarizes all signaling pathways downstream of CCR2.  
Several cell types were shown to produce CCL2, including endothelial, epithelial and smooth 
muscle cells as well as microglia, fibroblasts, astrocytes and monocytes 13. Moreover, CCL2 
signaling was shown to lead to firm arrest of rolling monocytes on endothelial cells expressing 
E-selectin 25 and monocyte arrest and transmigration on inflamed endothelium 26. Various kinds 
of tumor cells were shown to produce CCL2 27. Several studies showed that CCL2 expression 
levels correlate with tumor aggressiveness in various types of cancer such as prostate 28-30 or 
breast cancer 31-34. However, up to date, it is not known, which cell types are the main producers 
of CCL2 within the tumor microenvironment 27 and what exact role CCR2 activation plays in 
tumor cell extravastion and growth. 
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Figure 1: Schematic representation of signaling 
pathways activated through CCR2 35. Binding of the 
ligand induces dimerization of CCR2 and enables 
activation of the G-coupled protein receptor. JAK2 
becomes activated and one of the several downstream 
effector pathways, such as Stat, MAPK, PLC or PI3K 
signaling will be triggered. CCR2 signaling can be 
terminated via GRK and arrestin.  
 
 
 
 
 
 
In 1997, three research groups reported the generation of mice lacking CCR2 36-38. In all three 
cases, mice appeared to have a normal phenotype; however, upon challenge with pro-
inflammatory stimuli, defects due to the lack of CCR2 became obvious: Kuziel et al., reported 
severe reduction in leukocyte firm adhesion to microvascular endothelium and monocyte 
extravasation in Ccr2-/- mice. After thioglycollate injection they could observe that resolution of 
inflammatory responses can be independent of macrophage influx and the CCR2-mediated 
activation of peritoneal macrophages, meaning that CCR2 is essential for macrophage 
trafficking in vivo 38. Boring et al., could show that Ccr2-/- mice have an impaired monocyte 
migration and a reduced type 1 (TH1) cytokine response by confirming the results from Kuziel et 
al., and showing that the size of granulomas is reduced in these mice as well as interferon  
(IFN) production in draining lymph nodes. Therefore, they concluded that Ccr2-/- mice have a 
delayed type hypersensitivity response and production of TH1 type cytokines 36. Last but not 
least, Kurihara et al., reported defects in macrophage recruitment and host defense in Ccr2-/- 
mice by showing that these mice could not recruit macrophages in an experimental peritoneal 
inflammation model and that they were unable to clear infection (Listeria monocytogenes) 37.  
In 1998, Lu et al., reported the generation of mice lacking CCL2 expression. Similar to Ccr2-/- 
mice, Ccl2-/- mice showed abnormalities in monocyte recruitment and cytokine expression as 
tested by thioglycollate administration. Also in these mice, the accumulation of macrophages at 
the site of inflammation was altered and after induction of granulomas the expression of 
interleukin 4 (IL4), IL5 and IFN was reduced. However, in comparison to C57BL/6 mice, Ccl2-/- 
mice did not show any differences in the capacity to clear infections (with Mycobacterium 
tuberculosis) 39.  
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Due to intense research with Ccr2-/- mice in the past years, it was finally discovered in 2006 that 
CCR2 is indispensable for the emigration of Ly6Chi monocytes from bone marrow (BM) and 
therefore Ccr2-/- mice have strongly reduced numbers of circulating Ly6Chi monocytes. 
However, CCR2 is not needed for the trafficking of monocytes from the circulation into tissue. 
Furthermore, Ccr2-/- mice show an increased accumulation of activated monocytes in BM upon 
infection (with Listeria monocytogenes) suggesting that CCR2 signaling within BM is solely 
needed for the release of Ly6Chi monocytes into the blood 40. 
 
 
5.1.2 Tumor cell metastasis into the lung 
Tumors can be found in various tissues and are classified as benign or malignant tumors. 
Benign tumors only grow locally and do not invade adjacent tissue. Malignant tumors however 
can invade surrounding tissues and form secondary tumors throughout the body 41. Those 
secondary tumors are termed metastases – a word derived from ancient Greek meaning 
“displacement” and describing the spread of tumor cells from the primary tumor to various sites 
within the body.  
The metastatic process is a multi-stage process with fatal outcome as it is the leading cause of 
cancer-related death in humans. Approximately 90% of all cancer-related deaths are due to 
metastatic spread to vital organs, whereas only about 10% of all deaths are conditioned by 
primary tumors 2. Therefore, understanding the mechanisms driving metastasis is required for 
potential therapeutic intervention. Yet, metastasis is a highly inefficient process due to the 
complexity of the different steps involved. This might explain why only a small fraction of the 
large numbers of cells disseminating from the primary tumor finally result in the growth of 
metastases 42. But at which sites of the body can metastatic tumor growth be observed? The 
location of the metastatic sites varies among different primary tumors. Stephen Paget proposed 
already more than 120 years ago that disseminated cancer cells (which he called “seeds”) 
would only colonize organs where a specific microenvironment (“soil”) is present that would be 
compatible to their growth 43. Recently, studies suggested that a gene expression pattern in the 
primary tumor mediates metastasis 44 and that tumor cells can influence distal organs by 
inducing changes in the microenvironment prior to colonization 45. However, the exact 
mechanisms how the metastasis-supporting niche is created are only bit by bit revealed and it is 
very likely that many different processes work together. 
 
Figure 2 represents the metastatic cascade including all steps that tumor cells have to undergo 
in order to form metastasis at various sites of the body.  
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Figure 2: The metastatic cascade. Six distinct 
steps essential to tumor growth at distal sites in 
the body (e.g. in the lung) are depicted 46. 
Vascularization of the primary tumor, invasion into 
and transport via blood vessels, arrest in organs 
(adherence), extravasation into the parenchyma of 
various organs and ultimately colonization and 
subsequent growth are considered as main steps 
which lead to the growth of metastases at distant sites 
in the body.  
 
 
 
 
In a process called angiogenesis new blood vessels start to grow within the tumor, thereby 
assuring its supply with nutrients via the blood stream. When a certain size/mass is reached, 
single tumor cells can leave the primary tumor by invading either these newly formed blood 
vessels or the lymphatic system. If these cells manage to survive in the circulation where they 
can encounter different forms of stress, they are transported via the blood or the lymph flow to 
distant sites, where they may be captured in organs and adhere at the wall of the vessel. In the 
subsequent step, which is called extravasation and is considered to be one of the rate-limiting 
steps of the metastatic process 44, tumor cells can leave the vessel and move into the 
surrounding tissue. Thus, if a suitable microenvironment is formed tumor cells start to proliferate 
and colonize organs resulting in metastases in various sites of the body 3, 4, 41. 
The lung is an organ commonly affected in patients with metastatic disease, partly because the 
whole cardiac blood flow circulates through the lung-capillary network 44. Tumor cells can easily 
be captured and adhere to cell walls in the capillaries of the lung which are small vessels with 
many branchings. Many different types of primary tumors form metastases in the lungs, 
including breast cancer, gastrointestinal tumors, melanoma, sarcoma and kidney cancer 44.  
 
Figure 2 also summarizes the different mouse models available for studying metastasis (blue 
boxes). Depending on the tumor of interest, various tumor cell lines can be used and injections 
or implantations are made at different sites of the body. Many of them are used for studying 
metastatic disease in the lung. For spontaneous metastasis assays, tumor cells are implanted 
(e.g. in peripheral sites), a primary tumor is established and metastatic spread to distant sites 
can be followed. In experimental metastasis assays, no primary tumor is found, tumor cells are 
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intravenously injected (directly into the blood stream) and extravasation and subsequent tumor 
growth can be studied. Furthermore, tumor implantation at secondary sites allows study of 
metastatic growth 46.  
 
 
5.1.3 The microenvironment and the immune system in metastasis 
Tumor cell extravasation and outgrowth are considered to be the limiting steps in metastasis 44. 
The tumor cell microenvironment has been recognized to significantly influence both, tumor 
growth and metastatic dissemination 45. A variety of stromal cell types were found within tumors, 
including endothelial cells, pericytes and fibroblasts which have been associated with cancer 
progression 45, 47. However, BM-derived cells, including macrophages, mast cells, neutrophils, 
myeloid cell-derived suppressor cells and mesenchymal stem cells were also shown to 
contribute to tumor promotion 45. Tumor-associated macrophages are the major population 
detected at primary tumor sites while myeloid-derived and/or inflammatory monocytic cells make 
up the major part of stromal cells in metastatic lesions 48, 49. Myeloid-derived monocytes and 
macrophages were shown to facilitate tumor cell extravasation and metastatic outgrowth 48, 49. 
Host-derived as well as tumor cell-derived cytokines and chemokines actively shape the tumor 
microenvironment by recruitment of leukocytes and activation of pro-inflammatory mediators 50. 
In a screen for tumor promoting cytokine release by myeloid cells, conditioned medium from 
highly metastatic vs. non-metastatic cancer cell lines was used and it could be shown that 
highly metastatic cancer cell lines induce the expression of tumor promoting cytokines (such as 
tumor necrosis factor  (TNF) and IL6) in BM-derived macrophages via toll-like receptor (TLR) 
2 and TLR6 51. With this study it became obvious how tumor cells can manipulate the host 
immune system to induce a microenvironment beneficial for metastatic growth. Moreover, 
chemokines and chemokine receptors were found to be involved in metastasis and also 
represent direct targets of oncogene activation 52, 53.  
The sources of chemokine expression were postulated to be endothelial cells, infiltrating 
leukocytes and tumor cells themselves, both, at primary tumors and metastatic sites 50, 54, 55. 
Indeed, local activation of the endothelium by metastasizing tumor cells is associated with 
enhanced production of the chemokine CCL5. This led to enhanced recruitment of monocytes 
during the initial phase of metastasis, while inhibition of this CCL5-dependent monocyte 
recruitment strongly attenuated metastasis 56.  
Recently, another inflammatory chemokine, CCL2, has been identified as the major factor 
affecting breast cancer metastasis to the lung 5.  
Elevated levels of CCL2 and CCL5 have been detected at primary as well as metastatic sites in 
various cancers including breast, colon, prostate and cervix and correlated with poor prognosis 
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due to metastatic progression 6, 8, 9, 57. Monocytes recruited to tumors through the CCL2-CCR2 
chemokine axis polarized to an alternatively activated M2-phenotype of macrophages that 
contributes to immune-suppression, enhanced tumor cell survival and angiogenesis 57-59. CCL2 
has been shown to induce angiogenic activation of endothelial cells along with an inflammatory 
response 60 and CCL2-mediated recruitment of inflammatory monocytes promoted metastasis 5. 
Accordingly, treatment of mice carrying tumors with CCL2-neutralizing antibody significantly 
increased survival due to inhibition of metastasis 5, 60. Other studies using CCL2-neutralizing 
antibody report retarded tumor growth due to decreased macrophage infiltration and decreased 
microvascular density 61 as well as reduction of metastatic tumor burden in mouse models of 
metastatic prostate cancer 59, 62. Although, elevated CCL2 expression is clearly linked to 
metastasis through the recruitment of monocytes and macrophages, the exact mechanisms 
how CCL2 signaling facilitates tumor cell extravasation at the endothelial barrier and 
subsequent metastatic colonization remain elusive.  
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5.2 Scientific aims  
Increased expression of CCL2 was shown to correlate with poor prognosis and increased tumor 
burden in metastatic breast, prostate and colon cancer. Recent results suggest that tumor cell-
derived CCL2 attracts Ly6Chi monocytes which were shown to facilitate metastasis. However, 
the exact mechanisms how CCL2 expression by tumor cells can enable metastasis remain 
elusive. 
The goal of this project was to assess whether tumor cell-derived CCL2 has additional functions 
apart from the attraction of immune cells in metastasis and to investigate whether also other 
CCR2 expressing cells (e.g. radio-resistant cells) contribute to the CCL2-driven induction of 
tumor cell metastasis.  
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5.3 Material and methods 
5.3.1 Mice  
Animals were maintained under specific pathogen-free conditions and experiments approved 
and conform to the guidelines of the Swiss Animal Protection Law, Veterinary Office, Canton 
Zurich. C57BL/6 and Ccl2-/- mice were purchased from The Jackson Laboratory, Ccr2-/- mice 36 
were either purchased from The Jackson Laboratory or obtained from Marco Prinz 38; 
Tie2CCR2/Ccr2-/- 63 were also received from Marco Prinz; LysMCreCCR2loxP/loxP mice were 
received from Manolis Pasparakis and BacCCR2CFP 64 from Eric Pamer were bred in house. 
 
5.3.2 Bone marrow reconstitutions 
C57BL/6 and Ccr2-/- mice were used to generate BM chimeras. Recipient animals were 
irradiated with 900 rad in one dose and reconstituted by i.v. injection of purified BM cells 
(isolated from femur and tibia). Reconstitution efficiency was assessed by flow cytometry for 
CCR2+Ly6Chi cells in the blood 6-7 weeks after reconstitution and before injection of tumor cells.  
 
5.3.3 Cell lines  
Mouse colon carcinoma cell line MC-38 stably expressing GFP (MC38-GFP) 65, naive MC-38 
and mouse melanoma cell line B16-BL6 66, 67 were grown in DMEM supplemented with 10% 
FCS. Lewis lung carcinoma cells (3LL) were grown in RPMI supplemented with 10% FCS 54. 
MC-38GFP with low level expression of CCL2 (MC-38GFPCCL2kd) was generated by viral 
transduction with shRNA lentivirus construct (Sigma NM_002982). Tumor cells were seeded on 
24-well plates (3x104) until 50% confluence and incubated with lentivirus for 16 hrs. Cells were 
passaged after 48 hrs and plated into 6 well plates in the presence of puromycin (10µg/ml). 
Three days later, cells were split again and the knock-down efficiency was determined by 
quantitative PCR and immuno-blotting. Lentivirus containing a scrambled shRNA construct was 
used for preparation of control cells (MC-38GFPscr). 
 
5.3.4 Experimental metastasis model 
Mice were i.v. injected with syngeneic MC38-GFP+ cells (3x105) and metastasis was evaluated 
after 28 days. Metastatic foci were counted, macroscopic pictures of lungs were taken and 
tumor load was quantified by green fluorescent protein (GFP) measurement in lung 
homogenates 65. For experiments using 3LL and B16-BL6 cell lines, 1.5x105 cells were i.v. 
injected and the number of tumor foci was quantified on day 12 or day 14 days p.i. respectively.  
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5.3.5 Histology, immunohistochemistry and electron microscopy 
Paraffin sections (2μm) of lungs were stained with Hematoxylin/Eosin or various antibodies. 
Paraformaldehyde (4%) fixed and paraffin embedded lung tissue was incubated in Ventana 
buffer and staining was performed on a NEXES immunohistochemistry robot (Ventana 
instruments, Switzerland) using an IVIEW DAB Detection Kit (Ventana) or on a Bond MAX 
(Leica). Antibodies against murine B220+ B-cells (Pharmingen; 1:400), F4/80 (Serotec, 1:50) for 
macrophages, CD3+ T-cells (clone SP7, Neomarkers; 1:300) were kindly provided by R. 
Zinkernagel 68. Anti-GFP (Fitzgerald Industries International, clone 20R-GR011; 1:1000) 
antibody was used as tumor marker to visualize MC-38GFP. Ki67 (NeoMarkers Code RM-9106-
S; 1:200) stained proliferating tumor cells and lymphocytes. Image acquisition was performed 
on an Olympus SZX12, equipped with a JVC digital camera (KY-F70; 3CCD) using Analysis 
software. 
For electron microscopy, sections from epon-embedded, glutaraldehyde-fixed lungs were cut 
and stained with toluidine blue. The tissue was then trimmed and ultrathin cross sections of the 
lung were cut and treated with uranyl acetate and lead citrate as described previously 69. 
Electron micrographs were analyzed for cell composition and localization using the analySIS 
Docu System (Soft Imaging System GmbH, Germany). 
 
5.3.6 Endothelial cell stainings 
Cryosections (5m) were thawed and fixed in 4% paraformaldehyde for 20 mins at room 
temperature. Slides were incubated with 5g/ml anti-CD31 antibody (MEC 13.3; BD 
Biosciences) followed by 2g/ml Alexa594-conjugated anti-rat IgG (Molecular Probes). Nuclei 
were counterstained with Hoechst. Images were captured on an Olympus BX53 microscope 
fitted with an Olympus DP72 camera and processed with cellSens Dimension 1.4.1 software.  
 
5.3.7 Flow cytometry analysis 
Blood and lung cell samples were prepared at 4°C in buffer solution (PBS containing 2% FCS 
and 2mM EDTA) and stained against Ly6C, F4/80 (both eBioscience), CD45, CD19, CD4, CD8, 
Ly6G, NK1.1 (all BD Biosciences) and/or CCR2 70.  
For flow cytometry analysis of mononuclear cells in lung tissue, mice were perfused with PBS 
and lungs were removed, minced and subsequently digested under shaking conditions for 1 hr 
at 37°C in 2mg/ml Collagenase D (Roche). Cells were separated using 40µm cell strainers. For 
the analysis of blood samples, erythrocytes were lysed with BD FACS lysing solution and cell 
suspensions were analyzed on a FACS Calibur and FACS Canto II (BD Biosciences). Data 
were acquired using Cell Quest software version 6.0 (FACS Calibur) and FACS Diva software 
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v6.1.3 (FACS Canto II) analyzed using Flow Jo (v7.6 for FACS Calibur data and v8.8.4 for 
FACS Canto II data). For the analysis of spleen and BM samples, spleens were minced and BM 
was isolated from tibia and femur and cells were stained as described above. 
 
5.3.8 RNA isolation and real time PCR 
RNA isolation: Total RNA from flash-frozen PBS-perfused lungs, colon from C57BL/6 mice and 
cell pellets was isolated using RNeasy Mini Kit (Qiagen). The quantity and quality of the RNA 
was determined spectroscopically using a nanodrop (Thermo Scientific). Purified RNA was 
reversely transcribed into cDNA using Quantitect Reverse Transcription Kit (Qiagen) according 
to the manufacturer’s protocol.  
Real-time PCR: For mRNA expression analysis real-time PCR was performed using Fast Start 
SYBR Green Master Rox (Roche). Primers were custom made by Microsynth. Real-time PCR 
was performed on an ABI PRISM 7900 HT Fast Real-Time PCR System (AB). Data were 
generated and analyzed using SDS 2.4 and RQ manager 1.2 software. 
mRNA expression levels were normalized to the housekeeping gene Gapdh. For RT-PCR, -
actin served as a housekeeping gene and samples were run on a 2% agarose gel and images 
were acquired using red gel imaging system from Alpha Innotech with Pronto software.  
For human samples, GAPDH and -ACTIN served as housekeeping genes and CCL2 
expression levels were determined using the following primers: CCL2-FWD: 5’-GAA GCT CGC 
ACT CTC GCC TCC-3’ and CCL2-REV: 5’-TGA GCG AGC CCT TGG GGA ATG A-3’ 
 
5.3.9 Isolation of pulmonary endothelial cells 
Pulmonary endothelial cells were isolated using a positive immuno-magnetic selection as 
described previously 71. Briefly, perfused lungs were removed, minced and digested in 0.1% 
collagenase A (Roche). A single-cell suspension was generated by passing the digested lungs 
through 100μm and 40μm cell strainers (BD Falcon). Cells were incubated with FITC labeled 
anti-CD31 antibody (Invitrogen) for 30 mins. Anti-rat IgG beads (Miltenyi Biotec) were added to 
the cells and incubated for 15 mins, followed by magnetic separation. The purity of isolated 
endothelial cells was determined by flow cytometry and isolated endothelial cells were cultured 
in gelatin-coated 6-well plates in medium containing endothelial cell growth supplement (BD 
Biosciences). 
 
5.3.10 Tumor cell survival 
Cryosections (8m) of lungs were prepared at different time points after i.v. injection of MC-
38GFP cells as described previously 72. Lung sections were stained with DAPI and the number 
of surviving GFP+ tumor cells was counted per view field at 40x magnification. 
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5.3.11 Tumor cell extravasation assay 
Mice were i.v. injected with MC-38GFP cells and after 24 hrs lungs were perfused with PBS 
followed by perfusion with 100g tomato lectin conjugated with Texas red (Vector Laboratories). 
After 10 min, lungs were again perfused with PBS, fixed and frozen as described previously 72. 
Frozen lung sections (8m) were stained with DAPI. Three-dimensional images were captured 
with a SP5 confocal microscope (Leica) of total 5m in a z-section and were further analyzed 
with Imaris software (Bitplane). The contact area of tumor cells with the tomato lectin-stained 
vasculature was determined. 
 
5.3.12 Vascular permeability assay 
Permeability of the lung microvasculature was determined by the Evans blue dye extravasation 
technique 73. Briefly, mice were injected with tumor cells as described above. After 24 hrs, 2mg 
of Evans blue were i.v. injected followed by euthanasia 30 min later. In experiments using 
inhibitors of various signaling pathways [AG490 and SB202190 (Sigma), NSC23766 
(Calbiochem), S3I-310 and Stat5 inhibitor (Santa Cruz)], inhibitors were i.p. injected 1 hr before 
tumor cell injection and 5 hrs post-tumor cell injection at concentrations of 10-25mg/kg. Lungs 
were perfused with PBS, dissected, photographed and homogenized. Evans blue was extracted 
by incubation with formamide at 60°C for 18 hrs. The Evans blue concentration in the lung 
homogenates was measured spectrophotometrically (absorbance at 620 nm). 
 
5.3.13 Analysis of leukocyte-tumor cell association 
Cryosections (8µm) prepared from lungs of mice i.v. injected with MC-38GFP cells, were 
stained with following antibodies: CD11b (BD Biosciences) for myeloid cells, Ly6G (BD 
Biosciences) for neutrophils, F4/80 (AbD Serotec) for macrophages/monocytes, biotinylated 
Ly6C (BD Biosciences) for inflammatory monocytes. Alexa568-conjugated anti-rat antibody or 
Streptavidin-Alexa568 (Invitrogen) was used for the visualization of signals with a fluorescence 
microscope (Zeiss). Nuclei were stained with DAPI. Tumor cells were counted and the 
percentage of tumor cells associated with leukocytes was determined.  
 
5.3.14 Adoptive transfer 
Monocytes derived from C57BL/6 mice were prepared by conditional derivation of primary BM 
progenitors as described previously 74. Differentiated monocytes were characterized by 
expression of F4/80, CD11b and Ly6C staining (L. Borsig, unpublished data) 
In vitro-differentiated monocytes were labeled with PKH26-Red Fluorescent Cell Linker (Sigma), 
and 2x105 labeled cells were infused i.v. 6 hrs post tumor cell injection (MC38GFP). After 15 hrs 
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mice were terminated, lungs were perfused with PBS and frozen as previously described 72. 
Frozen lung sections (8m) were stained with DAPI. The extent of tumor cell association with 
macrophages was visualized with a SP5 confocal microscope (Leica) and quantified. 
 
5.3.15 Cytokine protein array 
For cytokine expression pattern of cell lines, Proteome Profiler arrays (mouse cytokine array 
panel A; R&D Systems) were used according to the manufacturer’s protocol. In brief, flash 
frozen cell pellets were lysed in buffer containing 20mM Tris HCl pH 8.0, 137mM NaCl, 2mM 
EDTA and 1% NP40. Protein concentration was determined using BCA protein assay reagent 
(Thermo Scientific) and 50g protein was used for each protein array. Membranes were 
developed using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) on 
Min-R 2000 films (Kodak) and quantified using Aida software (Raytest).  
 
5.3.16 Isolation of bone marrow monocytes 
Long bones from 6-8 week old mice were flushed with PBS containing 2% FCS and 2.5mM 
EDTA. Red blood cells were lysed using ammonium chloride solution. BM-nucleated cells were 
pre-enriched by magnetic activated cell sorting (MACS) using biotinylated M-CSFR antibody 
(clone AFS98, Biolegend) and streptavidin-conjugated magnetic beads (Miltenyi Biotec). 
Following staining with Gr-1 (Ly6G) monoclonal antibody conjugated to phycoerythrin and 
streptavidin-allophycocyanin (eBioscience), BM monocytes were sorted as M-CSFR+Gr-1int cells 
using a FACSAria III cell sorter (BD Biosciences). 
 
5.3.17 Transendothelial migration assay 
Primary lung microvascular endothelial cells (3x104) were seeded on gelatin-coated 24-well 
transwell inserts (8μm pores; BD) and allowed to grow to confluence for 2 days. Tumor cells 
(2x104) were seeded into transwell inserts with or without monocytes (1x105) in 5% FCS/RPMI 
in the upper chamber and 10% FCS/RPMI in the lower chamber. After 16 hrs of co-culture, the 
upper side of the insert was scraped off and the insert was fixed in 3% paraformaldehyde. The 
transwell membrane was removed and mounted on a slide. Tumor cells on the lower side of the 
membrane as well as in the lower wells were analyzed with a fluorescence microscope (Zeiss).  
For inhibitor studies AG490 (8μM final concentration), NSC23766 (20μM), SB202190 (10μM), 
S3I-201 (50M), Wortmannin (1M) and Stat5 inhibitor (100M) were added to the culture 
media in the upper and the lower chamber of the 24-well plates. All experiments were 
performed in duplicates and repeated several times. 
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5.3.18 Western blot analysis 
Lung homogenates (10%) were prepared in RIPA buffer (50mM Tris; 1%NP40; 0.25% 
Deoxycholic acid sodium salt; 150mM NaCl; 1mM EGTA) containing Halt Protease and 
Phosphatase Inhibitor Cocktail (Thermo Scientific) and quantified with a BCA protein assay kit 
(Thermo Scientific) according to the manufacturer’s manual. 50g protein were denatured in 
Laemmli buffer containing 5% β-mercaptoethanol and separated by gel electrophoresis on a 8% 
or 11% Tris-glycine SDS-PAGE with Tris-glycine running buffer and blotted with a semi-dry 
blotting system (Trans-Blot SD cell, Biorad) onto a nitrocellulose membrane (Protran BA 85 
pore size 0.45μm; Whatman). After blotting the membrane was blocked in 5% BSA-TBST for 2 
hrs at RT. Primary antibodies pJak2, Jak2, phospho-p38, p38, pStat5 and Stat5 (all Cell 
Signaling, 1:1000 dilution) were incubated at 4°C over night under shaking conditions. 
Incubation with the secondary antibody (HRP-anti rabbit IgG, 1:5000; Promega) was performed 
under shaking conditions for 1 hr. Detection was achieved with Supersignal West, 
chemiluminescent substrate (Pierce) using Stella 3200 imaging sytem (Raytech). To assure 
equal loading, the membranes were re-probed with anti-GAPDH antibody (Chemicon) and 
detected as described above. 
 
5.3.19 In vivo cell depletion  
For depletion of CCR2+Ly6Chi cells, 20g MC21 antibody 70 was i.v. injected into C57BL/6 mice 
24 hrs prior to MC-38GFP injection and every 24 hrs for the first 3 dpi of MC-38GFP tumor cells. 
On the day of tumor cell injection blood was checked for the presence of CD11b+Ly6Chi 
monocytes. For depletion experiments using diphtheria toxin (DT; Calbiochem), 10ng DT per g 
bodyweight were i.p. injected every 24 hrs for the first 4 days post tumor cell injection and one 
day prior. Inhibitor treatments: JAK2 inhibitor (AG490) and p38 inhibitor (SB202190) were 
injected every 24 hrs at 15mg/kg or 12mg/kg bodyweight for the first 3 days post tumor cell 
injection as well as 6 hrs prior to tumor cell injection. 
 
5.3.20 Resection of human colon tumor tissue 
Patients with colon carcinomas stage UICC I (n=10), II (n=10), III (n=10) and IV (n=9) were 
selected from the Erlangen Registry for Colorectal Carcinomas (ERCRC). The regulations of the 
local ethics committee of the clinical center Erlangen were obeyed.  
Tumors with a distance of at least 16cm proximal the anal verge measured with a rigid 
endoscope were classified as colon carcinomas. Cases arising from a history of inflammatory 
bowel disease or hereditary syndromes (e.g. familial adenomatous polyposis) were not 
included. Uninvolved colon tissues (n=4) at least 10cm distant from the tumor site were 
harvested as controls. The patients underwent colon resection with a standardized regional 
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lymph node dissection. This technique and standard oncological colon resections performed in 
our institution are described elsewhere 75. Adjuvant or palliative treatment was carried out 
following the current German guidelines for colorectal carcinomas 76. 
 
5.3.21 RNA isolation from human colon tumor tissue 
RNA was isolated using a fully automated extraction method from FFPE tissue (Tissue 
Preparation System with VERSANT Tissue Preparation Reagents, Siemens Healthcare 
Diagnostics, Tarrytown, NY) has been described previously 77. In brief, 5m paraffin sections 
were directly subjected to automated total nucleic acid extraction. Samples were heat-lysed in 
150L FFPE buffer at 80ºC for 30 mins with shaking. After cooling, enzymatic lysis was carried 
out at 65ºC for 30 mins with proteinase K. Any residual tissue debris was removed by 
nonspecific binding to silica-coated iron-oxide beads and subsequent magnetic separation. 
Deparaffinized and clarified lysates were transferred to new tubes and nucleic acids were bound 
to fresh silica-coated beads under chaotrophic conditions. Beads were washed 3 times and total 
nucleic acids were eluted with 100L of elution buffer at 70ºC followed by an automated DNase 
I digestion. 
 
5.3.22 Statistical analysis 
Statistical analysis was performed with the GraphPad Prism software (version 4.0). All data are 
presented as mean  SEM and were analyzed by ANOVA with the post-hoc Bonferroni multiple 
comparison test, unless specified differently. Analysis of two samples was performed with 
Student t test. 
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5.4 Results 
5.4.1 CCR2 promotes metastasis of syngeneic colon carcinoma cells 
We first investigated whether tumor cell extravasation and growth depend on CCR2 and are 
therefore altered in lungs of Ccr2-/- compared to C57BL/6 mice. Twenty-eight days post injection 
(dpi) of syngeneic GFP+ colon carcinoma cells (MC-38GFP), lungs of C57BL/6 mice were 
displaced with tumor foci. In contrast, significantly less or no tumors could be detected in lungs 
of Ccr2-/- mice on macroscopic level. Development of tumors in lungs of mice depended on 
CCR2 expression levels of the recipient host. Ccr2+/- mice showed a CCR2 expression level 
within lung tissue that is on average 30% of the expression level found in lungs of C57BL/6 
mice and displayed significantly less lung tumors than C57BL/6 (p<0.001) but significantly more 
than Ccr2-/- mice (p<0.5). This was confirmed by quantification of relative GFP fluorescence in 
lung homogenates of C57BL/6, Ccr2+/- and Ccr2-/- mice (Figure 3).  
 
 
Figure 3: Ccr2-/- mice show altered tumor growth upon injection with MC-38GFP cells. Macroscopy of lungs of 
C57BL/6, Ccr2+/- and Ccr2-/- mice 28 dpi with MC-38GFP (upper left panel). Quantification of macroscopically visible 
tumor foci in lungs of all genotypes (left: C57BL/6, n=9; middle: Ccr2+/-, n=5; right: Ccr2-/-, n=9; upper right panel). 
Quantification of tumor load by measurement of relative GFP fluorescence in lung homogenates of all three 
genotypes at 28 dpi (lower left panel). Relative mRNA expression of CCR2 in C57BL/6 (n=5), Ccr2+/- (n=5) and Ccr2-/- 
(n=5) mice normalized to C57BL/6 levels (lower right panel). Statistical significance: ***=p<0.001; **=p<0.01; 
*=p<0.05. 
 
Immunohistochemical analysis on paraffin-sections prepared from lungs derived from C57BL/6 
and Ccr2-/- mice 28 dpi with MC-38GFP cells revealed no obvious differences in the relative 
composition of Ki67+, CD3+, F4/80+ and B220+ cells within the tumors (Figure 4).  
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Figure 4: Histological analysis of colon carcinoma (MC-38GFP+) tumors in C57BL/6 and Ccr2-/- lungs. Low and 
high magnifications (scale bars) are indicated. H&E: Hematoxylin-Eosin, Ki67 stains for proliferating cells, CD3 stains 
for T-cells, F4/80 for monocytes and macrophages, B220 for B-cells.  
 
Next, I studied the immune cell composition in lungs of C57BL/6 and Ccr2-/- mice in order to find 
out whether potential differences could underlie the afore mentioned phenotype. I investigated 
the presence and composition of cells of hematopoietic origin in lung tissue derived from naïve 
C57BL/6 or Ccr2-/- mice using flow cytometry analysis. As expected, lungs of C57BL/6 or Ccr2-/- 
mice did not reveal significant differences in the numbers of CD4+ or CD8+ T-cells, CD19+ B-
cells, CD45+NK1.1+ NK cells and F4/80+ macrophages (Figure 5).  
 
 
 
Figure 5: Flow cytometry analysis of various immune cell types in naïve lungs of C57BL/6 and Ccr2-/- mice. 
No significant differences were found in the numbers of CD4+ and CD8+ T-cells, CD19+ B-cells, NK1.1+ NK cells or 
F4/80+ macrophages in Ccr2-/- (lower row) when compared to C57BL/6 (upper row) lungs. Representative FACS plots 
(left) and quantification of results (right panel) are shown. Each symbol represents one individual mouse (n=4-7). 
 
 
For studying the presence of monocytic cells in lung tissue of C57BL/6 or Ccr2-/- mice in detail, I 
used the following gating strategy (Figure 6). This allowed determination of the numbers of 
Ly6Chi cells and Ly6G+ cells as percentage of CD11b+ cells by flow cytometry in lung tissue and 
peripheral blood.  
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Figure 6: Gating strategy used for the flow cytometric analysis of CD11b+Ly6Chi cells in peripheral blood 
(upper panel) and lung tissue (lower panel). Cells of interest were located in the live cell gate and were 
characterized by the expression of CD11b and Ly6C and were negative for Ly6G.  
 
As indicated in the literature, the presence of monocytic cells is altered in blood of Ccr2-/- mice 
compared to C57BL/6 mice. Therefore I investigated, whether this reduction is also present in 
lung tissue. Ccr2-/- mice display a significant reduction of CD11b+Ly6ChiLy6G- monocytes in 
lungs (further denoted as Ly6Chi) 78 (p<0.001) and a significant, relative increase of 
CD11b+Ly6G+ cells (p<0.01; Figure 7).  
 
Figure 7: Flow cytometric analysis of 
monocyte subsets in naïve lungs of 
C57BL/6 and Ccr2-/- mice. A significant 
reduction of CD11b+Ly6Chi monocytes 
and relative significant increase of 
CD11b+LyG+ cells was found in Ccr2-/- 
lungs when compared to C57BL/6. 
Representative FACS plots and 
quantification of results are shown. 
Each symbol represents one individual 
mouse (n=5-6). Statistical significance: 
***=p<0.001; **=p<0.01. 
 
 
Next, I analyzed CCR2 expression on hematopoietic cells within the lung using BacCCR2CFP 
reporter mice, in which cells with an activated CCR2 promoter are CFP+ 64. Flow cytometric 
analysis of lung tissue-derived leukocytes and peripheral blood leukocytes revealed that most of 
the CD11b+Ly6Chi monocytes were CFP positive. In contrast, CD11b+Ly6G+ cells were CFP 
negative (p<0.001). Besides, lymphocytes, such as CD19+ B-cells, CD4+ and CD8+ T-cells 
lacked detectable CFP expression in peripheral blood and lung tissue (Figure 8). 
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Figure 8: Flow cytometric analysis of CFP/CCR2 expressing cells in peripheral blood and lung tissue of 
BacCCR2CFP transgenic mice. Ly6C+ cells (red) express CFP/CCR2 in peripheral blood and lung whereas Ly6G+ 
cells (blue) were negative for CFP as shown with representative FACS plots and histograms (left panel). Neither 
CD8+ or CD4+ T-cells nor CD19+ B-cells express CFP in these mice (right panel). Histograms do not reveal any 
difference in CFP expression between BacCCR2CFP mice (red line) and C57BL/6 (gray, filled) mice. 
 
 
I then investigated whether non-hematopoietic cells express CCR2 in the lungs of mice. From 
the literature, it was obvious that human endothelial cell lines express CCR2 60, however, there 
were no reports showing that CCR2 is expressed on murine endothelial cells in the lung. 
Therefore immunofluorescence staining for CD31 was carried out on frozen sections of lung 
tissue derived from BacCCR2CFP mice and confocal microscopy revealed that CD31+ lung 
endothelial cells are CFP+ (Figure 9). 
 
 
Figure 9: Representative confocal 
microscopy images of CD31+ lung 
endothelial cells in C57BL/6 and 
BacCCR2CFP mice.  
Upper row: The luminal side of the 
endothelium (indicated with asterisk) 
is positive for both CFP/CCR2 (green) 
and CD31/Pecam (red), whereas the basolateral side is only positive for CFP/CCR2. Nuclei are stained in blue 
(Hoechst). Size of scale bars is indicated. Lower row: Staining for CFP shows specific staining in BacCCR2CFP 
(right) but no signal in C57BL/6 mice (left).  
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To confirm these data, I analyzed mRNA expression levels of Ccr2 in isolated primary 
pulmonary endothelial cells of C57BL/6 and Ccr2-/- mice and could show that indeed CCR2 
expression is found in CD31-sorted endothelial cells from lungs of C57BL/6 mice (Figure 10).  
 
 
Figure 10: RT-PCR for Ccr2 expression in 
CD31-sorted primary endothelial cells 
isolated from lungs of C57BL/6 and Ccr2-/- 
mice. Two representative samples of each 
genotype are shown (+ RT), including controls 
without reverse transcriptase treatment (- RT). 
-actin served as control. One DNA marker 
band is indicated (bp = base pairs). 
 
 
The purity of the CD31-sorted endothelial cells was verified with flow cytometry for the presence 
of CD31-FITC signal (Figure 11), resulting in a purity of around 85-97% for the different lung 
preparations.  
 
 
Figure 11: Flow cytometric analysis to control 
for the purity of CD31-sorted pulmonary 
endothelial cells from C57BL/6 or Ccr2-/- mice. 
(A) Sideward scatter (SSC) and forward scatter 
(FSC) of a representative flow cytometry analysis 
for cells analyzed from a lung preparation (left). 
Histogram-analysis of the sorted CD31+ fraction 
(red line) derived from a representative lung 
preparation as well as the flow through (blue line) 
for CD31 expression (right). (B) Representative dot 
blot analyses for the presence of CD31-FITC+ cells 
in flow through (middle) and CD31-sorted fractions 
(right). Percent of CD31-expressing cells are 
indicated. 
 
 
Altered numbers of colon carcinoma cells in lungs of Ccr2-/- mice could explain the observed 
inability of MC-38GFP cells to form tumors in lungs. However, no difference in the amount and 
distribution of MC-38GFP cells in the lung vasculatur were found in either genotype as early as 
30 min post injection (Figure 12). At later time points (24 and 72 hrs), numbers of MC-38GFP 
cells decreased in both genotypes, although slightly more pronounced in Ccr2-/- mice.  
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Figure 12: Time course analysis of tumor cell 
survival in lung tissue. Numbers of tumor cells/ 
view field were analyzed on sections of C57BL/6 and 
Ccr2-/- lungs 30 min, 24 hrs and 72 hrs post injection 
(n=3). Statistical significance: **=p<0.01; n.s. = not 
significant. 
 
 
 
 
 
5.4.2 CCR2 controls endothelial permeability and tumor cell extravasation 
An alternative explanation for the observed alteration in tumor growth in lungs of Ccr2-/- mice 
could be a decreased capacity of MC-38GFP cells to extravaste into parenchyma of Ccr2-/- 
lungs. Confocal microscopy revealed that MC-38GFP cells remained attached to tomato lectin-
stained endothelia of blood vessels in Ccr2-/- mice at 24 hrs p.i. In contrast, in lungs of C57BL/6 
mice MC-38GFP cells had minimal contact with endothelia at 24 hrs p.i. indicating that tumor 
cells had already extravasated into lung parenchyma at that time point, thus having lost their 
interaction with the endothelium. Three-dimensional reconstruction of cell-cell contact between 
tumor and endothelial cells demonstrated a significantly increased interaction of MC-38GFP 
cells with endothelia in lungs of Ccr2-/- mice compared to C57BL/6 lungs (p<0.001; Figure 13).  
 
 
Figure 13: CCR2 deficiency reduces tumor cell extravasation. Confocal microscopy of MC-38GFP cells (green) 
and endothelial cells (red; lectin+) in C57BL/6 and Ccr2-/- lungs 24 hrs post-challenge with MC-38GFP cells (left panel; 
upper row). Size of scale bar is indicated. Three-dimensional reconstruction of the interaction of both cell types (left 
panel; lower row). Quantification of the 3D contact area in voxels performed in lungs of both genotypes (n=3) is 
shown as percentiles (right panel). Asterisks indicate statistical significance: ***=p<0.001.  
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This indicated an inability of tumor cells to extravasate in Ccr2-/- mice. The reduced capability of 
MC-38GFP cells to extravasate into Ccr2-/- lung parenchyma could be due to decreased 
permeability of the lung endothelium as tested by Evans blue accumulation. With this technique 
it is possible to test the integrity of the blood vasculature as blue staining of tissue is only found 
when blood vessels become permeable. Naïve lungs of either genotype were impermeable for 
Evans blue, resulting in white or only weakly stained lung tissue, indicating full vascular 
integrity. However, 24 hrs upon challenge with MC-38GFP cells, C57BL/6 mice displayed strong 
Evans blue accumulation, resulting in blue-colored lung tissue. In contrast, lungs of Ccr2-/- mice 
remained white, indicative of vascular impermeability. Spectrophotometric quantification of 
accumulated Evans blue in lung homogenates of both genotypes confirmed these macroscopic 
data (p<0.001; Figure 14).  
 
 
Figure 14: CCR2 deficiency reduces vascular permeability upon tumor cell injection. Macroscopy of Evans 
blue leakage in lungs of naïve C57BL/6 and Ccr2-/- mice (upper row) and in lungs at 24 hrs p.i. with MC-38GFP cells 
(lower row). Size of scale bar is indicated. Spectrophotometric quantification of Evans blue leakage (extracted from 
lung tissue) shows a significant increase in C57BL/6 mice 24 hrs post MC-38 challenge but not in Ccr2-/- mice (n=3, 
each; ***=p<0.001). 
 
 
Interestingly, the increase in permeability of endothelial cells of lung vessels is transient as 
revealed by time course analysis of Evans blue leakage (Figure 15). The strongest 
accumulation of Evans blue in the lung tissue of C57BL/6 mice was found between 12 and 24 
hrs p.i. with MC-38, indicating that indeed the very early phase of tumor cell seeding determines 
successful tumor cell extravasation and subsequent growth. After 7 days, the lung became 
completely impermeable again, meaning that the permeability of the endothelial cell layer is only 
transient and no continuous impairment of the vessel function and structure is caused by the 
extravasation process. 
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Figure 15: Induction of vessel permeability in lungs upon 
tumor cell challenge is transient. Macroscopy of lungs 
derived from C57BL/6 mice to study kinetics of Evans blue 
accumulation after MC-38GFP injection. Various time points 
between 6 hrs and 7 days p.i. with MC-38GFP are shown 
(upper panel). Quantification of Evans blue accumulation 
within lungs of C57BL/6 mice at 6 hrs, 12 hrs, 24 hrs, 96 hrs 
and 168 hrs p.i. with MC-38GFP, showing that the induction 
of lung permeability is transient, with the strongest 
accumulation between 12 and 24 hrs p.i. with tumor cells 
(lower panel). Statistical significance: ***=p<0.001; 
**=p<0.01; (n=3). 
 
 
 
Thus, besides a strong reduction in numbers of Ly6Chi cells and lack of endothelial CCR2 
expression, a reduced capacity of tumor cell extravasation and decreased permeability of lung 
endothelium was observed in lungs of Ccr2-/- mice upon tumor cell challenge.  
Next, I tested the hypothesis whether the reduced capacity of MC-38GFP cells to extravasate is 
linked to reduced recruitment of leukocytes 5, 79. Flow cytometry analysis of lungs derived from 
C57BL/6 mice injected with MC-38GFP cells revealed a specific recruitment of CD11b+Ly6Chi 
cells that was entirely absent in Ccr2-/- mice. The increased presence of Ly6Chi cells in lung 
tissue upon challenge with MC-38GFP cells persisted for approximately 12-24 hrs p.i. 
(Figure 16). No significant increase of other immune cells (e.g. CD4+, CD8+, CD11c+, NK1.1+) 
was found in lungs of both genotypes upon challenge with MC-38GFP cells (data not shown).  
 
 
Figure 16: Analysis of the influx of Ly6Chi cells into lung tissue upon tumor cell challenge of C57BL/6 and 
Ccr2-/- mice over time. Representative flow cytometry analyses of each time point are shown for both genotypes (left 
panel). Ly6Chi cells are quantified and presented in the right panel. Each symbol depicts an individual mouse (n=6-7). 
Asterisks indicate statistical significance: ***=p<0.001. 
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Next, we investigated whether infiltrating myeloid cell populations are recruited to MC-38GFP 
cells in lungs of both genotypes at sites of vascular arrest. Tumor cells in Ccr2-/- lungs were 
associated significantly less degree with F4/80+, Ly6C+ and CD11b+ cells when compared to 
C57BL/6. In contrast, endogenous Ly6G+ cells appeared to associate significantly stronger with 
MC-38GFP cells in Ccr2-/- lungs when compared to C57BL/6 mice (p<0.001; Figure 17). 
 
 
Figure 17: Confocal and quantitative analysis of tumor cell interaction with endogenous myeloid cells of 
C57BL/6 and Ccr2-/- lungs challenged with MC-38GFP cells. Representative images of the interaction of various 
myeloid cells (CD11b: left; F4/80: second from left; Ly6G: second from right, Ly6C; right; all red) with MC-38GFP 
cells (green) in C57BL/6 and Ccr2-/- mice 24 hrs post-injection (left panel). Quantification of the myeloid - tumor cell 
interaction in lungs of in C57BL/6 and Ccr2-/- mice; percentiles are indicated (right panel). Asterisks indicate statistical 
significance: ***=p<0.001. Scale bar: 20m; (n=3, each). 
 
To test whether MC-38GFP tumor cells injected into Ccr2-/- mice have still the ability to 
efficiently recruit myeloid cells, we adoptively transfered myeloid cells 6 hrs post tumor cell 
injection. MC-38GFP cells specifically recruited adoptively transferred myeloid cells in Ccr2-/- but 
not in C57BL/6 lungs (p<0.001; Figure 18) since MC-38GFP cells were already bound by 
endogenous myeloid cells (e.g. CD11b+, F4/80+ or Ly6C+) in C57BL/6 lungs. These results 
indicated that the capability of tumor cells to bind myeloid cells in Ccr2-/- lungs is not altered, 
however, the cellular environment within tumor cell challenged Ccr2-/- lung is different.  
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Figure 18: Tumor cells in lungs of Ccr2-/- mice are capable of interacting with myeloid cells. Confocal analysis 
and representative images of the interaction of adoptively transferred, PKH26-labeled monocytes (green) with MC38-
GFP cells (white) and endogenous F4/80+ macrophages (red) in C57BL/6 and Ccr2-/- mice 16 hrs post injection (left 
panel). Scale bar: 10m. Quantification of myeloid - tumor cell interaction in lungs of in C57BL/6 and Ccr2-/- mice; 
percentiles are indicated (right panel). Asterisks indicate statistical significance: ***=p<0.001 (n=3, each). 
 
Therefore, a plausible explanation for the strongly decreased extravasation of MC-38GFP cells 
in Ccr2-/- lungs is the lack of vascular permeability together with a reduction in interacting Ly6Chi 
inflammatory cells 5.  
 
 
5.4.3 Depletion of CD11b+Ly6Chi cells does not reduce lung metastasis 
As a next step, I tested whether depletion of Ly6Chi inflammatory cells would alter tumor cell 
extravasation and subsequent lung metastasis. Therefore, MC21 antibody (a CCR2 depleting 
antibody) 70 was injected for 5 days, starting one day prior to tumor cell injection. On the day of 
tumor cell injection, the presence of CD11b+Ly6Chi cells was tested by flow cytometry 
(Figure 19), indicating that numbers of CD11b+Ly6Chi cells were significantly reduced compared 
to C57BL/6 mice injected with ratIgG. Still, the reduction was only to a level comparable to 
Ccr2+/- mice.  
 
 
Figure 19: Depletion of Ly6Chi cells using MC21 
antibody led to monocyte levels comparable to 
Ccr2+/- mice. Quantification of flow cytometry analysis 
of CD11b+Ly6Chi cells in blood of C57BL/6 mice 
injected with ratIgG control or MC21 antibody as well as 
Ccr2+/- mice. Statistical significance: **=p<0.01; n.s. = 
not significant (n=3-4). 
 
 
After 28 days, lungs were analyzed for tumor load and measurement of GFP fluorescence 
revealed no difference between untreated C57BL/6 mice and C57BL/6 mice treated with MC21 
or ratIgG control antibody (Figure 20). 
 
Figure 20: Lung metastasis is unaltered upon 
depletion of CCR2+Ly6Chi monocytes. Quantification 
of relative fluorescence in lungs of untreated C57BL/6, 
control antibody injected (ratIgG) and CCR2-depleting 
antibody (MC21) mice at 28 dpi (n=4-5).  
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These results indicate that even in situations with significantly reduced numbers of Ly6Chi 
monocytes within the circulation, metastatic growth of MC-38GFP tumors is not altered. This 
also suggests that an approximately 50% reduction of inflammatory monocytes does not suffice 
to induce a biological effect in our seeding model. 
To further study the role of Ly6Chi monocytes in metastatic growth of lung tumors, I used 
BacCCR2DTCFP mice, in which all CCR2 expressing cells can be depleted upon injection of 
diphtheria toxin (DT). I established a protocol, which allowed me to efficiently deplete 
CCR2+Ly6Chi monocytes for the first 4 days after tumor cell injection as tested by flow cytometry 
analysis for the presence of CD11b+Ly6Chi cells in blood of DT-injected mice each 24 hrs. 
Figure 21 shows the experimental set-up used in the BacCCR2DTCFP model system as well as 
the efficient depletion of CD11b+Ly6Chi cells in the peripheral blood of these mice.  
 
 
Figure 21: Efficient depletion of CFP+Ly6Chi cells in BacCCR2DTCFP mice upon DT injection. Injection of DT 
every 24 hrs allowed conditional depletion of Ly6Chi cells for at least the first 52 hrs after tumor cell injection. The time 
line represents the treatment protocol (upper panel) and the representative FACS plots for the presence of 
CD11b+Ly6Chi cells in blood confirm efficient depletion of this cell type (lower panel).  
 
Mice were injected with MC-38GFP and after 28 days lungs were analyzed for tumor load. 
Quantification of metastatic foci within the lungs revealed no reduction in tumor burden in DT-
treated BacCCR2DTCFP mice. In contrary, an increase in tumor burden was found, which might 
be due to the fact that CCR2 is expressed on endothelial cells and DT treatment might have 
increased vessel permeability leading to an increased extravasation of tumor cells and 
subsequent metastasis (Figure 22).  
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Figure 22: Depletion of CFP/CCR2+ cells in 
BacCCR2DTCFP mice leads to enhanced tumor 
growth. Quantification of metastatic foci in lungs 
of C57BL/6 (n=5) and BacCCR2DTCFP (n=4) 
mice 28 dpi with MC-38GFP cells. 
 
 
 
These results suggest that depletion of Ly6Chi monocytes does not suffice to attenuate 
metastasis. 
 
 
5.4.4 CCR2 on radio-resistant cells contributes to efficient tumor metastasis 
Next, we tested whether reconstitution of Ccr2-/- mice with CCR2+ BM cells could restore the 
ability of MC-38GFP cells to extravasate and metastasize in lungs. Therefore, I performed 
reciprocal BM reconstitution of C57BL/6Ccr2-/- and Ccr2-/-C57BL/6 mice as well as control 
groups (C57BL/6C57BL/6 and Ccr2-/-Ccr2-/- mice) and analyzed blood 6-8 weeks after 
reconstitution for the presence of CCR2+Ly6Chi monocytes by flow cytometry. Successfully 
reconstituted mice (efficiency >90%) were administered MC-38GFP cells and analyzed for 
tumor growth in lungs 28 dpi. As expected C57BL/6C57BL/6 mice displayed robust lung 
metasasis, whereas Ccr2-/-Ccr2-/- mice lacked or had strongly reduced tumor metastases in 
lungs. However, CCR2 expression on radio-resistant cells (Ccr2-/-C57BL/6 mice) resulted in 
more lung tumors when compared to mice devoid of CCR2 expression in the stromal 
compartment (C57BL/6Ccr2-/- mice; p<0.05; Figure 23). 
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Figure 23: CCR2 expression in the stromal and the hematopoietic compartment is crucial for tumor cell 
extravasation and tumor growth. Representative FACS plots of peripheral blood from C57BL/6C57BL/6 (n=8), 
C57BL/6Ccr2-/- (n=7), Ccr2-/-C57BL/6 (n=9) and Ccr2-/-Ccr2-/- chimeric mice (n=5) for the presence of 
CCR2+Ly6Chi monocytes (left row). Macroscopy of lungs 28 dpi with MC-38GFP cells. Size of scale bar is indicated 
(middle and right row). Quantification of metastatic foci in lungs of C57BL/6C57BL/6 (black; n=8), Ccr2-/-C57BL/6 
(blue; n=6); C57BL/6Ccr2-/- (green; n=9) and Ccr2-/-Ccr2-/- (red; n=6) mice. Statistical significance: ***=p<0.001; 
**=p<0.01; *=p<0.05 (right panel). 
 
These data indicate that hematopoietic – but even more important – stromal expression of 
CCR2 is involved in efficient tumor cell extravasation of MC-38GFP cells in lung tissue.  
 
 
To delineate the role of stromal CCR2 expression in metastasis in more detail, we next 
assessed whether CCR2 expression specifically on endothelial cells under the Tie2 promoter in 
Ccr2-/- mice (denoted as Tie2CCR2/Ccr2-/- mice 63, 80) would enable tumor cell extravasation and 
formation of metastasis. First, I analyzed Tie2CCR2/Ccr2-/- mice by flow cytometry extensively 
for CCR2 expression on hematopoietic and stromal cells as well as for the presence of Ly6Chi 
cells. The obtained data clearly show that Tie2CCR2/Ccr2-/- mice lack Ly6Chi monocytes in 
peripheral blood and lung tissue similar to Ccr2-/- mice (Figure 24).  
 
 
 
Figure 24: Tie2CCR2/Ccr2-/- mice lack Ly6Chi monocytes in peripheral blood and lung tissue. Representative 
FACS plots for CD11b+Ly6Chi monocytes in blood (upper row) and lungs (lower row) of naïve C57BL/6, 
Tie2CCR2/Ccr2-/- and Ccr2-/- mice (left panel). Quantification of Ly6Chi cells is presented in the right panel. Each 
symbol depicts an individual mouse (n=6 for each genotype). Asterisks indicate statistical significance: ***=p<0.001. 
 
 
Further, Tie2CCR2/Ccr2-/- mice are devoid of CCR2 expression on CD11b+, CD19+ or CD3+ 
cells in peripheral blood, spleen or BM, indistinguishable from Ccr2-/- mice (Figure 25). 
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Figure 25: Characterization of mice with endothelium specific over-expression of CCR2. Representative FACS 
plots for the expression of CCR2 on CD3+ T-cells, CD19+ B-cells and CD11b+ monocytes in the blood (upper row), 
spleen (middle row) and bone marrow (lower row) of C57BL/6 (red), Tie2CCR2/Ccr2-/- (green) and Ccr2-/- mice (blue). 
Histograms reveal no difference in the CCR2 expression pattern between Tie2CCR2/Ccr2-/- and Ccr2-/- mice (lower 
panel). 
 
In addition, I analyzed expression levels of Ccr2 mRNA in whole lung tissue and primary 
endothelial cells of Tie2CCR2/Ccr2-/- mice. Overall, Ccr2 mRNA expression levels in lungs of 
Tie2CCR2/Ccr2-/- mice were reduced by more than 50% when compared to C57BL/6 mice, 
most likely due to the lack of infiltrating CCR2+Ly6Chi monocytes. However, transcriptional 
analysis of Ccr2 expression in purified lung endothelial confirmed that Tie2CCR2/Ccr2-/- mice 
express Ccr2 in pulmonary endothelial cells (Figure 26).  
 
Figure 26: Characterization of endothelium specific over-expression of CCR2 in Tie2CCR2/Ccr2-/- mice. Real-
time PCR for the expression of Ccr2 mRNA in lung tissue derived of C57BL/6, Tie2CCR2/Ccr2-/- and Ccr2-/- mice. 
Each symbol represents an individual mouse (n=4, for each genotype); values are normalized to the average of Ccr2 
mRNA expression in C57BL/6 lungs and shown in percentage of the average C57BL/6 expression level. Statistical 
significance: ***=p<0.001; *=p<0.05 (left panel). RT-PCR for the expression of Ccr2 in CD31-sorted endothelial cells 
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isolated from lungs of C57BL/6, Tie2CCR2/Ccr2-/- and Ccr2-/- mice. All samples are shown in duplicates, -actin 
served as control (right panel). 
 
 
Upon injection of Tie2CCR2/Ccr2-/- mice with MC-38GFP cells, tumor cell extravasation and 
tumor growth was restored approximately to a 50% level of C57BL/6 mice. The macroscopic 
finding was further confirmed by quantification of GFP fluorescence in lungs of C57BL/6, 
Tie2CCR2/Ccr2-/- and Ccr2-/- mice as well as by immunohistochemical analysis (Figure 27). 
 
 
 
Figure 27: Endothelial expression of CCR2 facilitates lung metastasis. Macroscopy of lungs of C57BL/6, 
Tie2CCR2/Ccr2-/- and Ccr2-/- mice 28 dpi with MC-38GFP cells. Size of scale bar is indicated (upper left panel). 
Quantification of GFP fluorescence in lung homogenates of C57BL/6 (n=5), Tie2CCR2/Ccr2-/- (n=5) and Ccr2-/- (n=5) 
mice. Asterisks indicate statistical significance: ***=p<0.001; **=p<0.01 (upper right). Histological analysis of colon 
carcinoma (MC-38GFP) tumors in lung sections of Ccr2-/- and Tie2CCR2/Ccr2-/- mice 28 dpi. H&E: Hematoxylin-
Eosin, GFP for tumor cells, Ki67 stains for proliferating cells, F4/80 for monocytes and macrophages. Size of scale 
bar: 50m (lower panel). 
 
Hence, expression of CCR2 on endothelial cells was sufficient to partially restore tumor cell 
extravasation and metastasis. 
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5.4.5 CCR2 expression by myeloid cells is dispensable for tumor cell extravasation and 
metastasis 
Over-expression of CCR2 on endothelial cells was sufficient to partially restore tumor cell 
extravasation and metastasis. To assess the role of CCR2 expression on myeloid cells during 
metastasis, we bred Ccr2loxP/loxP mice with LysMCre 81 mice, resulting in a mouse potentially 
devoid of CCR2 expression on myeloid cells. Flow cytometry analysis of peripheral blood 
revealed similar amounts of Ly6Chi cells in LysMCreCcr2loxP/loxP and C57BL/6 mice, however 
depletion of CCR2 expression was found to be 90-95% efficient on Ly6Chi monocytes in 
LysMCreCcr2loxP/loxP mice (Figure 28) indicating that the LysMCre promoter is active on 
circulating monocytes 82, 83. 
 
 
Figure 28: Characterization of mice lacking CCR2 expression specifically on myeloid cells. Upper panel: 
representative FACS plots for CD11b+Ly6Chi cells in peripheral blood of C57BL/6, LysMCreCcr2loxP/loxP and Ccr2-/- 
mice (left panel). Quantification of Ly6Chi cells is presented in the right panel. Each symbol depicts an individual 
mouse (n=5-7). Asterisks indicate statistical significance: ***=p<0.001; n.s. = not significant. Lower panel: 
representative FACS plot for CCR2 expression on Ly6Chi cells in blood of C57BL/6 and LysMCreCcr2loxP/loxP mice. 
The histogram depicts CCR2 expression on Ly6Chi cells of C57BL/6 (gray, filled) and LysMCreCcr2loxP/loxP mice (red 
line). The isotype control is shown as dashed line. 
 
I next challenged LysMCreCcr2loxP/loxP mice with MC-38GFP cells and analyzed the lungs for the 
presence of Ly6Chi monocytes 12 hrs p.i. Interestingly, LysMCreCcr2loxP/loxP mice did not display 
a specific recruitment of Ly6Chi monocytes at 12 hrs p.i. or at later time points, indicating that 
lack or reduction of CCR2 on Ly6Chi monocytes leads to a shortened retention in tumor cell-
challenged lungs (Figure 29). 
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Figure 29: Lack of CCR2 on Ly6Chi cells abrogates influx of Ly6Chi cells upon tumor cell injection. 
Representative FACS plots for the presence of CD11b+Ly6Chi cells in the lung of naïve C57BL/6, C57BL/6 and 
LysMCreCcr2loxP/loxP mice 12 hrs p.i. with MC-38GFP (left panel). Quantification of Ly6Chi cells in the right panel. 
Each symbol depicts an individual mouse (n=5-7). Asterisks indicate statistical significance: ***=p<0.001; *=p<0.05; 
n.s. = not significant. 
 
To gain insight into the role of myeloid cell derived CCR2 expression in tumor cell growth, 
LysMCreCcr2loxP/loxP, Ccr2-/- and C57BL/6 mice were injected with MC-38GFP. A significantly 
reduced amount of tumor nodules was found in lungs of LysMCreCcr2loxP/loxP mice, when 
compared to C57BL/6 mice (p<0.05). This was confirmed by quantification of GFP fluorescence 
in lung homogenates and by immunohistochemistry on lung tissue (Figure 30).  
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Figure 30: Lack of CCR2 on Ly6Chi cells leads to reduced tumor growth in LysMCreCcr2loxP/loxP mice. 
Macroscopy of lungs of C57BL/6, LysMCreCcr2loxP/loxP and Ccr2-/- mice 28 dpi with MC-38GFP cells. Size of scale bar 
is indicated (left upper panel). Quantification of GFP fluorescence in lung homogenates of C57BL/6 (n=5), 
LysMCreCcr2loxP/loxP (n=6) and Ccr2-/- (n=6) mice. Each symbol depicts an individual mouse. Asterisks indicate 
statistical significance: ***=p<0.001; *=p<0.05 (right upper panel). Histological analysis of colon carcinoma tumors 
(MC-38GFP) in Ccr2loxP/loxP (upper row, lower panel) and LysMCreCcr2loxP/loxP (lower row, lower panel) lungs 28 dpi 
H&E: Hematoxylin-Eosin, Ki67 stains for proliferating cells, GFP for tumor cells, F4/80 for monocytes and 
macrophages. Scale bar: 200µm. 
 
Similar to our data obtained from reconstitution experiments as well as from Tie2CCR2/Ccr2-/- 
mice, these results demonstrate that CCR2 expression on the stromal compartment suffices for 
tumor cell extravasation and metastasis of MC-38GFP cells. However, CCR2 expression on 
Inflammatory monocytes facilitates metastasis. 
 
 
5.4.6 Tumor cell-derived CCL2 expression controls myeloid cell recruitment 
To test whether CCR2-dependent lung metastasis of MC-38GFP colon carcinoma cells could 
be also observed with different tumor cells, we injected C57BL/6 and Ccr2-/- mice with Lewis 
lung carcinoma cells (3LL). Similar to MC-38GFP cells, attenuation of metastasis was observed 
in Ccr2-/- lungs when compared to C57BL/6 lungs as demonstrated by quantification of tumor 
nodules in lungs (p<0.05; Figure 31).  
Figure 31: Tumor cell-derived CCL2 
dependent mechanisms of tumor cell 
extravasation. Macroscopy of C57BL/6 
and Ccr2-/- lungs at 12 dpi with Lewis lung 
carcinoma cells (3LL) (left panel, size of 
scale bar is indicated) and quantification of 
tumor nodules (right panel; n=5). Asterisks 
indicate statistical significance: *=p<0.05. 
 
 
Next, we investigated the metastatic behaviour of B16-BL6 melanoma cells. Of note, B16-BL6 
melanoma cells showed lung metastases both in C57BL/6 and Ccr2-/- mice to a similar extent, 
indicating that these melanoma cells extravasate independently from CCR2 (Figure 32).  
 
 
Figure 32: Tumor cell-derived CCL2 
independent mechanisms of metastasis. 
Macroscopy of C57BL/6 and Ccr2-/- lungs at 
14 dpi with melanoma cells (B16-BL6) and 
quantification of tumor numbers (right). Each 
symbol depicts one individual mouse (n=6). 
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Tumor cell intrinsic mechanisms are likely to contribute to the observed CCR2 dependent 
differences in respect to extravasation and tumor metastasis. I first analyzed chemokine and 
chemokine receptor mRNA expression levels in lungs of C57BL/6 and Ccr2-/- mice injected with 
MC-38GFP cells. A strong increase in transcription levels of Ccl2, Ccl7, Ccl12, Cxcl1 and 
Cxcl10 was detected already at 4 hrs post tumor cell injection in lungs of C57BL/6 mice. 
Transcriptional changes of these genes persisted at 8 and 12 hrs p.i. however decreased over 
time. A similar pattern in the expression levels of chemokines upon injection of MC-38GFP was 
found in Ccr2-/- lungs (Figure 33, upper panels). This suggested that the majority of the induced 
chemokine expression in lung is unlikely to dependent on host derived CCR2. Alternatively, 
tumor cells could directly contribute to chemokine expression, altering the cellular composition 
and the activation status of cells in MC-38 challenged lungs. Besides, mRNA expression levels 
of most chemokine receptors were not altered in lungs of C57BL/6 and Ccr2-/- mice upon tumor 
cell injection (Figure 33, lower panels). 
 
 
Figure 33: Real time PCR analysis for 
the expression of selected chemokines 
(upper panel) and chemokine receptors 
(lower panel) in lungs of C57BL/6 and 
Ccr2-/- mice. Untreated, 4 hrs p.i., 8 hrs p.i. 
and 12 hrs p.i. with MC-38GFP is shown 
from left to right. Data are presented in a 
log2 scale  (red: up-regulated; blue: down-
regulated). Columns indicate individual 
mice; rows represent particular genes. 
Each data point reflects the median 
expression of a particular gene resulting 
from three to four technical replicates, 
normalized to the mean expression value 
of the respective gene in C57BL/6 lungs.  
 
Therefore, the majority of the induced chemokine expression found in lung tissue was probably 
CCR2 independent. We hypothesized that the observed expression pattern might derive from 
tumor cells themselves. Consequently, I analyzed chemokine mRNA expression in MC-38GFP 
in comparison to colon tissue. Indeed, Ccl2, Ccl7 but also Cxcl1 and Cxcl10 were strongly 
expressed by MC-38GFP tumor cells (Figure 34, left panel). 
Next, I investigated whether expression of CCR2 ligands (e.g. Ccl2 and Ccl7) correlated with 
the inability of MC-38 and 3LL cells to extravasate and to form tumor nodules in Ccr2-/- mice. 
Similar to MC-38GFP cells, 3LL cells express high levels of Ccl2 and Ccl7 on mRNA level 
whereas B16-BL10 melanoma cells – which extravasated and formed tumors in lungs 
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independent of CCR2 – lacked or expressed extremely low Ccl2 and Ccl7 mRNA levels 
(Figure 34, right panel).  
 
 
Figure 34: mRNA expression levels of selected chemokines in tumor cell lines. Real time PCR analysis for the 
expression of Ccl2, Ccl7, Cxcl1 and Cxcl10 mRNA in MC-38GFP cells compared to colon tissue derived from 
C57BL/6 mice (left panel). Quantitative mRNA analysis for the expression of Ccl2 and Ccl7 in MC-38, 3LL and B16-
BL6 compared to mRNA isolated from lungs of C57BL/6 mice (right panel). Data are presented as ct values on a 
log2 scale. Each bar reflects the median expression of a particular gene resulting from three to four biological 
samples with three to four technical replicates.  
 
These results were also confirmed on protein level – MC-38 expressed high levels of CCL2 
(left), 3LL medium levels (middle) and B16-BL6 melanoma cells did not show any CCL2 protein 
expression. Interestingly, B16-BL6 cells in general expressed only minimal amounts of 
cytokines and chemokines when compared to the other cell lines investigated (Figure 35).  
 
 
Figure 35: Cytokine and chemokine expression pattern in 
MC-38, 3LL and B16-BL6 cells. MC-38 cells (left blot) highly 
express a variety of cytokines and chemokines, whereas B16-
BL6 in general only express low levels of these proteins. The 
box represents CCL2 expression, which was highly expressed 
in MC-38 cells, medium levels were found in 3LL cells 
(middle) and almost no CCL2 expression was found in B16-
BL6 cells. Proteins dots in the upper right and left as well as 
lower right corners of each blot serve as positive controls for 
loading. Lower left corner serves as negative control.  
 
Thus, we next investigated whether tumor cell-derived CCL2 is essential for the capacity of 
colon tumor cells to extravasate. Therefore, endogenous CCL2 was silenced in MC-38GFP 
cells (further denoted as MC-38GFPCCL2kd) by lentiviral transduction and the silencing efficiency 
was around 75-90% on mRNA and 60-85% on protein level leaving the expression pattern of 
other investigated chemokines and cytokines unaltered (Figure 36). Cells stably transfected with 
scrambled RNA were prepared as control (further denoted as MC-38GFPscr).  
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Figure 36: Efficient silencing of 
CCL2 in MC-38GFPCCL2kd cells. 
Expression profile of chemokines 
and cytokines in MC-38GFP and 
MC-38GFPCCL2kd cells. Only the 
protein level of CCL2 (1) is 
reduced, other  expression levels 
(2: CCL12; 3: CXCL10; 4: TIMP-
1; 5: CCL5) remain unaffected. 
Protein dots in the upper right and left corners serve as positive controls for loading (left). Quantification of pixel 
density (shown in arbitrary units [a.u.] of the before described chemokines; right). Statistical significance: 
***=p<0.001; n.s. = not significant. 
 
First, I examined the capability of MC-38GFPCCL2kd cells to recruit monocytes. Therefore, 
C57BL/6 mice were injected MC-38GFP or MC-38GFPCCL2kd cells and investigated by flow 
cytometry analysis for the capacity to recruit Ly6Chi monocytes 4 and 12 hrs p.i. Similar 
amounts of Ly6Chi cells were detected in lungs of C57BL/6 mice 4 hrs p.i. with MC-38GFPCCL2kd 
or MC-38GFP cells, indicating that primary recruitment of inflammatory Ly6Chi monocytes is 
rather systemic and most likely independent of tumor cell-derived CCL2 expression. However, 
12 hrs p.i. Ly6Chi cells were no longer efficiently retained in C57BL/6 lungs injected with MC-
38GFPCCL2kd tumor cells when compared to mice injected with MC-38GFP cells (Figure 37).  
 
Figure 37: CCL2 expression levels of tumor 
cells determine retention of CD11b+Ly6Chi cells 
in the lungs after tumor cell challenge. 
Quantification of naïve C57BL/6 mice and 4 and 12 
hrs post challenge with MC-38GFP (blue) and MC-
38GFPCCL2kd (red) cells. Each symbol depicts an 
individual mouse (n=6-7). Asterisks indicate 
statistical significance: ***=p<0.001; **=p<0.01; n.s. 
= not significant. 
 
 
Therefore, the CCL2-CCR2 signaling axis controls the specific recruitment of Ly6Chi cells upon 
tumor cell challenge. We next studied tumor cell extravasation and metastasis in lungs of 
C57BL/6 mice upon injection of MC-38GFPCCL2kd, MC-38GFP or MC-38GFPscr cells. C57BL/6 
mice injected with MC-38GFPCCL2kd cells displayed minimal or no lung metastasis, whereas MC-
38GFP or MC-38GFPscr cells induced strong tumor burden within lungs. These macroscopic 
findings were confirmed by quantification of GFP fluorescence of lungs of the respective groups 
(p<0.001; Figure 38). 
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Figure 38: Loss of CCL2 expression in tumor cells leads to reduced tumor growth in the lungs of C57BL/6 
mice. Macroscopy of lungs derived from C57BL/6 mice challenged with MC-38GFP (left), MC-38GFPscr (middle) and 
MC-38GFPCCL2kd (right) cells at 28 dpi. Size of scale bar is indicated. Quantification of GFP-fluorescence at 28 dpi in 
lung homogenates from C57BL/6 mice challenged with MC-38GFP (n=7), MC-38GFPscr (n=6) and MC-38GFPCCL2kd 
(n=9) cells. Each symbol represents an individual mouse (n=6-9). Asterisks indicate statistical significance: 
***=p<0.001. 
 
Interestingly, the extent of reduction in tumor growth observed in MC-38GFPCCL2kd-injected 
C57BL/6 mice was similar to MC-38GFP-injected Ccr2-/- mice, indicating that CCL2-CCR2 
interaction is important for efficient extravasation and metastasis of colon carcinoma cells. 
To further assess the crucial role of tumor cell-derived CCL2 in metastasis, C57BL/6 mice were 
challenged with 3LL cells with reduced CCL2 expression (further denoted as 3LLCCL2kd).  
A strong decrease in lung metastasis was observed on macroscopic level in lungs of C57BL/6 
mice challenged with 3LLCCL2kd cells when compared to injection with 3LL cells. This was also 
confirmed by quantification of tumor foci (p<0.01; Figure 39). 
 
Figure 39: Loss of CCL2 expression on 
tumor cells leads to reduced tumor 
growth in the lungs of C57BL/6 mice. 
Macroscopy of lungs from C57BL/6 mice 
challenged with 3LL (left) and 3LLCCL2kd 
(right) cells at 12 dpi. Size of scale bar is 
indicated. Quantification of tumor nodules of 
C57BL/6 mice injected with 3LL (n=4) and 
3LLCCL2kd (n=4) cells at 12 dpi. Statistical 
significance: **=p<0.01. 
 
We next addressed whether tumor cell-derived CCL2 expression is crucial for efficient 
recruitment and association with myeloid cells in lungs of C57BL/6 mice. Reduced expression of 
CCL2 on MC-38GFP cells (MC-38GFPCCL2kd) significantly diminished the capacity to interact 
CD11b+, F4/80+ or Ly6C+ cells (p<0.001). Instead, MC-38GFPCCL2kd tumor cells showed 
significantly enhanced interaction with Ly6G+ cells (p<0.001; Figure 40) that was similar to 
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observations with MC-38GFP cells injected Ccr2-/- mice. Interestingly, MC-38GFPCCL2kd tumor 
cells failed to recruit adoptively transferred myeloid cells, when compared to MC-38GFP cells 
(Figure 40). The failure of MC-38GFPCCL2kd to recruit myeloid cells, independent of the mouse 
genotype (Ccr2-/- or C57BL/6), supports the conclusion that CCL2 expression on tumor cells is a 
physical denominator for efficient myeloid cell – tumor cell interaction. 
This indicates that recognition of tumor cells by monocytes is strongly decreased if CCL2 
expression is missing or reduced on MC-38GFP cells.  
 
 
Figure 40: Tumor cell-derived CCL2 is important for interaction with myeloid cells. Quantitative analysis of 
confocal microscopy of tumor cell interaction with endogenous myeloid cells in C57BL/6 lungs challenged with MC-
38GFP (white percentiles) and MC-38GFPCCL2kd (gray percentiles) cells. Myeloid cell - tumor cell interaction in lungs 
of in C57BL/6 mice (from left to right: myeloid cells positive for CD11b, F4/80, Ly6G or Ly6C are quantified) 24 hrs 
post tumor cell challenge. Asterisks indicate statistical significance: ***=p<0.001; n.s. = not significant. Quantification 
of interaction of tumor cells (MC-38GFP: white percentiles, MC-38GFPCCL2kd: gray percentiles) with adoptively 
transferred, PKH26-labeled monocytes in lungs of C57BL/6 and Ccr2-/- mice 16 hrs p.i. of tumor cells. Asterisks 
indicate statistical significance: ***=p<0.001; n.s. = not significant. 
 
 
5.4.7 Interaction of CCR2+ endothelial cells and tumor cell-derived CCL2 determines lung 
permeability 
To determine whether endothelial CCR2 expression was sufficient to induce vascular 
permeability, we injected Tie2CCR2/Ccr2-/- mice with MC-38GFP cells. Elevated levels of Evans 
blue in Tie2CCR2/Ccr2-/- lungs strongly indicate that endothelial CCR2 activation is sufficient to 
induce lung vascular permeability. As host-derived CCL2 has been implicated in metastasis 5, 
we injected Ccl2-/- mice with MC-38GFP cells. Interestingly, upon injection of tumor cells, 
increased lung vascular permeability has been detected both by macroscopical analysis and 
quantification of Evans blue in lung tissue. In line, MC-38GFPCCL2kd cells failed to induce 
vascular permeability in C57BL/6 lungs (Figure 41).  
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Figure 41: Permeability of lung tissue upon tumor cell injection depends on tumor cell-derived CCL2 and 
endothelial CCR2. Macroscopy of lungs with Evans blue accumulation derived from untreated C57BL/6 mice (very 
left) or C57BL/6 (left), Ccr2-/- (second from left) and Ccl2-/- mice (second from right) 24 hrs post-challenge with MC-
38GFP and C57BL/6 mice 24hrs post-challenge with MC-38GFPCCL2kd cells (right). Size of scale bar is indicated. 
Spectrophotometric quantification of Evans blue (extracted from lung tissue) from C57BL/6 mice (white), Ccr2-/- mice 
(gray), Ccl2-/- mice (hatched) 24 hrs post challenge with MC-38GFP and MC-38GFPCCL2kd cells. Statistical 
significance is indicated: ***=p<0.001. 
 
These results strongly suggest that tumor cell-derived CCL2 as well as endothelial CCR2 
expression are sufficient for induction of lung vascular permeability and that CCL2 production 
from the host tissue can be neglected in this context. 
 
 
To investigate whether the local microenvironment (e.g. CCL2 expression; monocytes; stromal 
cells) could rescue the incapability of CCL2-deficient tumor cells (MC-38GFPCCL2kd) to 
extravasate and metastasize, we co-injected equal amounts of MC-38 and MC-38GFPCCL2kd 
cells into C57BL/6 mice. Similar numbers of metastases were observed in lungs of C57BL/6 
mice injected with MC-38 versus MC-38GFPCCL2kd/MC-38 mixed cells 28 dpi (p=0.6).  
As observed before, injection with MC-38GFPCCL2kd cells led to significantly reduced numbers of 
metastases. Of note, in lungs of mice injected with equal amount of MC-38GFPCCL2kd and MC-
38 cells, histological analyses revealed more GFP- than GFP+ tumors (p<0.001; Figure 42). 
Only few GFP+ metastases were found, suggesting that tumors have mainly originated from 
CCL2-expressing MC-38 cells.  
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Figure 42: An identical microenvironment does not lead to lung metastasis in tumor cells devoid of CCL2 
expression. Macroscopy of lungs derived from C57BL/6 mice at 28 dpi upon injection of MC-38 (left, n=3) MC-38 
and MC-38GFPCCL2kd (1:1 ratio; middle, n=5) and MC-38GFPCCL2kd cells (right, n=3). Quantification of tumor nodules 
on step cuts through lungs (black bars represent MC-38 cells, green bars MC-38GFPCCL2kd cells). Statistical 
significance: ***=p<0.001 (right panel). Representative images of step cuts used for the quantification of tumor 
nodules. GFP and Ki67 staining served as markers for tumor cells. Size of scale bar is indicated. 
 
This indicates that the inability of MC-38GFPCCL2kd cells to establish lung metastases cannot be 
restored by a local microenvironment, where CCL2, inflammatory monocytes and lung 
permeability were generally increased. The fact that only CCL2 expressing tumor cells can 
extravasate efficiently and form lung tumors, suggests that cell-cell interaction mediated by the 
CCL2-CCR2 axis is essential for efficient tumor cell extravasation and subsequent metastasis.  
 
We next examined lungs of C57BL/6 and Ccr2-/- mice 12 hrs p.i. with MC-38 tumor cells at 
ultrastructural level. In general, injection of MC-38 cells induced broad changes in C57BL/6 lung 
tissue including increased thickness of airway epithelial cells in the bronchi and thickened 
smooth muscle cells. Tumor cells were found inside the alveoli (Figure 43, left panel) and rarely 
in the vessels. Alveoli in C57BL/6 mice appeared shrunken and contained numerous alveolar 
macrophages and type I, II pneumocytes. Moreover, we observed an intimate interaction 
between MC-38 tumor cells and endothelium in C57BL/6 mice, with tumor cell protrusions 
spanning through the apical side of the endothelium resembling ongoing tumor cell 
transmigration (Figure 43, middle panel, inset). In contrast, Ccr2-/- lung endothelium appeared to 
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be grossly unaffected by the injection of MC-38 tumor cells with no visible indication for 
endothelial attachment (Figure 43, right panel, inset).  
 
 
Figure 43: Electron microscopical images of lungs of C57BL/6 (left and middle) and Ccr2-/- mice (right) 12 hrs 
p.i. with MC-38GFP cells. Left panel: arrowhead points towards a tumor cell in the alveolar space in close contact to 
a type II pneumocyte (arrow). Middle panel: arrowhead shows an attached and transmigrating tumor cell localized 
within the vessel. The arrow indicates a monocyte within the vessel. The insert shows the interaction between the 
tumor cell and the vessel wall at higher magnification. Right panel: No visible transmigration of tumor cells. 
Arrowhead shows a tumor cell, arrow indicates a monocyte within the vessel. Size of scale bar: 5m.  
 
 
5.4.8 Endothelial CCR2 signaling controls tumor cell extravasation through the JAK2-
Stat5 and p38MAPK pathways 
Our data suggest that tumor cell extravasation depends on the CCR2-mediated increase in 
endothelial permeability induced through tumor cell-derived CCL2. In addition, recruitment of 
Ly6Chi monocytes through CCR2 significantly contributes to metastasis. To delineate the exact 
mechanism of this signaling cascade we examined the efficiency of tumor cell transmigration on 
endothelial cells derived either from C57BL/6 or Ccr2-/- mice, in presence or absence of 
monocytes in vitro. MC-38GFP cells incubated on C57BL/6 endothelial cells for 16 hrs 
transmigrated only minimally towards an FCS gradient. In contrast, co-cultivation of MC-38GFP 
cells with BM-derived monocytes induced efficient transmigration of MC-38GFP cells through 
C57BL/6 endothelial cells (p<0.001; Figure 44). We next asked whether endothelial cells 
isolated from Ccr2-/- mice would impair tumor cell transmigration. Similarly to CCR2+ endothelial 
cells, MC-38GFP cells alone were unable to transmigrate through the CCR2-deficient 
endothelial monolayer. However, co-cultivation with monocytes failed to induce significant 
transmigration of MC-38GFP tumor cells through the CCR2-deficient endothelial monolayer, 
although monocytes were able to interact with the tumor cells through the CCL2-CCR2 axis 
(p=0.6; Figure 44).  
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Figure 44: Transmigration of MC-38GFP cells through endothelial cells is facilitated by monocytes. BM-
derived monocytes were co-cultured with MC-38GFP cells on a monolayer of endothelial cells derived either from 
C57BL/6 or Ccr2-/- mice for 16 hrs. Transmigrated GFP+ tumor cells in the lower chamber were counted. Statistical 
significance is indicated: ***=p<0.001; n.s. = not significant. Representative images of transmigrated tumor cells for 
each co-culture are presented in the right panel. Scale bar: 10µm. 
 
Monocytes were observed to efficiently transmigrate through the Ccr2-/- endothelial monolayer – 
similar to experiments with a C57BL/6 monolayer (data not shown), indicating that the CCR2-
deficient endothelium per se allows cell transmigration. Taken together, our in vitro and in vivo 
experiments provide evidence for the specific role of endothelial CCR2 signaling to facilitate 
tumor cell transmigration without affecting monocyte transmigration.  
To examine whether transmigration of tumor cells is dependent on tumor cell-derived CCL2, we 
tested the capability of MC-38GFPCCL2kd cells to transmigrate through CCR2+ endothelial cells. 
In contrast to MC-38GFP, MC-38GFPCCL2kd cells could not efficiently transmigrate through the 
monolayer of C57BL/6 endothelium in the presence of monocytes (p<0.001; Figure 45).  
 
Figure 45: Transmigration of tumor 
cells is dependent on tumor cell-
derived CCL2 expression. MC-38GFP 
cells were compared with MC-
38GFPCCL2kd cells for their efficiency to 
migrate through C57BL/6 endothelial cells 
in the presence or absence of monocytes. 
Statistical significance: ***=p<0.001.  
 
 
 
We next set out to identify the signaling mechanism(s), induced by CCR2 activation on 
endothelial cells, responsible for tumor cell extravasation. The CCR2 receptor has been 
identified to integrate CCL2 activation via the Janus kinase 2 (JAK2) 19, thereby activating 
downstream targets such as Stat1, Stat3 and Stat5, p38MAPK and the PI3K pathway 35, 84.  
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We first tested whether inhibition of JAK2 phosphorylation with AG490 can block tumor cell 
transmigration. Inhibition of JAK2 phosphorylation indeed blocked tumor cell transmigration, 
demonstrating the requirement of CCR2-JAK2 signaling cascade (p<0.001). We next tested 
inhibitors of Stat3 or Stat5 phosphorylation for its efficacy to block tumor cells transmigration. 
Inhibition of Stat3 (S3I-201) failed to significantly affect tumor cell migration (p=0.8), while 
inhibition of Stat5 significantly blocked tumor cell transmigration of MC-38GFP cells compared 
to untreated controls (p<0.001). This finding suggested the CCR2-JAK2-Stat5 axis as important 
for tumor cell transmigration. Whereas inhibition of the PI3K pathway (Wortmannin) did not alter 
efficacy of tumor cell extravasation, inhibition of p38 (SB202190) significantly blocked tumor cell 
extravasation (p<0.001). Therefore, the CCR2-JAK2-Stat5 and the p38MAPK pathways 
appeared to efficiently block in vitro transmigration of MC-38GFP cells through the C57BL/6 
endothelium. We next addressed, whether tumor cells would transmigrate through endothelial 
junctions or transinvade endothelial cells, which was shown to depend on Rac/Rho GTPases 85. 
However, inhibition of Rac1 (with NSC23766) failed to block tumor cell transmigration, indicating 
that tumor cell transmigration occurs via junctions in the endothelial barrier (Figure 46).  
 
Figure 46: CCL2-CCR2 mediated permeabilization 
of the endothelium is driven by JAK2-Stat5 and 
p38MAPK activation. Transmigration of tumor cells 
through an endothelial monolayer is dependent on 
JAK2-Stat5 and p38MAPK pathway. Inhibitors of 
JAK2 (AG490), Rac1 (NSC23766), Stat3 (S3I-201), 
p38MAPK (SB201290), PI3K (Wortmannin) and 
Stat5 pathway were added to the co-culture of MC-
38GFP cells with monocytes. Transmigrated tumor 
cells were counted in the lower chamber. Statistical 
significance: ***=p<0.001; **=p<0.01. 
 
 
To provide further evidence for the involvement of CCR2-JAK2 axis in tumor cell extravasation, 
I analyzed JAK2 phosphorylation in lung homogenates of tumor cell-challenged C57BL/6 and 
Ccr2-/- mice. Indeed, increased JAK2 phosphorylation was observed at 8 and 12 hrs p.i. in lungs 
of C57BL/6 mice, whereas JAK2 protein levels remained unaltered. AG490 strongly reduced 
JAK2 phosphorylation, while keeping JAK2 protein levels comparable to controls. Since 
p38MAPK is thought to be downstream of JAK2, inhibition of p38 phosphorylation with 
SB202190 did not affect JAK2 phosphorylation. Importantly, no or minor phosphorylation of 
JAK2 has been detected in Ccr2-/- mice after tumor injection proving that CCR2 expression in 
lungs is crucial to integrate and activate this signaling cascade. Similarly, p38MAPK 
phosphorylation and Stat5 activation are induced upon tumor challenge in C57BL/6 lungs 
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(between 8 to 12 hrs p.i.) and were minimal or missing in lungs of Ccr2-/- mice. Taken together, 
these data strongly indicate that both the JAK2-Stat5 and the p38MAPK pathways are linked to 
tumor cell transmigration (Figure 47).  
 
Figure 47: JAK2, p38 and Stat5 become activated in lungs of C57BL/6 but not in lungs of Ccr2-/- mice upon 
challenge with MC-38 tumor cells. Immuno-blot analysis of lung samples derived from C57BL/6 mice (untreated, 8 
hrs p.i. and 12 hrs p.i.), C57BL/6 mice treated with AG490 (JAK2 inhibitor) or SB202190 (p38 inhibitor) and Ccr2-/- 
mice (untreated, 8 hrs p.i. and 12 hrs p.i.). Left panel from top to bottom: pJAK2, JAK2, GAPDH are shown, middle 
panel from top to bottom: phospho-p38, p38 and GAPDH are shown, right panel from top to bottom: pStat5, Stat5 
and GAPDH are shown.  
 
Next, I investigated whether the observed effects of the CCR2-JAK2-Stat5 or p38MAPK 
pathway activation in C57BL/6 mice upon tumor cell injection are triggered exclusively in 
endothelial cells, in monocytes or in both cell types. I therefore challenged Tie2CCR2/Ccr2-/- 
mice (which lack Ly6Chi monocytes but express CCR2 on the endothelium) with MC-38GFP 
cells in order to see whether endothelial activation of CCR2 would suffices to induce Stat5 and 
p38MAPK phosphorylation. Phosphorylation of JAK2, Stat5 as well as p38MAPK was observed 
in lungs of Tie2CCR2/Ccr2-/- mice 8 and 12 hrs p.i. with tumor cells to a similar degree as in 
C57BL/6 mice. Therefore, JAK2 and p38MAPK phosphorylation in endothelial cells occur in the 
absence of Ly6Chi monocytes, indicating that this activation is due to CCR2 expression on 
endothelial cells (Figure 48).  
 
 
 
 
Figure 48: JAK2-Stat5 becomes phosphorylated in Tie2CCR2/Ccr2-/- mice upon tumor cell challenge. Immuno-
blot analysis of lung samples derived from Tie2CCR2C57BL/6 mice (untreated, 8 hrs p.i. and 12 hrs p.i.) and 
C57BL/6 mice (8 hrs p.i.). From top to bottom: pStat5, Stat5, pJAK2, JAK2, GAPDH are shown. 
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We next aimed at investigating the effect of JAK2, p38MAPK, Stat5, Stat3 and Rac1 inhibition in 
vivo. First we analyzed whether MC-38GFP cells increase vascular permeability in presence of 
JAK2 inhibition. Lungs of C57BL/6 mice injected with MC-38GFP cells and concomitant 
treatment with JAK2 inhibitors were analyzed for Evans blue accumulation. As previously shown 
injection of MC-38GFP significantly induced vascular permeability, resulting in blue-colored lung 
tissue. In contrast, JAK2 inhibition prevented endothelial permeability. Treatment of mice with 
Rac1 (NSC23766) and Stat3 (S3I-201) inhibitors failed to block endothelial permeability, while 
treatment with inhibitors of Stat5 and p38MAPK (SB202190) blocked or strongly reduced the 
vascular permeability induced by MC-38GFP cells. These data were confirmed by 
spectrophotometrical quantification of Evans blue in lung homogenates (Figure 49). Taken 
together, these data suggest that inhibition of Stat5 and p38MAPK signaling pathways block 
tumor cell-triggered induction of vascular permeability in vivo. 
 
 
Figure 49: Inhibition of JAK2-Stat5 and p38MAPK signaling reduces vascular permeability upon tumor cell 
challenge. Vascular permeability of lungs was tested in presence or absence of inhibitors for Stat5 (upper panel) 
Stat3 (S3I-201), pJAK2 (AG490), Rac (NSC23766), and p38MAPK (SB202190) (lower panel) at 16 hrs after 
intravenous challenge with MC-38GFP cells. Evans blue extracted from lung tissue was quantified 
spectrophotometrically (n=4, each). Statistical significance: ***=p<0.001; **=p<0.01. 
 
Having observed that endothelial CCR2 expression is essential for tumor cell extravasation, I 
investigated whether lack of CCR2 signaling in vivo would result in the deregulation of particular 
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target genes downstream of Stat5 and p38MAPK being tightly associated with the interaction 
and vascular integrity of endothelial cells. For this reason, I analyzed E-selectin, Vcam, Icam, 
Vegfa, Vegfb, Occludin, Claudin5 and VE-Cadherin expression on mRNA levels in lung tissue of 
C57BL/6 and Ccr2-/- mice 8 hrs p.i. with MC-38GFP. Indeed, I could find a significantly 
decreased induction of E-selectin and Icam expression (p<0.05) in lungs of Ccr2-/- mice upon 
tumor cell injection when compared to C57BL/6 mice (Figure 50). These data suggest the pro-
inflammatory endothelial response associated with metastasis 86 was reduced in Ccr2-/- mice. 
 
Figure 50: The inflammatory response of 
endothelial cells is altered in lungs of 
Ccr2-/- mice. Real-time PCR analysis for E-
selectin and ICAM-1 expression in lungs of 
C57BL/6 (black) and Ccr2-/- (gray) mice 8 
hrs p.i. with MC-38GFP. Each bar reflects 
the median expression resulting from three 
to four technical replicates, normalized to 
the mean expression value of the 
respective gene in C57BL/6 lungs (control). 
Data are presented in a log2 scale; (n=3). 
Statistical significance: ***=p<0.001; 
*=p<0.05.  
 
Finally, to test whether targeting phosphorylation of JAK2 and p38MAPK pathways would affect 
lung metastasis, we treated MC-38GFP-injected mice with AG490 and SB202190 during the 
first 3 dpi. Indeed both, blocking of JAK2 and p38MAPK signaling pathways, led to a significant 
decrease in tumor burden in lungs of C57BL/6 mice, as confirmed by quantification of 
metastatic foci in lungs of JAK2 and p38 inhibitor treated mice 26 dpi (p<0.05). These findings 
strongly indicate that these two pathways resemble valid therapeutic targets for blocking CCL2-
mediated tumor cell extravasation and metastasis (Figure 51).  
 
 
Figure 51: Inhibition of JAK2-Stat5 and p38MAPK signaling leads to reduced lung metastasis. Macroscopy of 
C57BL/6 lungs at 26 dpi with MC-38GFP cells of untreated control mice or mice treated with AG 490 or SB202190. 
Size of scale bar: 5mm (left panels). Quantification of metastatic foci in lungs of untreated C57BL/6 (n=4), AG490- or 
SB202190-treated mice (n=3, each). Asterisks indicate statistical significance: ***=p<0.001; **=p<0.01. 
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5.4.9 CCL2 expression correlates with metastatic potential in human colon cancer tissue 
Elevated CCL2 expression correlates with metastasis and poor prognosis in various cancer 
types, including breast, prostate and colon cancer 6, 87, 88. I therefore analyzed CCL2 expression 
in human primary non-metastasized colon tumors (UICC stages I and II) and in colon tumors 
that metastasized into the lymph nodes (UICC stage III) or into distant organs (UICC stage IV). 
RNA from these tissues was obtained from Prof. Michael Stürzl from the University Hospital 
Erlangen. CCL2 transcripts were more abundant in primary colon tumors of stages I, II and III 
when compared to healthy colon samples. However CCL2 expression was particularly high in 
colon tumors stage IV that have developed metastases in distant organs indicating that 
upregulation of CCL2 correlates with metastatic potential (Figure 52). 
 
Figure 52: Transcriptional analysis of CCL2 levels 
in tissue obtained from colon-cancer patients. 
mRNA expression levels in healthy control tissues 
(ctrl.; n=4), in tumor samples classified as stage I 
(white bar; n=10), stage II (light gray bar; n=10) both 
being non-metastatic; stage III: metastastic in lymph 
nodes (gray bar; n=10), stage IV: metastatic in distant 
organs (black bar; n=9) colon carcinomas were 
studied. Data are presented in a log2 scale. Each bar 
reflects the median expression of a gene resulting 
from three to four technical replicates, normalized to 
the mean expression value of CCL2 in control 
samples. Statistical significance: * = P<0.05. 
 
If tumor cell-derived CCL2 expression is also involved in facilitating extravasation of metastatic 
colon carcinoma cells in the human situation remains to be determined. It seems to be feasible 
to test this in an in vitro model systems using human endothelia and tumor cell lines, however, 
to determine in patients whether CCL2 mediates extravasation for at least some types of tumors 
will be very challenging. 
CCR2 IN TUMOR CELL EXTRAVASATION AND LUNG METASTASIS 
 
 
62
5.5 Discussion 
5.5.1 Tumor cell-derived CCL2 induces vascular permeability and extravasation 
This study uncovered a novel role for chemokine receptors in regulating tumor cell 
extravasation. We could show that activation of the chemokine receptor CCR2 on endothelial 
cells by tumor cell-derived CCL2 is crucial for enabling efficient tumor cell extravasation and 
metastatic colonization of the lung. Using MC-38 colon carcinoma and 3LL lung carcinoma cells 
in an experimental metastasis mouse model in chimeric, transgenic and knock-out mice we 
could define the role of tumor cell-derived CCL2 in inducing lung vascular permeability and 
facilitating extravasation into the surrounding parenchyma, recruitment of Ly6Chi monocytes and 
thereby metastasis.  
Upon injection of MC-38 cells, C57BL/6 mice displayed strong metastatic growth within the 
lungs upon tumor cell challenge, whereas metastases were significantly reduced or almost 
absent in the lungs of Ccr2-/- mice. Tumor cell-derived CCL2 controlled this extravasation 
process not only by attracting Ly6Chi monocytes but also – and even more important – by direct 
signaling via the CCL2-CCR2 axis between tumor cells and endothelial cells as tested with 
tumor cells devoid of CCL2 expression.  
During the multistep process of metastasis chemokine-chemokine receptor interactions have 
been described to have pro- or anti-tumorigenic effects 5, 42, 89. So far, the understanding of the 
involvement of chemokine receptors in metastasis was that cancer cells were shown to express 
chemokine receptors (e.g. CXCR4, CCR7, CCR9 and CCR10) 90-93 and therefore the tropism of 
cancer cell metastases was explained by chemokine production in the future host tissue. 
CXCL12, the ligand for CXCR4 was found to be expressed at high levels in the lung, liver and 
lymph nodes – organs that are frequently sites of metastases. In addition, CCL21 the ligand of 
CCR7 is expressed in lymph nodes 91, 94. However, there have been no reports so far in the 
literature that chemokine receptors are capable of deciding about the fate of tumor cells by 
allowing tumor cell extravasation and induction of vessel permeability.  
In line, the description of CCR2 expression in metastasis was mainly restricted to its expression 
on tumor cells, which was assessed in several studies. In prostate to bone metastasis, knock-
down of CCR2 on prostate cancer cells led to reduced invasion 95 and expression levels of 
CCR2 in prostate tumors correlated with aggressiveness and progression 96. Furthermore, it 
was shown that human multiple myeloma cells express CCR2, which facilitates the bone 
marrow homing of these tumor cells 97.  
The importance of CCR2 expression on endothelial cells (HUVECs and HMECs) was only 
described in the context that CCL2 is important for angiogenesis 60. Besides, several reports 
addressed the role of CCR2 expression on monocytes in tumor progression and metastasis. 
CCR2 expression on myeloid suppressor cells, which are thought to contribute to the immune 
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evasion of tumor cells, was shown to be essential for efficient migration of these cells to tumor 
sites and for tumor growth 98.  
It was shown that over-expression of CCL2 in metastatic tumor cell lines increased metastasis 
of breast cancer cells to the lung and to the bone 95. In line, elevated CCL2 levels in lungs have 
been linked to malignancy and increased metastasis in various types of cancer 6, 7, 9, 87. 
Furthermore increased infiltration with tumor associated macrophages was reported. By using 
macrophages and bone marrow cells isolated from Ccr2-/- mice it could be clarified that CCR2 
expression in these stromal cells is essential for tumor-derived CCL2 to recruit macrophages 
and to promote osteoclastogenesis – the first step to bone metastasis 96. Another study focused 
on the tumor growth and tumor infiltrating cells comparing C57BL/6 and Ccr2-/- mice. 
Interestingly, no alterations in tumor growth were observed (in a model with subcutaneous 
injections of tumor cells), however, tumors in Ccr2-/- mice seemed to be more necrotic and their 
cellular composition was altered, with more tumor infiltrating neutrophils (CD11b+Gr1+ cells) and 
less macrophages (CD11b+Ly6Chi) 99. However, the differences in the cellular composition of 
tumors in C57BL/6 and Ccr2-/- mice are not surprising considering that Ccr2-/- mice lack 
CD11b+Ly6Chi cells. In line with these data we could show increased interaction of MC-38GFP 
tumor cells with CD11b+Gr1+ (in our case Ly6G) cells in lungs of Ccr2-/- mice in the early phase 
of tumor seeding.  
A recent publication showed that CCR2+Gr1+ inflammatory monocytes are preferentially found 
in pulmonary metastases of breast tumors and not within the primary tumors 5. These cells 
facilitate metastasis via the CCL2-CCR2 axis and subsequent attraction of growth-promoting 
metastasis-associated macrophages. Depletion of tumor-derived CCL2 could attenuate 
metastatic seeding 5 – however with poor efficiency and leaving the question unanswered which 
cell type is responsible for the CCL2 production. The weak rescue in metastasis could be 
explained by the fact that treatment with neutralizing antibodies always leads to residual 
presence of the ligand, which might suffice to allow growth of some metastatic cells. Especially 
when our data are taken into account, it becomes obvious that tumor cell-derived CCL2 is 
important in the induction of vessel permeability and extravasation and knock-down or depletion 
of CCL2 must be very efficient to avoid these steps. Moreover, we could also show that 
depletion of CCR2+Ly6Chi cells with MC21 (a CCR2-depleting antibody) does not suffice to 
attenuate metastasis – most likely due to the unaltered presence of tumor cell-derived CCL2 as 
well as stromal CCR2 expression. Also in the approach chosen by Qian et al., the expression of 
CCR2 on the endothelium is unaltered and therefore it is not astonishing that metastatic spread 
at relatively high levels is still found in this model.  
We identified that increase in vascular permeability in the lung, tumor cell extravasation and 
recruitment of Ly6Chi monocytes are initiated by CCL2-expressing tumor cells at the sites of 
vascular arrest. Furthermore, initial seeding of tumor cells to the lungs appeared to be 
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independent of CCL2 expression, indicating that tumor cell-derived CCL2 is critical for the 
subsequent steps of metastasis. Increase in lung vascular permeability has also been recently 
identified as a prerequisite for lung metastasis of Lewis lung carcinoma 100. Challenging of 
C57BL/6 mice with MC-38GFP cells significantly increased lung vascular permeability as tested 
by Evans blue accumulation, while no alteration in Ccr2-/- mice was observed. 
To test the contribution of host (microenvironmental)-derived CCL2 on tumor cell extravasation 
we examined Ccl2-/- mice. Increased vascular permeability was detected both in Ccl2-/- and 
C57BL/6 mice suggesting that the contribution of host-derived CCL2 seems to be less likely. 
Our data rather demonstrated that tumor cell-derived CCL2 is sufficient for the induction of 
vascular permeability. This was further confirmed by the observation that silencing of CCL2 
expression in two different syngeneic tumor cell lines (MC-38GFP or 3LL) resulted in inability to 
induce lung vascular permeability, and as a consequence could not form metastasis. Tumor 
cell-derived CCL2 is essential for this retention of monocytes within the lungs as MC-
38GFPCCL2kd cells failed to retain Ly6Chi cells and to interact with CD11b+, F4/80+ or Ly6C+ cells 
within lungs of C57BL/6 mice. 
 
 
5.5.2 CCR2 – a chemokine receptor involved in controlling tumor cell extravasation and 
metastatic growth 
Which cellular compartment integrates CCL2 signaling through CCR2 and thereby facilitates 
tumor cell extravasation and metastasis?  
From the literature, it is obvious that human endothelial cell lines express CCR2 60 however, 
there were no reports showing that CCR2 is expressed on murine endothelial cells in the lung. I 
could confirm expression of CCR2 on endothelial cells both on histological and mRNA 
expression level in C57BL/6 mice, suggesting that CCR2 expression on endothelial cell might 
play an important role – besides Ly6Chi monocytes – in tumor cell extravasation and metastasis 
leading to the decreased metastatic tumor load in the lungs of Ccr2-/- mice. Therefore we 
examined mice expressing CCR2 exclusively on endothelial cells (Tie2CCR2/Ccr2-/- mice) – 
which resemble C57BL/6 mice depleted of Ly6Chi monocytes. In these mice the expression 
levels of Ccr2 mRNA are comparable to the levels found in pulmonary endothelial cells of 
C57BL/6 mice. Upon challenge with MC-38GFP cells, reduced but still marked metastatic tumor 
growth in the lungs of Tie2CCR2/Ccr2-/- mice was observed – emphasizing the importance of 
stromal CCR2 expression and that CCR2+Ly6Chi monocytes are important in facilitating some 
but not all steps of metastasis. Testing the induction of lung permeability in Tie2CCR2/Ccr2-/- 
mice upon tumor cell challenge using Evans blue further revealed that the induction of lung 
permeability is dependent on the expression of CCR2 on endothelial cells.  
CCR2 IN TUMOR CELL EXTRAVASATION AND LUNG METASTASIS 
 
 
65
In line, ultrastructural analyses of lungs derived from C57BL/6 and Ccr2-/- mice challenged with 
tumor cells further confirmed these data. Tumor cells failed to closely interact with endothelial 
cells in lungs of Ccr2-/- mice 12 hrs p.i. with MC-38 cells, which is necessary for allowing 
activation of the endothelium and subsequent transmigration and observed in lungs of C57BL/6 
mice at this time point. 
Next, we analyzed the contribution of CCR2+ monocytes as CCL2-dependent recruitment of 
monocytes to metastatic sites has been shown to contribute to tumor cell metastasis and to 
facilitate colonization in lung and bone 5, 62, 96. In line, I have observed significant recruitment of 
Ly6Chi monocytes in lungs of C57BL/6 mice but not in Ccr2-/- mice correlating with metastasis. 
Efficient depletion of CCR2 from inflammatory monocytes in LysMCreCcr2loxP/loxP mice without 
altering the numbers of Ly6Chi monocytes in blood and in lung tissue led to reduced numbers of 
metastases. In the early phase after tumor cell seeding a reduced recruitment of inflammatory 
monocytes was found within the lungs of LysMCreCcr2loxP/loxP mice compared to C57BL/6 mice 
confirming the data that interaction of CCR2+ monocytes and tumor cells expressing CCL2 are 
needed in this step. However, we cannot exclude that in these experiments the presence of any 
other myeloid cell type is assisting to facilitate tumor cell extravasation as a recent study 
showed that Ly6G+Ly6C+ granulocytes facilitates metastasis 101.  
Yet, the amount of metastases in LysMCreCcr2loxP/loxP mice as well as in C57BL/6 mice 
reconstituted with BM from Ccr2-/- mice was considerably higher than in Ccr2-/- mice, indicating a 
role of stromal CCR2 in metastasis. Ccr2-/- mice reconstituted with C57BL/6 BM showed 
minimal lung metastasis of MC-38GFP cells, comparable to Ccr2-/- mice. Taken together, these 
data indicate that endothelial CCR2 expression is sufficient for induction of vascular 
permeability and thereby metastasis. Moreover, these data indicate that inflammatory 
monocytes appear to be necessary but not sufficient for metastasis.  
To our knowledge, we show for the first time that endothelial CCR2 signaling facilitates and 
licenses metastasis through promoting tumor cell-extravasation. But what is the exact function 
of endothelial CCR2? We hypothesized that CCR2 on endothelial cells could resemble a “key-
lock” signal for opening the vasculature and enabling extravasation of CCL2+ tumor cells into 
the lung parenchyma. Indeed, we found that expression of CCR2 on endothelial cells is linked 
to the induction of vascular permeability. This “key-lock” relation was solely dependent on CCL2 
expression by tumor cells since MC-38CCL2kd cells failed to induce vascular permeability and 
metastasis in C57BL/6 mice. Of note, proximate interaction of CCL2 expressing colon 
carcinoma cells with the CCR2+ endothelium but not just a local CCL2 gradient is needed for 
efficient tumor cell-extravsation and subsequent metastasis, as MC-38GFPCCL2kd/MC-38 co-
injection only induced efficient metastasis of MC-38 but not of MC-38GFPCCL2kd cells.  
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5.5.3 JAK2-Stat5 and p38MAPK pathways facilitate tumor cell extravasation and 
metastasis downstream of CCR2 expressed on endothelial cells 
We established an in vitro tumor cell transmigration assay with primary pulmonary endothelial 
cells isolated from C57BL/6 and Ccr2-/- mice to delineate the molecular mechanisms of CCR2 
dependent tumor cell extravasation. Efficient tumor cell transmigration in the presence of 
monocytes was only observed through a CCR2+ endothelial monolayer while no increase in 
tumor cell transmigration was detected through a CCR2- endothelial monolayer, confirming the 
crucial role of CCR2 expression on endothelial cells. Interestingly, monocyte transmigration 
through endothelial cells was not affected by CCR2 expression, indicating that CCR2- 
endothelium per se allows cell transmigration. Moreover, in this approach tumor cells devoid of 
CCL2 expression failed to transmigrate – indicating that tumor cell-derived CCL2 is not only 
needed for retention and interaction with monocytes but as well for the transmigration through 
the endothelial barrier. These results highlight that the ability of monocytes to cross endothelial 
barriers does not affect the capacity of tumor cells to migrate and that CCR2 expression on 
endothelial cells specifically enables transmigration of CCL2+ tumor cells underlining our in vivo 
results that endothelial-derived CCR2 signaling is a major contributor to efficient tumor cell 
extravasation. 
CCR2 deficiency of endothelial cells did not allow tumor cell transmigration, indicating that this 
chemokine receptor most likely triggers a signaling which leads to opening of the endothelial 
cell layer and therefore allows passage of tumor cells.  
Several signaling pathways where shown to participate in endothelial cell activation for 
diapedesis of leukocytes during inflammation 102, 103 and some of them are pathways 
downstream of CCR2 (e.g. Stat3; PI3K) 35, 104. Therefore, we used the transmigration assay to 
test which downstream pathways could be involved in efficient tumor cell transmigration. 
Inhibition of JAK2 as well as Stat5 and p38MAPK led to efficient blockage of tumor cell 
transmigration indicating that these pathways might be involved in extravasation of colon 
carcinoma cells from blood vessels within the lung. Inhibition of PI3K, Rac or Stat3 pathway 
however did not affect endothelial transmigration.  
Testing these inhibitors in vivo, we could reproduce these findings as inhibition of either JAK2, 
Stat5 or p38MAPK pathways almost completely reduced vascular permeability upon tumor cell 
challenge. Previously, the p38MAPK pathway has been identified in endothelial cells to be 
activated by transmigrating tumor cells 105. Our data provide evidence about the upstream 
activation of p38MAPK pathway that is triggered by CCR2 and integrated through JAK2 leading 
to priming of endothelia. Western blot analysis of JAK2, Stat5 and p38 phosphorylation in 
homogenates prepared from lungs of C57BL/6 mice challenged with MC-38 cells revealed that 
these two pathways act independently of each other, since inhibition of p38 phosphorylation did 
CCR2 IN TUMOR CELL EXTRAVASATION AND LUNG METASTASIS 
 
 
67
not block Stat5 or JAK2 phosphorylation. In contrast, JAK2 inhibition blocked Stat5 but not p38 
phosphorylation. It was therefore plausible that the two identified signaling pathways originated 
from two different cell types and that the significant effects of the two inhibitors stem from a 
timely organized cascade. By challenging Tie2CCR2/Ccr2-/- mice with MC-38GFP cells and 
subsequently analysing lung tissue for Stat5, JAK2 and p38MAPK phosphorylation, I could rule 
out that both pathways are triggered by CCR2 expressed on endothelial cells as JAK2, Stat5 
and p38MAPK were activated 8 and 12 hrs after tumor cell challenge. Analysis of downstream 
targets of both pathways indicated a Stat5-dependent inflammatory-like induction of E-selectin 
and Icam-1 expression which was CCR2-dependent 86. 
Mice treated with AG490 (JAK2 inhibitor) or SB202190 (p38 Inhibitor) during the first three days 
upon MC-38GFP injection showed a significantly reduced metastasis. These observations 
indicate that targeting pathways downstream of the CCR2 receptor might have a potential 
therapeutically application in CCL2 expressing cancers. 
Based on the presented data, we propose the following model describing the involvement of 
CCR2 in metastasis (Figure 53).  
 
 
Figure 53: CCL2-CCR2 mediated tumor 
cell extravasation. This schematic model 
depicts the four steps how tumor cells may 
extravasate in a CCR2-dependent manner: 
Tumor cells attract Ly6Chi monocytes by 
secreting CCL2 (step 1) and then closely 
interact with the monocytes (step 2). 
Binding of CCL2 to CCR2 on endothelial 
cells activates the endothelium and 
triggers JAK2-Stat5 and p38MAPK 
signaling downstream of CCR2 (step 3). 
These signaling pathways lead to an 
induction of permeability of the endothelial 
barrier and tumor cells can extravasate 
presumably via local opening of tight or 
adherent junctions (step 4). 
 
 
 
 
Upon vascular arrest, CCL2 expressing tumor cells induce a local chemokine gradient that 
mediates the recruitment of CCR2-expressing inflammatory monocytes and interaction of 
monocytes and tumor cells. At the same time or subsequently, direct activation of the 
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endothelium is triggered by tumor cells through CCR2. This is required for efficient tumor cell 
extravasation, which is depends on activation of the JAK2-Stat5 or p38MAPK pathway. 
Induction of one of these signaling pathways leads to local opening of tight or adhesive 
junctions and extravasation of tumor cells facilitated by inflammatory monocytes.  
 
Elevated CCL2 levels have been previously linked to malignancy and increased metastasis in a 
number of cancers 6, 8, 9, 57, 88. The analysis of primary colon tumors (UICC stages I to IV) 
confirmed the link between CCL2 upregulation in stage IV colon carcinoma and metastatic 
capacity. Chemokines and chemokine receptors are more and more evaluated as potential 
targets for therapy in various diseases including metastasis 50, 106, 107. Further studies will be 
required to understand the temporal and spatial hierarchy of chemokine-mediated crosstalk 
between monocytes, endothelial cells and metastasizing tumor cells. Certainly, the CCL2-CCR2 
axis is just one possible chemokine-chemokine receptor axis that tumor cells utilize. 
Nevertheless, further studies will be required to identify which tumor use chemokine-chemokine 
receptor interactions for efficient tumor cell extravasation and metastasis. Our data describe 
that efficient inhibition of CCR2 or its downstream targets (JAK2/Stat5/p38MAPK) represents a 
novel, potential therapeutical strategy for preventing CCL2-mediated metastasis. 
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6 LYMPHOTOXIN’S ROLE IN INFLAMMATION-INDUCED CARCINOGENESIS 
Parts of the ‘Introduction’, ‘Material and Methods’, ‘Results’ and ‘Discussion’ section are 
reproduced or adapted from the following publications: 
 
“Lymphotoxin’s Link to Carcinogenesis: Friend or Foe? From Lymphoid Neogenesis to 
Hepatocellular Carcinoma and Prostate Cancer” 
Monika Julia Wolf, Gitta Maria Seleznik, and Mathias Heikenwalder 
Institute of Neuropathology, Department of Pathology, University Hospital Zurich, Switzerland 
Published in Adv Exp Med Biol (2011) 691:231-49 
 
“The unexpected role of lymphotoxin  receptor signaling in carcinogenesis: from 
lymphoid tissue formation to liver and prostate cancer development” 
MJ Wolf1, GM Seleznik1, N Zeller1 and M Heikenwalder1,2 
1 Department of Pathology, Institute of Neuropathology, University Hospital Zurich, Switzerland 
2 Institute of Virology, Technische Universität München/Helmholtz Zentrum München, Munich, Germany 
Published in Oncogene (2010) 29(36):5006–5018 
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J Haybaeck,1,16 N Zeller,1,15,16 MJ Wolf,1 A Weber,2 U Wagner,3 MO Kurrer,4 J Bremer,1 G Iezzi,5 
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13 University of California, San Diego and University of California, Los Angeles, USA 
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6.1 Introduction 
6.1.1. Inflammation-induced carcinogenesis 
In the last decade, several experimental and epidemiological studies have reported a tight link 
between chronic inflammation, tissue damage and the risk of developing cancer 108. However, 
only recently, the inflammatory microenvironment was indeed added as the seventh hallmark of 
cancer 108, being now generally accepted to be on eye level with self-sufficiency in growth 
signals, insensitivity to anti-growth signals, tissue invasion and metastasis, limitless replicative 
potential, sustained angiogenesis, and evasion from apoptosis, as defined by Hanahan and 
Weinberg in 2000 109 and summarized in Figure 54. 
 
Figure 54: The seven hallmarks of cancer 108. Hanahan 
and Weinberg summarized that most if not all types of 
cancer show six biologically common features acquired 
during the development of tumors. They described that 
evasion from cell death, insensitivity to growth suppressing 
signals from the surrounding tissue, self-sufficiency in 
proliferative signaling, constant formation of new vessels, 
limitless replicative potential and the capacity to invade 
adjacent tissue and to form metastases 109. Due to 
increasing knowledge that inflammation can be pro-
tumorigenic by increasing e.g. genomic instability, the 
inflammatory microenvironment is now also recognized as 
a hallmark of cancer 108. 
 
This was ultimately the result of more than 100 years of research – indeed – the concept of a 
potential link between cancer and inflammation is dating back to the second half of the 
nineteenth century when Rudolph Virchow and others made the observations that tumors often 
arise at sites of chronic inflammation, scars and wound healing 110. 
In the last few years, it became more and more obvious that chronic inflammation cannot only 
induce tissue damage and compensatory proliferation which can drive cancer development. It 
can also provide a microenvironment consisting of various mediators such as cytokines, 
chemokines, and prostaglandins possessing tumor-promoting effects by enhancing cell 
proliferation, cell survival, angiogenesis, and tumor cell migration 111. At the same time, the 
inflammatory microenvironment can as well execute immune-suppressive effects on e.g. 
cytotoxic T-cells or NKT-cells and thereby weaken the anti-tumor immune response 112, 113. 
In line, it was shown that tumors can contain immune cells, secreting various cytokines, e.g., 
TNF, IFN, IL1, IL6, IL8, reactive oxygen species (ROS), growth factors such as hepatocyte 
growth factor (HGF) and transforming growth factor  (TGF), as well as matrix-degrading 
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enzymes which unexpectedly can promote DNA damage, cell proliferation leading to pre-
neoplastic lesions or cancer 114-116.  
Due to their cellular and molecular composition, tumors are considered as “wounds that do not 
heal” and the tumor stroma was found to be similar to the tissue of healing skin wounds 117. 
Indeed, several studies revealed similarities between wound healing and tumorigenesis as both 
processes aim at the clearance of dead cells and restoration of tissue integrity 118. Even more 
interestingly, in both processes inflammatory responses are found, however in tumorigenesis, 
the inflammatory response seems to have lost its self-limiting control 119.  
Several types of cancer were shown to be preceded by chronic inflammation, which is often due 
to chronic infections; estimations assume about 15% of human cancers being associated with 
inflammation 120. Chronic hepatitis, most often caused by hepatitis B or C virus (HBV, HCV), 
was shown to lead to the development of hepatocellular carcinoma (HCC) 121-123, intestinal 
inflammation, e.g. in patients suffering from ulcerative colitis or Crohn’s disease, have an 
increased risk of developing colorectal carcinoma 124, 125, increasing with the duration and the 
severity of the inflammatory disorder 125. Gastritis, which is mainly caused by Helicobacter 
pylori, is a risk factor for the development of gastric cancer and mucosa-associated lymphoid 
tissue (MALT) lymphoma 126, 127. Furthermore, chronic inflammation due to infection with 
parasites (e.g. Schistosoma) can facilitate the development of bladder cancer 128.  
Early this year, Hanahan and Weinberg modified their description of the hallmarks of cancer by 
adding some key features that are common to many types of cancer. They note that there are 
emerging hallmarks such as deregulation of cellular energetics and avoidance of immune 
destruction. Furthermore, so-called enabling characteristics such as genome instability and 
mutation as well as tumor promoting inflammation were shown to support development and 
growth of tumors 4. 
 
 
6.1.2. Lymphotoxin and its link to inflammation 
Lymphotoxin (LT) was described and denoted as a “cytotoxic factor” in the late 1960s by Nancy 
Ruddel and colleagues. Isolated lymph node cells from rats showed cytotoxic effects on 
syngeneic or allogeneic fibroblasts in the presence of specific antigens 129, 130. 
Besides, in vitro stimulation of murine lymphocytes led to secretion of these earlier described 
cytotoxic factors into the culture medium, capable of killing various cell types (e.g., L cells, 
fibroblasts) 131, 132. LT was later isolated from stimulated lymphocytes and characterized in 
various species including mouse, guinea pig, and human 133, 134 and defined as a “lymphokine” 
being a non-antibody mediator of cellular immunity generated by lymphocyte activation 135. In 
1984, human LT was the first cytokine to be purified from a b-lymphoblastoid cell line 136 and 
thereafter its amino-acid sequence and structure were determined 137, 138. 
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The amino-acid sequence determination revealed a close relationship of LT to TNF, first 
described in 1975 as a substance causing efficient necrosis in various tumor types in vivo by 
cytotoxic activity 139. As a consequence LT was renamed into TNF 136, 137, 140. It became 
evident that these two cytokines are prototypic members of a gene superfamily, later defined as 
the TNF superfamily (TNFSF) 141. These molecules subsequently caught attention of several 
research groups using these cytotoxic, tumor necrotizing capabilities for their therapeutic 
potential in the treatment of human cancer. 
Later a third ligand – homologous to TNF – was identified within the major histocompatibility 
complex locus and named LT (TNFSF3) 142-145, as a result TNF was termed backed to LT or 
TNFSF1B. At present, 19 different ligands belong to the TNFSF, including, for example, TRAIL, 
RANKL, BAFF, CD40 146, mediating their cellular response through 29 receptors, which contain 
an extracellular cysteine-rich domain 146 and in some cases (for example, TNFR1, TNFR2, 
TRAIL R1, TRAIL R2, Fas) a death domain.  
Interestingly, besides their biochemical similarities LT, LT, and TNF (TNFSF1A) are found in 
close proximity on genomic level within the major histocompatibility complex region (mouse, 
chromosome 17 147, 148; man, short arm of chromosome 6 149, 150. 
Under physiological conditions, LT and LT are expressed by activated T-, B-, natural killer 
(NK) and lymphoid tissue inducer cells 146. LT expression is inducible in B-cells, whereas LT 
mRNA is constitutively produced 144, 151. Like most of the TNFSF ligands, LT is a type II 
transmembrane protein (intracellular N-terminus), while LT is soluble, but can be recruited to 
the cell membrane to form membrane-anchored heterotrimeric complexes with membrane-
bound LT (LT12 and LT21) 144, 152. Recently it was described that LT heterotrimers can 
also be cleaved from the cell surface by matrix metalloproteases eliciting responses on distal 
cells 153. Similar to TNF, LT can be secreted as a soluble LT3 homotrimer and bind to and 
signal via the TNF receptors TNFR1 (p55) or TNFR2 (p75) and herpes virus entry mediator 
(HVEM). LT12 exclusively and LT21 mainly trigger LTR 154, which is predominantly found 
on stromal and parenchymal cells but apparently also on myeloid cells 155. LTR signaling might 
enable the communication between lymphocytes and stromal cells, thereby influencing various 
biological processes such as lipid metabolism, proliferation, etc 154, 156-158. 
In addition LT21 was reported to bind TNFR1 and TNFR2, but this is a diminutive LT form 
expressed by T-cells (<2%) with a yet undefined biological role 154. LIGHT (TNFSF14) is an 
alternative ligand for the LTR but also interacts with HVEM 159. Figure 55 summarizes the 
above mentioned TNF and LT/LIGHT pathway. 
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Figure 55: Ligands and receptors of the 
TNF/LT system 156 
The TNF pathway is characterized by the 
expression of two receptors – TNFR1 (p55) 
and TNFR2 (p75). These receptors become 
activated by binding either LT3, TNF 
(being both secreted molecules) or 
membrane bound TNF (left). The LT/LIGHT 
pathway involves two receptors, namely 
LTR and HVEM, which can both bind 
LIGHT. Furthermore, LT and LT 
serve also as ligands for LTR.  
 
 
 
 
 
 
6.1.3. Pathways incorporating lymphotoxin signaling 
The pro-inflammatory signals from LT, LT, LTR, or other TNFSF members can be integrated 
by the transcription factor nuclear factor B (NFB) 160. Signaling via NFB is usually triggered 
in response to microbial and viral infections as well as pro-inflammatory cytokines and can 
activate the canonical (classical) or non-canonical (alternative) pathway 154. The NFB pathway 
is thought to be a major regulator of innate and adaptive immune responses, inflammation and 
homeostasis, cell survival or apoptosis, cellular stress responses, development and 
maintenance of lymphoid organs 160, 161. Figure 56 summarizes and explains the most important 
events downstream of TNFR or LTR which lead to activation of the canonical or non-canonical 
NFB pathway. Activation of the canonical NFB pathway mainly occurs in response to 
inflammatory cytokines such as TNF, and IL1, engagement of the T-cell receptor and in 
response to bacterial infection (e.g. LPS). Interestingly, LTR activation (through LIGHT or 
LT heterotrimers) can also activate the canonical NFB 162-164. 
This leads to activation of the IB kinase complex (IKK, , ) complex and degradation of IB 
inhibitors enabling the translocation of transcription factors RelA, cRel, and p50 161. The non-
canonical pathway is independent of IKK but depends on the NFB-inducing kinase (NIK) and 
IKK 165. 
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Phosphorylation of IKK by NIK results in the phosphorylation and processing of p100 leading 
to nuclear translocation of RelB/p52 dimers. Both pathways lead to the transcription of target 
genes being involved in the mediation of various biological functions 161. 
 
Figure 56: TNFR and LTR signaling pathways lead to the activation of NFB through different pathways. 
(Left): The canonical NFB pathway is induced by a large number of agonists, representatively, TNF and LT3 are 
shown. Stimulation of TNFR leads to the activation of the TAK1 complex through TRAF proteins. This leads to the 
activation of the IKK complex by phosphorylation of NEMO/IKK and IKK, which results in the phosphorylation of 
IB, its subsequent ubiquitylation and proteasomal degradation. Finally, the heterodimeric p50/RelA complex 
translocates to the nucleus, where it binds to specific B-sequences and induces the expression of target genes, 
including pro-inflammatory cytokines or genes involved in cell survival, cell proliferation and pro-carcinogenesis. 
(Right): The non-canonical pathway becomes activated by membrane-bound LT12 heterotrimers, which results in 
the activation of NFB-inducing kinase (NIK). This leads to the phosphorylation and activation of the homodimeric 
IKK complex. As a consequence, the precursor p100 becomes phosphorylated and proteasomally processed to the 
p52 subunit establishing now the RelB/p52 heterodimeric complex that translocates to the nucleus and induces the 
expression of target genes. Besides, LTR was shown to activate the canonical NFB signaling pathway. 
 
Despite the well-characterized involvement of NFB signaling in immunity and inflammation 160, 
the role of this signaling in cancer development and progression is only bit by bit revealed and 
actually very controversial 166. Only recently, two independent studies showed NFB-dependent 
activation as a molecular link between inflammation and cancer. Using a colitis-associated 
cancer model, it was shown that although the absence of IKK in intestinal epithelial cells does 
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not decrease inflammation it leads to a dramatic decrease in tumor incidence without affecting 
tumor size 167, 168. Moreover, NFB signaling was shown to drive the development of HCC in 
mice lacking multidrug resistance gene 2 (mdr2-/- mice) 169. In line, in another study constitutive 
NFB activity was found in diffuse large B-cell lymphoma indicating a role for this signaling 
pathway as a primary pathogenic event in the development of lymphoma 170. 
On the other hand, a controversial role of NFB signaling was described in mice lacking IKK 
specifically in hepatocytes 171, which display an increased HCC formation after DEN application, 
suggesting a protective, anti-carcinogenic function of canonical NFB signaling under the 
conditions of chemically-induced carcinogenesis. Interestingly, mice lacking IKK/NEMO 
specifically in hepatocytes develop steatohepatitis and HCC 172. Therefore, the role of NFB 
signaling in liver cancer development most likely depends on the mouse model and the type or 
degree of liver inflammation and injury 166. 
 
 
6.1.4 Chronic inflammation and carcinogenesis in the liver 
Within the human body the liver is the largest metabolic organ conducting several essential 
tasks to support metabolism and homeostasis to ensure the health of the individual. Key 
functions of the liver are to detoxify the body from endogenously produced or absorbed 
substances, production of complement components (involved in innate immune response), 
blood filtration as well as synthesis of amino acids and proteins (e.g. albumin). The most 
prominent cell type within the liver are hepatocytes, which are exposed to permanent cell stress 
and damaged cells have to be removed to maintain tissue homeostasis and physiological 
function. Liver homeostasis requires an efficiently regulated balance, thus it is not surprising 
that the liver has a remarkable capacity to regenerate. Complete regeneration of the liver is 
possible even if up to two-thirds of the hepatic mass is removed (e.g. partial hepatectomy) 173. 
Constantly imbalanced liver homeostasis, which can be caused by various etiologies, including 
chronic alcohol consumption, chronic drug abuse, autoimmune disorders, toxins (e.g., aflatoxin), 
or infections with hepatotropic viruses (e.g. HBV or HCV), can lead to liver disease. Continuous 
destruction and regeneration of the liver parenchyma causes chronic hepatitis, liver fibrosis, and 
cirrhosis. HBV and HCV infections are by far the most common cause of chronic hepatitis in 
humans 174. Chronic HBV and HCV infections are frequently associated with HCC 175, the most 
prevalent primary human liver cancer 176, and except for HBV infections, liver cirrhosis precedes 
HCC in most cases. The world-wide spread of HBV and HCV not only in developing but also in 
industrialized countries has led to approximately 500 million people persistently infected with 
HBV or HCV. This has resulted in a strong rise in HCC incidence 10. HCC is one of the most 
lethal human cancers, being the third leading cause of cancer-related deaths worldwide 119, 177.  
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A causal relationship between chronic hepatitis, hepatocellular damage, fibrosis, and 
carcinogenesis is well established 176. The exact mechanisms driving hepatitis-induced liver 
cancer remain elusive, however, compensatory proliferation preceded by hepatocyte cell death 
and inflammatory cell infiltration are thought to be critically involved 178. Moreover, aberrant 
expression of cytotoxic cytokines is thought to play an important role in the progression from 
hepatitis to HCC 166, 168, 179, 180. Pre-malignant hepatocytes can obtain a competitive advantage 
over normal liver cells by possessing proliferative and survival advantages that can drive 
preneoplastic lesions and hepatocarcinogenesis 181.  
In recent studies a possible involvement of LTR signaling in the host response to liver infection 
in the case of hepatitis B (HBV) and hepatitis C viruses (HCV) was investigated in vivo and in 
vitro. Increased LT expression was found in livers of HCV-infected patients especially not only 
in liver progenitor (oval) cells but also in small portal hepatocytes as well as immune cells 179. 
Besides, LT was shown to be up-regulated as a consequence of hepatitis B virus X protein 
expression in liver cell lines 180 and siRNA knockdown of various components of the LTR 
signaling pathway (e.g., LT; RelA) was shown to interfere with HCV replication in vitro 182. 
Indeed, several reports suggest an interaction of the HCV core protein with the LTR, leading to 
the modulation of the LTR signaling pathway 183-185. Results from these studies suggest that 
HCV core protein is very likely to be a modulator of the host’s immune system by enabling HCV 
to evade mechanisms of host defense 183. Moreover, cytolytic effects triggered by LTR 
signaling are aggravated by binding of HCV core protein to LTR 185, however the exact 
mechanisms of this interaction remain elusive. 
LT can directly act on hepatocytes, which physiologically express high levels of LTR but little 
LT 186. LT and LIGHT signaling from T-cells to hepatocytes controls lipoprotein homeostasis 157. 
In addition, LTR signaling was shown to be important for liver regeneration through T-cell 
derived LT expression 158 and regulates hepatic stellate cell function and wound healing 187. 
Thus, hepatic LTR signaling controls liver homeostasis in both health and disease. Moreover, it 
has recently been demonstrated that pharmacological inhibition of LTR signaling reduces 
virus-, bacteria- and concavalin A-induced liver injury 188-190. 
Promotion of HCC formation by chronic inflammatory stimuli has been recapitulated in various 
animal models. Chronic inflammation, NFB activation and signaling by members of the TNFSF 
have been shown to contribute to hepatocellular carcinoma (HCC) progression. Ablation of 
MDR2 induces spontaneous cholestatic hepatitis, elevated hepatocyte proliferation and 
subsequently HCC 169. In this study, it was shown that NFB signaling promotes HCC 
development in mdr2-/- mice and that anti-TNF treatment was protective. 
Liver-specific expression of the hepatitis B surface antigen (HBsAg) in mice demonstrates that 
chronic immune-mediated liver cell injury is critical for HCC formation 191. 
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Triggering TNFR1 or LTR induces the classical and alternative NFB signaling pathways, 
which are linked to inflammation-induced carcinogenesis 168. However, the precise role of these 
pathways in HCC pathogenesis is controversial 166. In a model of chemically-induced 
carcinogenesis, the anticipated pro-tumorigenic role of canonical NFB signaling in hepatocytes 
was confounded by the finding that mice lacking IKK only in hepatocytes (Ikkhep) exhibited a 
profound increase in hepatocarcinogenesis after diethlynitrosamine (DEN) application 171, 192, 
suggesting a protective function of IKK in HCC development. This was associated with 
augmented hepatocyte death, indicating that compensatory proliferation might be a crucial step 
in HCC development. Further, the authors describe that the absence of IKK in both 
hepatocytes and BM-derived Kupffer cells (macrophages in the liver) decreased compensatory 
proliferation and carcinogenesis. This suggests that canonical NFB activation in Kupffer cells is 
essential for the promotion of compensatory hepatocyte proliferation resulting in DEN-induced 
HCC. 
Only recently, late events of tumor progression and malignant conversion in the DEN model 
were studied by using a transplant system which allows initiated mouse hepatocytes to form 
HCC 193. In this study deletion of IKK long after tumor initiation accelerated HCC development 
in a cell-autonomous manner. Furthermore, the absence of IKK in hepatocytes was associated 
with STAT3 activation. Hepatocyte-specific ablation of STAT3 blocked HCC development, 
suggesting an interface between NFB and STAT3 signaling in the context of DEN-mediated 
HCC development.  
Other members of the IKK complex were also shown to be crucially involved in the protection or 
promotion of HCC. Ablation of NEMO/IKK in hepatocytes results in the development of 
steatohepatitis and HCC 172. In this model, spontaneous HCC development is preceded by 
steatohepatitis, increased hepatocyte apoptosis and compensatory liver regeneration. These 
findings suggest that NFB has an active role in protecting the liver from cancer and 
emphasizes the role of IKK as a tumor suppressor 172. Moreover, in this context, it was 
described that the MAP3-kinase TGF-activated kinase 1 (TAK1) suppresses a NEMO-
dependent but NFB-independent pathway to liver cancer 194. Consequently, the role of NFB 
signaling in hepatocarcinogenesis might depend on the mouse model and the type or degree of 
liver inflammation and injury 166.  
Future experiments will aim at developing new mouse models but also at investigating the 
already generated models of HCC. A major aim will be to analyze what pathological features 
those models contain and what subtypes or types of HCC they resemble when compared to 
human HCC. It remains to be determined, which of these already generated models are of 
importance for understanding hepatocarcinogenesis (especially in the human situation) and can 
potentially lead to new and effective treatments against HCC and which mouse models do only 
reflect minor sub-forms of HCC and do not have any impact for the clinics 10.  
LYMPHOTOXIN’S ROLE IN INFLAMMATION-INDUCED CARCINOGENESIS 
 
78
6.2 Scientific aims  
Lymphotoxin was shown to be important for liver homeostasis and regeneration. Involvement of 
LTR signaling in HCV replication and increased hepatic LT expression related to HBV and 
HCV infections suggested a link between virus-induced hepatitis and LT signaling. 
The goal of this project was to assess LT’s role in various cases of human chronic hepatitis and 
HCC and to characterize a mouse model over-expressing LT and LT in a hepatocyte-specific 
manner under the albumin promoter.  
I aimed to identify the expression profile of LT in various forms of hepatitis and HCC, which cells 
express LT in hepatitis and HCC and whether HCV replication can be influenced by altered LT 
signaling. 
Since mice over-expressing LT on hepatocytes develop chronic hepatitis and HCC at a late 
time point, I further characterized this mouse model on RNA and protein level.  
LYMPHOTOXIN’S ROLE IN INFLAMMATION-INDUCED CARCINOGENESIS 
 
79
6.3 Material and methods 
6.3.1 Mice 
Mice were housed under specific-pathogen-free conditions and performed animal experiments 
in accordance with the Swiss Animal Protection Law and conform to the regulations of the 
Veterinary Office (Canton Zurich). Mouse experiments were performed under licenses 
198/2007, 83/2007, and 30/2005 according to the regulations of the Veterinary Office of the 
Canton Zurich. Tg1223, tg1222, Tnfr1-/-, Tnfr2-/-, Rag1-/-, Ltr-/-, IkkAA/AA, and Ikkhep mice were 
generated as previously published 171, 195-199. 
 
6.3.2 Genotyping 
PCR specific for tg1222 and tg1223 mice: For transgenic LT the following primers were 
used: Forward primer: (Prp 5’): 5’-CTG AGT ATA TTT CAG AAC TG-3’. Reverse primer: (LT 
rev): 5’-CAG AGA AAA CCA CCT GGG AG-3’. For transgenic LT the following primers were 
used: Forward primer (Prp 5’): 5’-CTG AGT ATA TTT CAG AAC TG-3’. Reverse primer: (LT 
rev): 5’- GAG TCT CTG AGA GGC TAG AG-3’. The following PCR conditions were established 
on a Gene Amp® PCR System 9700 PCR machine (Applied Biosystems): 95°C 60 sec 
denaturation; 55°C 50 sec annealing; 72°C 50 sec elongation; 35 cycles. 
 
6.3.3 Human liver tissue 
Human liver biopsy specimens were obtained from University Hospitals Zurich, Freiburg, 
Grenoble, Heidelberg, and Graz. Biopsy specimens were registered in the respective biobanks 
and kept anonymous. The research project was authorized by the ethical committees of the 
‘‘Gesundheitsdirektion Kanton Zürich’’ (Ref. Nr. StV 26-2005), Freiburg (Nr. 299/2001), 
Heidelberg (Prof. Bannasch), Graz (Ref. Nr. 1.0 24/11/2008), and Grenoble (Ref. Nr. 
03/APTF/1). The study protocol was in accordance with the ethical guidelines of the Helsinki 
declaration. Patients were enrolled after giving their written informed consent. HBV- or HCV-
infected patients with chronic hepatitis were not treated with ribavirin or other immuno-
modulatory drugs at the time point of needle biopsy. 
 
6.3.4 RNA isolation and quantitative PCR 
RNA isolation: Total RNA from human and mouse liver samples was isolated using RNeasy 
Mini kit (Qiagen). The quantity and quality of the RNA was determined spectroscopically using a 
nanodrop (Thermo Scientific). For microarray analysis, RNA quality was tested using a 
bioanalyzer (Agilent). Purified RNA was reversely transcribed into cDNA using Quantitect 
Reverse Transcription Kit (Qiagen) according to the manufacturer’s protocol.  
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Real-time PCR: For mRNA expression analysis real-time PCR was performed using Fast Start 
SYBR Green Master Rox (Roche) or specific TaqMan probes (Applied Biosystems, AB). 
Primers were custom made by Microsynth or purchased from AB or on a LightCycler® 480 
Probes Master (Roche Diagnostics). Real-time PCR was performed on an ABI PRISM 7700 
Sequence Detection System or on a 7900 HT Fast Real-Time PCR System (AB). Data were 
generated and analyzed using SDS 2.3 and RQ manager 1.2 software. 
For human LT and LT Taqman Gene Expression assays from AB were purchased. Hu-LT: 
Hs00242739_m1 (FAM-labelled); probe sequence: 5’-GCC CAC CTC ATA GGC GCT CCG 
CTG A-3’. Hu-LT Hs00236874_m1 (FAM labeled); probe sequence 5’-ACC TCA TTG GAG 
ACC CCA GCA AGC A-3’. TaqMan analysis for human 18S rRNA was performed with a 
TaqMan® ribosomal RNA control reagent (VICTM Probe; AB; Part. No. 4308329). mRNA 
expression levels were normalized to the housekeeping gene GAPDH (mouse) or 18S rRNA 
and HPRT (human). Further primers used are listed in the following table. Efficiency of DNase 
digest was controlled by PCR of DNase+RT- treated liver RNA samples. 
 
6.3.5 Histology and immunohistochemistry 
Paraffin sections (2μm) and frozen sections (5 or 10μm) of livers were stained with 
haematoxylin/eosin or various primary and secondary antibodies. Paraformaldehyde (4%) fixed 
and paraffin embedded liver tissue was incubated in Ventana buffer and staining was performed 
on a NEXES immunohistochemistry robot (Ventana instruments, Switzerland) using an IVIEW 
DAB Detection Kit (Ventana). Antibodies against B220+ B-cells (Pharmingen; 1:400), F4/80 
(Serotec, 1:50) for macrophages, CD4+ (YTS 191; 1:200) and CD8+ T-cells (YTS 169; 1:50), 
CD3+ T-cells (clone SP7, Neomarkers; 1:300) were kindly provided by R. Zinkernagel 68. Anti-
murine GP73 (both Santa Cruz Biotechnology, Inc.) and anti-murine Glutamine Synthetase 
(Abcam, Code ab16802; 1:500) were used as tumor markers. Liver microarchitecture was 
evaluated by Collagen IV (IVIEW DAB Kit; 1:50), oval cell proliferation by A6 staining (1:50), 
kindly provided by Dr. Valentina Factor; both on a Ventana stainer from Roche. Ki67 
(NeoMarkers Code RM-9106-S; 1:200) stained proliferating hepatocytes and lymphocytes. 
Image acquisition was either performed on an Axiophot-microscope (Zeiss), or an Olympus 
SZX12, equipped with a JVC digital camera (KY-F70; 3CCD) or on an Olympus BX61TRF 
fluorescent microscope equipped with an F-View camera and analyzed with the Analysis 
software. 
 
6.3.6 Extraction of human liver cells and freezing 
For the isolation and analysis of liver cells we included six patients with histologically proven 
HCC who had undergone curative hepatectomy and proven persistent HCV infection in the 
University Hospital, Grenoble. 
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Exclusion criteria included co-infection with human immunodeficiency virus, hepatitis B or 
hepatitis delta virus other causes of liver disease, alcohol consumption higher than 30g/day, 
inflammatory syndrome, previous antiviral treatment and previous liver transplantation. Liver 
and tumor tissues derived from curative hepatectomy were washed twice in a complete 
medium, containing RPMI 1640 supplemented by 10% Fetal Calf Serum (Gibco), and 
continuous shaking for 2 min. Tissues were cut into pieces with in Petri dishes containing 10ml 
complete medium and 100μl DNase (3mg/ml) (Boehringer Mannheim). 10% collagenase D 
(10mg/ml) (Roche Diagnostic Germany) was added and incubated for 20 to 30 min at 37°C. Cell 
suspensions were then filtered (100μm mesh) and 10% of fetal calf serum (FCS) was added in 
the final volume and then centrifuged at 15000 rpm twice to remove debris. The cells were then 
counted with a hemocytometer and stored in 10% DMSO in liquid nitrogen or on -80°C. 
Cell sorting of human liver cells requires large numbers of cells and thus was conducted only on 
pieces of liver tissues derived from surgical resections. Liver specimens from healthy and 
untreated donors are extremely rare and reserved, in case they are accessible, to liver 
transplantation. It was therefore not possible to obtain larger pieces of healthy livers, since 
ethical concerns exclusively allow preservation of healthy donor livers for transplantations in a 
medically precisely indicated setting. Therefore, for healthy livers only mRNA could be isolated 
via liver needle biopsies. The amount of this material sufficed for various analyses but was not 
sufficient for cell sorting. 
 
6.3.7 Separation of CD45+ and CD45- cells by microbeads 
Frozen cell suspensions were thawed and viability was checked by Acridine/propidium iodide 
with the help of fluorescent microscope and the percentage of living cells was quantified. 
Leukocytes numbers were then counted with a hemocytometer. Cell sorting was performed as 
previously described 200 with the following modifications: Cells were incubated with a 
biotinylated antihuman CD45 antibody (BD Pharmingen) (1μl of anti CD45 for 1×106 of target 
cells) for 20 min on ice and in dark followed by a washing step with 10 volumes of PBS to 
remove unbound antibody. Then the cells were incubated with streptavidin-coupled microbeads 
(Invitrogen, Norway) in PBS with 0.1% BSA and 2mM EDTA, pH 7.4 for 30 min at 2-8°C with 
gentle tilting and rotation according to the manufacturer instructions (50μl of microbeads for 
2.5×106 target cells). Cells were then separated into two fractions with a magnetic column i.e. 
one with cells bound to microbeads (leukocytes) and the second fraction consisting of unbound 
cells (hepatocytes, tumor cells and others). After performing additional washing steps to remove 
trapped liver or tumor cells, cells were eluted from the column. Both cell fractions were then 
used for RNA extraction. 
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6.3.8 Cell culture with HCV replicon cells 
EN5-3+ 201 cells were cultured in DMEM containing 10% FCS and G418 (Sigma). Cells were 
transfected with 10µM siRNA against LTR (Santa Cruz) or LT (Sigma) using Oligofectamine 
(Invitrogen) according to the manufacturer’s protocol. For experiments triggering LTR 
signaling, EN5-3+ cells were split and plated in 6 wells plates and left over night. LTR peptide 
(Santa Cruz) or IFN (R&D Systems) was added at various concentrations. 72 hrs after 
transfection or addition of the peptide, cells were lysed and RNA was isolated using RNeasy 
Mini Kit (Qiagen). Real-time PCR analysis for LT, LTR and HCV was carried out as described 
in section 6.3.4 
 
6.3.9. Infectious HCV experiments 
For cytokine/chemokine expression Huh7.5 202 was challenged with HCVcc 203. After 48 and 72 
hrs, cells were lysed, RNA was isolated and real time PCR analysis was carried out. For HCV 
replication experiments, Huh7.5 and Huh7-Lunet 204 cells were transfected with Con1 luciferase 
construct as described previously 205. Luciferase counts were measured after 72 hrs 205. BS1 
antibody (Biogen Idec) or LTR peptide (Santa Cruz) were added at various concentrations 4 
hrs post-transfection. 
 
6.3.10 Western Blot analysis 
Liver homogenates (10%) were prepared in RIPA buffer (50mM Tris; 1%NP40; 0.25% 
Deoxycholic acid sodium salt; 150mM NaCl; 1mM EGTA) containing 1mM Na3VO4 and a 
protease inhibitor cocktail (Complete Mini Tablets; Roche) and quantified with a BCA protein 
assay kit (Pierce) according to the manufacturer’s manual. 60μg protein were denatured in 
Laemmli buffer containing 5% β-mercaptoethanol and separated by gel electrophoresis on a 
12% Bis-Tris gel (Invitrogen) with a 1x NuPAGE MES-SDS running buffer (Invitrogen) and 
blotted by wet blotting onto a nitrocellulose membrane (Protran BA 85 pore size 0.45μm; 
Whatman). After blotting the membrane was blocked in Roti-Block (Carl Roth) for 2 hrs at RT. 
Primary antibody GP73 (sc-48011; Santa Cruz; 1:500 dilution) was incubated at 4°C over night 
under shaking conditions. Incubation with the secondary antibody (HRP-donkey anti goat IgG 
H+L; 705.035-147 Lot72963; 1:15000; Jackson) was performed under shaking conditions for 1 
hr. Primary antibody AFP (#2137; Cell Signaling; 1:500 dilution) was incubated at 4°C over night 
under shaking conditions. 
Detection was achieved with SuperSignal West, Chemiluminescent Substrate (Pierce). For 
signal detection a VersaDoc, standard exposure 15-30 sec was used. To assure equal loading, 
the membranes were re-probed with anti-β-actin antibody (Sigma) and detected as described 
above. 
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6.3.11 ELISA 
CXCL10 protein levels from liver homogenates or sera were measured using a Quantikine-
Elisa-Kit from R&D Systems. The procedures closely followed the manufacturer’s instructions. 
The detection limit was 16pg/ml. The homogenization buffer was tested as a negative control. 
 
6.3.12 Cytokine assay for TNFα 
Livers were homogenized with a Dispomix (Medic tools) in 10 vol of Tris-HCl buffer (50mM, pH 
7.4) with NaCl (0.6M), Triton X-100 (0.2%) and bovine serum albumin (0.5%) containing freshly 
dissolved protease inhibitors: benzamidine (1mM), phenylmethyl-sulfonyl fluoride (0.1mM) and 
Complete Mini Tablets (protease inhibitor cocktail Tablets; Roche). The supernatants were 
aliquoted and frozen at -80°C until the cytokine assays were performed. Profiling mouse kit for 
TNFα was purchased from R&D Systems. The procedures closely followed the manufacturer’s 
instructions. The analysis was conducted using a conventional flow cytometer (LSRII from 
Becton Dickinson). The detection limit for TNFα was 0.4pg/ml. 
 
6.3.13 Multiplex-bead assay 
Cytokine protein levels from liver homogenates or sera were measured using a multiplexed 
particle-based flow cytometric cytokine assay 206. Bioplex mouse cytokine kits were purchased 
from BioRad. The procedures closely followed the manufacturer’s instructions. The analysis 
was conducted using a conventional flow cytometer (FC500 MPL, BeckmanCoulter). Detection 
limits were as follows: CCL2 (12pg/ml), CXCL1 (1pg/ml), IL1β (0.3pg/ml), IL6 (0.3pg/ml), IFN 
(2.8pg/ml). The homogenization buffer was tested as a negative control. 
 
6.3.14 TNF and 3C8 treatment 
Twelve to fourteen-week-old male mice (C57BL/6 and knock-out mice) were intravenously 
injected with either PBS, murine recombinant TNF (50 mg/kg bodyweight; R&D Systems), 
agonistic LTR antibody (50 mg/mouse; clone 3C8; eBioscience), or rat IgG (50 mg/mouse; 
eBioscience) and sacrificed for analysis 45 min after injection. All substances were injected at a 
total volume of 100 ml dissolved in PBS. 
 
6.3.15 Measurement of aminotransferases 
The analysis for AST and ALT was performed with mouse serum on a Roche Modular System 
(Roche Diagnostics) with a commercially available automated colorimetric system at the 
Institute of Clinical Chemistry at the University Hospital Zurich using a Hitachi P-Modul (Roche). 
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6.3.16 Analysis of different HCV genotypes 
Different HCV genotypes were analyzed as recently published 207. 
 
6.3.17 mRNA microarray experiment of liver samples 
Gene expression microarray experiment and data analysis: An Agilent one-color 
microarray-based gene expression analysis (Mouse DNA Microarray 4x 44K) was performed on 
3 and 9 month-old tg1223 (n=4) and Ikkhep (n=4) livers in comparison to age matched 
C57BL/6 livers (n=3). For HCC arising in 12 or 18 month-old tg1223 (n=3) or tg1223/tnfr1-/- (n=4) 
liver tissue was compared to non-affected tg1223 (n=3), non-affected tg1223/tnfr1-/- (n=4) liver 
regions as well as age matched C57BL/6 livers. In addition to biological replicates technical 
replicates were investigated. 
RNA was extracted from liver tissue using the RNeasy Mini kit (Qiagen). RNA quality was tested 
on a Bioanalyzer (Agilent), only samples with RNA integrity index (RIN) of at least 7.45 were 
used for further analysis. For microarray, 600ng of RNA were used and prepared according to 
the manufacturer’s protocol. For further analysis only those samples with a yield of at least 2 g 
were accepted. Dye incorporation rate – calculated as 1000x (pmol/l divided by ng/l) – was 
between 9.0 and 14.3pmol/ng.  
Gene expression was quantified using Agilent Feature Extraction Software Version 9.5.3.1. 
Expression values were imported into GeneSpring 7.3 (Agilent Technologies, USA) and 
following Agilent’s recommendation, all values less than 5.0 were set to a value of 5.0. For each 
sample all values were normalized to the respective 50th percentile. In case of the 
characterization of the tg1223 and Ikkβhep liver samples at 3 and 9 months of age, hierarchical 
clustering and principal component analysis of the normalized values indicated a slight 
confounding effect based on different dates for the hybridization of the different samples. In 
order to compensate this effect, for each gene on each array, the expression values were 
normalized to the median of the values obtained from the C57BL/6 control samples on the 
respective day, giving rise to ratio values. Those genes were filtered out that did not have at 
least 75% present flags in at least one of the C57BL/6, tg1223 or IkkβΔhep conditions at 3 or 9 
months. Assuming normal distribution of the data, statistically significant, differentially 
expressed genes in tg1223 or IkkβΔhep livers were selected using a one-sample t-test that 
assessed whether the respective ratios did significantly differ from 1. The false discovery rate 
was controlled at a level of 0.05 using the method of Benjamini and Hochberg. 
Gene Ontology microarray data analysis: Lists of significantly differentially expressed genes 
were investigated in respect to enrichment of Gene Ontology categories using the Gene 
Ontology Browser as implemented in GeneSpring 7.3. A Fisher’s exact test was used to show 
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whether more genes belonging to a Gene Ontology category are found in the list under 
investigation than in a randomized gene list of the same size. 
Accession numbers: Gene expression microarray data are deposited in the ArrayExpress 
database under accession number E-MEXP-1998. 
 
6.3.18 Counting of proliferating hepatocytes 
The total number of Ki67+ hepatocytes was counted (number of Ki67+ hepatocytes / visual field 
of 2 mm2). For each mouse/ genotype (n=8) 10 visual fields were counted. Statistics was 
performed (tg1223 versus C57BL/6 mice). 
 
6.3.19 Statistical analysis 
Human specimens and various mouse groups were compared using a one-way ANOVA with 
post-hoc Bonferroni test and a Fisher’s exact test with Bonferroni correction and a chi-square 
test with exact P-values to evaluate statistical significance. 
Analyses were evaluated by using the program SPSS 13.0 (SPSS Inc., Chicago, IL). Student’s 
t-test was used to evaluate the statistical significance of hepatic cytokine and transaminase 
levels.  
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6.4 Results 
6.4.1 Up-regulation of LT, LT, and LTR in HBV- or HCV-infected human livers and in 
HCC 
The role of LT signaling in the pathogenesis of virus-induced hepatitis and HCC formation has 
remained elusive. Together with Johannes Haybäck, I analyzed transcriptional levels of various 
members of the TNFSF (LT, LT, LIGHT, TNF, LTR, and TNFR1) in biopsies of human 
HBV- or HCV-induced chronic hepatitis and HCC or in non-viral HCC and compared them to 
healthy liver specimens (Figure 57).  
 
 
Figure 57: Analysis of hepatic LT, LT, LTR, LIGHT, TNFR1, and TNF transcription by real-time PCR. 
Healthy individuals (Ctrl; n=15), patients chronically infected with HBV (n=19) or HCV (n=49), affected by HCC 
(n=30), or suffering from various non-virus related liver disorders were investigated. Non-virus related liver diseases 
with hepatitis include alcoholic steatohepatitis (ASH; n=13), cholestasis (CH; n=3), primary biliary cirrhosis/ 
autoimmune cholangitis (PBC; n=5), end-stage liver cirrhosis due to alcoholic liver disease (CIR; n=8), a1-antitrypsin 
deficiency (a1AT; n=1), and focal liver fibrosis (FLF; n=2). Non-virus related liver diseases without hepatitis include 
steatosis (ST; n=5), hemochromatosis/siderosis (HE/SID; n=3), and Wilson’s disease (WD; n=1). Focal nodular 
hyperplasia (FNH; n=8) was investigated as a benign primary liver tumor. Diseases such as a1AT (black circles), FLF 
(black triangles), HE/SID (black diamonds), and WD (white diamonds) are listed under ‘‘other liver diseases’’ (OLD). 
Horizontal bars represent the average mRNA expression level. The y axis describes the CT values on a log2 
scale. Asterisks indicate statistical significance: * p≤0.05; ** p<0.001; *** p<0.0001 
 
LT, LT, and LTR mRNA expression was dramatically increased, on average, ~27 to 210 fold 
in HBV- or HCV-induced hepatitis and HCC (p<0.001); LIGHT transcripts were less, but still 
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significantly, elevated (on average, ~23 to 25 fold; p<0.001). Likewise, TNFR1 mRNA expression 
was significantly increased in HBV- or HCV-induced hepatitis and HCC (on average, ~27 to 29 
fold; p<0.0001). In contrast, TNF was only slightly up-regulated in HBV-induced hepatitis 
(p=0.04) but not in HCV-induced hepatitis (p=0.3) and HCC (p=0.4). 
To determine whether up-regulation of LT and its receptors was specific for HBV- and HCV-
induced liver diseases, Johannes Haybäck and I examined transcript levels in biopsies from 
non-viral liver diseases. These included liver disorders with hepatitis (alcoholic steatohepatitis 
[ASH], cholestasis [CH], primary biliary cirrhosis/autoimmune cholangitis [PBC], and end-stage 
liver cirrhosis due to alcoholic liver disease [CIR]) and liver diseases without inflammation 
(steatosis [ST] and focal nodular hyperplasia [FNH]). Additionally, other liver diseases (OLD), 
such as hemochromatosis/siderosis, Wilson’s disease, focal liver fibrosis, a1-antitrypsin 
deficiency (Figure 57), and non-viral HCC (NVH; Figure 58) were investigated. 
Levels of LT, LT, and LTR mRNA were significantly lower in all non-viral liver diseases 
analyzed except NVH, compared with virus-induced chronic hepatitis and HCC (LT, p<0.0001; 
LT, p=0.05; LTR, p<0.0001).  
 
Figure 58: mRNA expression 
levels of various members of 
the TNFSF in non-virus related 
HCC. Real-time PCR analysis for 
LT, LT, LIGHT, LTR, TNF 
and TNFR1 transcripts in non-
virus related HCC (NVH). Each 
symbol represents one individual 
patient. Horizontal bars represent 
the average LT or LT mRNA 
expression level. The y-axis 
describes the ΔΔCT values on a log2 scale. Ctrl: healthy control liver tissue. NVH: HCC without HBV or HCV 
infection.  
 
This was irrespective of non-viral liver diseases being associated with inflammation. LIGHT and 
TNFR1 mRNA expression in non-viral liver diseases including NVH was similar to HBV- or 
HCV-induced chronic hepatitis and HCC. In contrast, TNF mRNA expression was significantly 
higher in non-viral liver diseases with inflammation and NVH, compared with healthy livers 
(p<0.0001), HBV- or HCV-induced hepatitis and HCC (p<0.0001). 
 
In most cases, HCV genotype, degree of inflammation (Knodell score), fibrosis (Metavir score), 
and liver enzyme levels (ALT; AST) were assessed. 
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No significant correlation between patient age (p=0.05) or gender (p=0.05) and the expression 
levels of LT, LT and LTR mRNA was found (Figure 59). 
 
Figure 59: Correlation analysis of LT and LT expression in HCV-infected livers with patient age. LT (left) or 
LT (right) mRNA expression levels for individual patients are presented as a ΔΔCT values on a log2 scale (y-axis) 
with horizontal bars representing the average. Patients were ranging from the 3rd to the 8th decade (x-axis). 
 
 
Furthermore, levels of LT and LT mRNA did not correlate with the degree of liver 
inflammation (p=0.5) as assessed with Knodell score for HCV-infected patients or fibrosis 
(p=0.5) (classified with Metavir score). Also HCV genotype or type of virus infection (HBV, HCV, 
HBV/HCV co-infection in the case of some HCC did not show any correlation with LT and LT 
expression levels (p=0.5) (Figure 60). 
 
Figure 60: Correlation analysis of 
LT and LT mRNA expression 
with inflammation, fibrosis score 
and HCV genotype in HCV infected 
patients. LT (left) and LT (right) 
mRNA expression levels did not 
correlate with Knodell score (for 
inflammation; ranging from 0-16; 
upper row), with fibrosis score 
(Metavir; ranging from 0-4; middle 
row) and HCV genotype (lower row) 
in HCV-infected livers. Each symbol 
represents one individual patient. 
Horizontal bars represent the average 
LT or LT mRNA expression level. 
The y-axis describes the ΔΔCT 
values on a log2 scale.  
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6.4.2 Increased chemokine expression in HBV- or HCV-induced hepatitis and HCC 
To confirm that pro-inflammatory signaling cascades are activated during HBV- or HCV-induced 
hepatitis and HCC formation, chemokine mRNA levels were measured (Figure 61). 
CCL2, CCL3, CCL5, and CXCL10 mRNA expression was significantly higher in human HBV-
induced (p<0.0001) or HCV induced (p<0.0001) hepatitis and HCC (p<0.0001) than in healthy 
controls. CXCL1 mRNA expression was significantly increased in HBV-induced hepatitis 
(p<0.0001) and HCC (p=0.02), but not in HCV-induced hepatitis (p=0.07). 
 
 
 
Figure 61: Analysis of CCL2, CCL3, 
CCL5, CXCL1 and CXCL10 mRNA 
expression by real-time PCR in 
human liver biopsies. Healthy controls 
(n=15), patients chronically infected with 
HBV (n=19) or HCV (n=49) and patients 
suffering from HCC (n=30) were 
analyzed. Horizontal bars represent the 
average mRNA expression level. The y-
axis describes the ΔΔCT values on a 
log2 scale. 
 
 
 
 
6.4.3 Up-regulation of LT, LT and LIGHT in human hepatocytes upon in vitro HCV 
infection 
Next, I investigated whether LT, LT, LIGHT and LTR transcripts can be up-regulated in 
hepatocytes as a consequence of viral infection. Together with Prof. Dr. Thomas Pietschmann 
and Dr. Sandra Ciesek at the Twincore Center, Hannover, the human hepatocyte cell line Huh-
7.5 202 was challenged with infectious, cell culture derived HCV (HCVcc) 203, and expression of 
selected cytokines and chemokines was measured (Figure 62).  
At 48-72 hrs post infection, I found that transcripts of LT (p=0.05), LT (p=0.05), LIGHT 
(p=0.05), LTR (p=0.05), and chemokines (CCL2, CCL3, CXCL1, and CXCL10) were increased 
(2- to 32-fold) in HCVcc-infected, compared with non-infected Huh7.5 cells. 
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Figure 62: HCVcc infection of human 
hepatocytes in vitro up-regulates several 
chemokines and cytokines. Real-time PCR 
analysis for the mRNA expression of LT, 
LT, LIGHT, LTR, CXCL1, CXCL10, CCL2 
and CCL3 in a human hepatocyte cell line 
upon challenge with infectious HCVcc at 48 
and 72 hrs post infection compared to non-
infected Huh7.5 cells. Horizontal bars 
represent the average mRNA expression 
levels. The y-axis describes the ΔΔCT values 
on a log2 scale.  
 
 
 
 
 
6.4.4 Identification of liver cells expressing LTR and its ligands in HBV or HCV 
infections 
Having observed with the previously described infection experiment that stromal cells, in this 
case a human hepatocytic cell line, are capable of producing LT and LT, I planned to identify 
the cellular source of LT, LT, LTR, and LIGHT expression in human HCV-infected livers. 
Therefore, with the help of Dr. Patrice Marche from the University Hospital Grenoble, 
lymphocytic cells were collected from fresh, curative resections derived from patients with HCV-
induced hepatitis and HCC with HCV etiology (further denoted as HCV/HCC).  
The following representative images should first give an overview of the obtained material from 
the curative hepatectomy (Figure 63). 
 
 
Figure 63: H&E staining of paraffin sections of HCV-infected livers, HCC with HCV etiology and healthy 
controls. HCV-infected livers (HCV) and tumors (HCV/HCC) display leukocyte infiltration. The tumor border is 
indicated by a dashed line (scale bar, 100m). 
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Compared to healthy control tissue, samples from HBV- or HCV-infected patients as well as 
HCC-derived samples display increased infiltration of the liver with immune cells (CD20+ B-cells 
and CD3+ T-cells; Figure 64).  
 
Figure 64: Immunohistological analysis of 
human healthy controls, HBV- and HCV-
infected livers or HCC. H&E staining and 
staining for CD20 (B-cells) and CD3 (T-cells) was 
performed. H&E staining indicates morphological 
features of inflamed and fibrotic liver tissues 
(HBV- and HCV-infected livers). HCC display 
transformed hepatocytes. The HCC border zone 
is indicated by a dashed line (upper row, right 
column). Inflammatory infiltrates were detected in 
HBV- or HCV-infected livers as well as at the 
border zones of HCC (scale bar: 100μm). 
 
To determine the cell types responsible for LT and LTR up-regulation, liver cells were sorted 
according to their CD45 surface expression, resulting in CD45-enriched (T-, B- and NK-cells; 
monocytes, macrophages, Kupffer cells; dendritic and cells) or CD45-depleted (hepatocytes, 
oval cells and bile duct epithelial and endothelial cells) fractions. Purity of these fractions was 
assessed by real-time PCR for lymphocyte (CD3, CD20, and CD45) or hepatocyte (cytokeratin 
18) markers (Figure 65).  
 
 
Figure 65: Real-time PCR analysis for CD45 and Cytokeratin 18 expression on CD45-sorted liver cells. To 
quantify the purification efficiency of CD45-enrichment or CD45-depletion, cells were prepared from HCV-infected, 
inflamed livers (HCV) or from HCC with HCV etiology (HCV/HCC). Horizontal bars represent the average mRNA 
expression level. The y-axis describes the relative expression in percentage normalized to healthy controls. 
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CD45-depleted fractions displayed only a minor contamination with CD45 mRNA (~1%–10%), 
and CD45-enriched fractions showed only a minor amount of cytokeratin 18 mRNA transcripts 
(~2%–20%). Unsorted liver cells of healthy individuals were included as controls. Because of 
ethical consideration, not enough human healthy liver tissue was available in order to perform 
cell sorting. 
Within HCV-induced HCC, CD45-enriched and -depleted liver cells expressed similar LT and 
LT mRNA levels (LT, p=0.8; LT, p=0.1) that were significantly higher than in controls 
(p<0.0001) (Figure 66).  
 
 
Figure 66: Identification of cell types expressing members of LT signaling pathway. Real-time PCR analysis of 
sorted, CD45-enriched or CD45-depleted liver cells. For control, whole liver cell populations derived from healthy or 
diseased livers (HCV infected/HCC) were used. mRNA expression levels are normalized to unsorted, total cell 
populations of the respective liver disease and calculated as 100%. The average expression level is indicated as 
percentage of control (unsorted cells of the respective disease) and demarcated by horizontal bars. Asterisks indicate 
statistical significance (Student’s t test): *p< 0.05; **p < 0.001; ***p < 0.0001. 
 
LTR transcript levels were significantly higher in CD45-depleted cells, compared with CD45-
enriched cells (p=0.006) or controls (p<0.0001). In contrast, LIGHT mRNA expression was 
significantly increased in CD45-enriched cells when compared to CD45-depleted cells (p=0.008) 
or controls (p=0.0007). 
Within HCV-induced hepatitis, CD45-enriched cells exhibited a trend toward increased LT 
mRNA levels (p=0.089) and a significant increase in both LT and LIGHT transcripts, compared 
with CD45-depleted cells (LT, p=0.006; LIGHT, p=0.01), or controls. Similar to HCV-induced 
HCC, LTR mRNA expression was significantly higher in CD45-depleted cells than in CD45-
enriched cells (p=0.002) or controls (p<0.0001). 
Thus, both CD45-enriched and CD45-depleted cell fractions express LT, LT, and LIGHT in 
HCV-induced hepatitis and HCC. Our analysis revealed that most likely the hematopoietic non-
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parenchymal cells express more LT when compared to the parenchymal compartment. 
Immunohistochemical and immune-fluorescent analysis for LT confirmed these data as CD3+ 
and CD20+ lymphocytes as well as hepatocytes in HBV- or HCV-induced hepatitis and HCC - 
but not in healthy liver specimens - express LT protein (Figure 67). 
 
Figure 67: LT is expressed by B-cells, T-
cells and hepatocytes.  
Immunohistochemical (upper and lower 
panels) and immunofluorescent analysis 
(middle panels) for LT expression in 
healthy, HBV- or HCV-infected and HCC-
affected livers (scale bar, 50m). Arrowhead 
depicts LT+ leukocytes and arrows depict 
LT+ hepatocytes. 
 
 
 
 
 
6.4.5 LTR signaling directly influences HCV replication 
Having observed that in situations of chronic infection with HCV, not only lymphocytes express 
LT, but also hepatocytes up-regulate LT expression levels, I next wanted to address the 
question, whether LT signaling has a direct influence on HCV replication. These experiments 
were performed using a liver cell line (Huh7) that is stably transfected with a subgenomic HCV 
replicon 201. The HCV construct contains only non-structural parts of HCV genotype 1b, which 
are non-infectious, and replication can be tested by quantitative PCR for HCV. Figure 68 shows 
the organization of the subgenomic HCV replicon.  
 
 
Figure 68: HCV subgenomic construct used for studying LTR signaling and HCV replication. The HCV 
genotype 1b construct contains the non-structural proteins of HCV (NS3, NS4A, NS4B, NS5A and NS5B), and a tat-
2A-neo cassette, containing a neomycin resistance (Neo), FMDV2A proteinase (foot-and-mouth disease virus 
polypeptid possessing autocatalytic activity resulting in the release of Neo) and HIV tat protein (transcriptional 
transactivator).  
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In a first set of experiments, I tested whether silencing of LT or LTR would inhibit HCV 
replication. For LT, I could reproduce the findings from Ng et al, who showed that HCV 
replication is decreased, when LT is transiently silenced using siRNA. When LTR is knocked-
down in the replicon cells, HCV replication could be also decreased, meaning that LT signaling 
most likely influences the extent of HCV replication in an infected cell in a dose-dependent 
manner (Figure 69). 
 
 
Figure 69: HCV replication 
is suppressed when LT 
or LTR expression levels 
are decreased. Replicon 
cells were transfected with 
siRNA for LT (upper row) 
or LTR (lower row) and 
expression levels of HCV 
mRNA were assessed by 
real time PCR after 72 hrs. 
Statistical significance: * = 
p<0.05. 
 
 
 
For comparison, I investigated how strong the inhibitory effects of blocking LTR signaling on 
HCV replication are, cells were treated with IFN, which leads to an efficient inhibition of HCV 
replication (Figure 70).  
 
 
Figure 70: HCV replication is suppressed after IFN treatment. 
HCV replicon cells were treated with IFN (50 U/ml and 100 U/ml) 
for 72 hrs and expression levels of HCV mRNA were assessed by 
real time PCR after 72 hrs. Statistical significance: *** = p<0.001; 
n.s. = not significant 
 
 
 
 
As a next step, I tested whether increased LT signaling would also lead to increased HCV 
replication. Therefore, I used a small 20 amino-acid peptide, which binds between aa25 and 
aa75 to LTR, a region which is thought to lead to oligomerization of LTR. Interestingly, 
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addition of this peptide to the medium led to a strong increase in HCV replication over time 
(Figure 71).  
 
Figure 71: Agonistic stimulation of LTR leads to an 
increase in HCV replication. HCV replicon cells were treated 
with a peptide binding to LTR (200ng/ml and 1000ng/ml) for 
72 hrs and expression levels of HCV mRNA were assessed 
by real time PCR after 72 hrs. Statistical significance: * = 
p<0.05; n.s. = not significant. 
 
 
 
Having observed that HCV replication can be influenced by modulating LTR signaling in a non-
infectious setting, I next studied whether these findings could be reproduced using fully 
infectious HCV. Again, these studies were performed in collaboration with Prof. Dr. Thomas 
Pietschmann and Dr. Sandra Ciesek from the Twincore Center, Hannover.  
In a first experiment, we used the LTR peptide and assessed the replication of HCV-Con1, a 
full length genotype 1b replicon in Huh7.5 cells, a clone of the human hepatoma cell line Huh7. 
Assessing HCV replication after 72 hrs showed that also in this infectious setting an 
approximately 5-fold increase in HCV replication was found (Figure 72). 
 
 
Figure 72: HCV genotype 1b replication can be increased 
by agonistic stimulation of LTR signaling. Huh7.5 cells 
were electroporated with HCV-Con1 and treated with various 
concentrations of LTR peptide (0.1-2g/ml). HCV replication 
was assessed by measuring luciferase counts after 72 hrs.  
 
 
 
 
These findings could be reproduced in an experiment using HCV-Con1 infection in Huh7.5 and 
in Lunet cells – which is another clone of Huh7 being highly susceptible to HCV infections. In 
both cell lines, triggering of LTR signaling using the peptide binding to LTR increased HCV 
replication approximately 3 fold – however it seemed like the effect was slightly more 
pronounced in Lunet cells (Figure 73; left panel). Therefore we used this cell line to test whether 
triggering of LTR signaling with another substance would also lead to an increase in HCV 
replication. For this experiment, BS1, a tetravalent, bispecific anti-human LTR antibody was 
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used. Also with this antibody, an approximately 3 fold increase in HCV replication was observed 
(Figure 73; right panel). 
 
 
Figure 73: HCV-Con1 replication can be increased by agonistic stimulation of LTR signalling in various cell 
lines. Huh7.5 and Lunet cells were electroporated with HCV-Con1 and treated with various concentrations of LTR 
peptide (0.1-2g/ml). HCV replication was assessed by measuring luciferase counts after 72 hrs (left). Using Lunet 
cells and BS1 (an anti-LTR antibody) led to similar results.  
 
 
6.4.6 Hepatocyte-specific LT and LT over-expression induces chronic hepatitis 
To determine whether sustained hepatic LTR signaling is causally linked to chronic hepatitis 
and liver cancer, Johannes Haybäck and I analyzed two transgenic mouse lines that expressed 
LT and  under the Albumin promoter in a liver specific manner at low (tg1222) or high 
(tg1223) level 208 (Figure 74). 
 
Figure 74: Liver specific over-expression of lymphotoxin. Scheme of constructs used for the over-expression of 
LT or LT (inserted into a “half genomic” Prnp minigene); arrows indicate the primers used for RT-PCR analysis 
(left).Transgene-specific real-time RT-PCR analysis identifying tg1222 as low expressor and tg1223 as high 
expressor line (right) 208.  
 
We analyzed this mouse model at various time points (3, 6, 9, 12 and 18 months) for 
macroscopical, microscopical and molecular alterations within the liver.  
At three months of age, no histological changes were visible in livers of tg1222 and tg1223 mice 
compared to those of control littermates. No increase in the numbers of infiltrating B-cells, T-
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cells or macrophages was found in both transgenic lines at three months of age (Figure 75), 
indicating that no signs of liver inflammation were found at that early time point. 
 
 
 
Figure 75: Immunohistological analysis of paraffin-
sections derived from 3 month-old C57BL/6 and 
transgenic livers. C57BL/6, tg1222 and tg1223 livers 
lacked detectable inflammatory infiltrates as highlighted 
by H&E (scale bar: 200μm), by staining for B-cells 
(B220), T-cells (CD3), macrophages, Kupffer cells 
(F4/80) (scale bar: 100μm). 
 
 
 
 
 
 
 
However, the hepatic transcriptome was already considerably altered in tg1223 and to a lesser 
degree in tg1222 mice. Genes with the most dramatic expression changes were first identified 
by DNA microarray analysis in an unbiased manner and I then subsequently tested the 30 most 
up- and down-regulated candidates by real-time PCR (Figure 76), confirming the previously 
gained data from microarray analysis. 
As expected, Lt and Lt transcripts were increased in tg1222 and tg1223 livers. Additionally, 
mRNA expression of chemokines (Ccl2, Ccl7, Cxcl1, and Cxcl10), genes involved in early 
growth response (e.g., Egr1 and Egr2), cholesterol metabolism (e.g., Ch25h), and immediate 
early response (e.g., c-Fos, Jun-b, and Socs3) were significantly (p<0.0001) elevated. Besides, 
other genes described in the context of carcinogenesis in the liver (e.g., Gaddg45) or cancer in 
general (e.g., E-selectin and P-selectin) were found to be up-regulated.  
In contrast, genes involved in cell cycle control, histone modifications, and cell metabolism were 
significantly down-regulated (p<0.0001). The most down-regulated gene we could find was the 
g0/g1 switch gene, which – if normally expressed – should prevent the exit of hepatocytes from 
G0 into G1 phase of the cell cycle and thereby inhibit mitosis.  
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Figure 76: Real-time PCR analysis 
for mRNA expression in liver of 
candidate genes at the age of 3 
months. Data are presented in a log2 
scale (blue, up-regulated; red, down-
regulated). Rows indicate individual 
mice; columns represent particular 
genes. Each data point reflects the 
median expression of a particular 
gene resulting from three to four 
technical replicates, normalized to the 
mean expression value of the 
respective gene in C57BL/6 livers. 
 
At the age of 4 months, a slight increase in intrahepatic CD11b+, CD68+, and MHCII+ cells was 
detected in tg1223 mice, compared with age-matched C57BL/6 mice (Figure 77 left).  
At this time point, no significant increase in IL1, IFN, IL6, and TNF protein levels was found 
in the livers or serum of transgenic mice when compared to wild-type littermates (data not 
shown). At 4-6 months, transgenic livers started to develop strong portal and lobular (tg1223) or 
weak portal (tg1222) inflammation consisting of CD3+ T-cells, B220+ B-cells, and F4/80+ 
macrophages (Figure 77, right). 
 
Figure 77: Immunohistological 
analysis for myeloid cells at the 
age of 4-6 months in tg1223 and 
C57BL/6 livers. A slight increase 
in the number of CD11b+, CD68+ 
and MHCII+ cells was detected on 
cryosections of tg1223 livers at 4 
months of age when compared to 
age matched C57BL/6 livers (left 
panel). Already at this time-point, 
small aggregates mainly 
consisting of myeloid cells (arrow 
heads) could be detected. At the age of 4-6 months, B220+, CD3+ or F4/80+ cells accumulated at portal sites of 
tg1223 livers (right panel). In tg1222 livers, only small portal inflammatory infiltrates could be observed (scale bar: 
200μm). 
 
At 9 months of age, tg1223 livers exhibited strong portal and lobular lymphocytic infiltrates 
(Figure 78). A pronounced influx of F4/80+ macrophages and proliferation of A6+ oval cells was 
observed by immunohistochemical analysis. Chronic inflammation coincided with increased 
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proliferating Ki67+ hepatocytes (tg1223, 17 ± 5 Ki67+cells/mm2 liver section; C57BL/6, 0.5 ± 0.3 
Ki67+cells/mm2 liver section; p=0.003), which was not significant in age-matched tg1222 livers 
(p = 0.08; data not shown). Chronic hepatitis was observed in 100% of the tg1223 mice at 9 
months of age (n=65) whereas none of the C57BL/6 control mice showed signs of inflammation 
within their liver (n=40).  
 
Figure 78: Lymphocytic infiltrates 
are found in 9-month old tg1223 
mice. Immunohistochemical analysis 
of representative paraffin sections 
from livers of 9-month-old C57BL/6 
and tg1223 mice. B220+ B-cells, CD3+ 
T-cells, F4/80+ macrophages (Kupffer 
cells) and A6+ oval cells (scale bar, 
150m). Proliferating Ki67+ 
hepatocytes (arrowheads) and 
inflammatory cells are indicated (scale 
bar, 50m). 
 
At this stage, hepatitis was accompanied by increased protein levels of IL1 (p<0.05), IFN 
(p<0.05), and IL6 (p<0.05), and, to a lesser degree, TNF in tg1223 livers. In tg1222 livers, we 
observed only a slight elevation of these cytokines, compared with C57BL/6 (Figure 79).  
 
 
Figure 79: Increased chemokine and cytokine expression in 9-
month-old tg1223 mice. ELISA for IL1, TNF, IFN, and IL6 in liver 
homogenates from 9-month-old C57BL/6 (hollow symbols), tg1223 (filled 
symbols), or tg1222 (dotted symbols) mice (left).  
 
 
 
 
6.4.7 LT and LT over-expression induces hepatotoxicity 
To determine whether chronic hepatitis leads to hepatocyte damage and cell death in tg1222 or 
tg1223 mice, Johannes Haybäck and I analyzed serum transaminase levels (alanine 
transaminase ALT and aspartate transaminase AST). From the age of 19 weeks on, serum ALT 
and AST levels were significantly elevated (p=0.05) in tg1223, but not in tg1222 mice 
(Figure 80), and apoptotic hepatocytes were frequently detected in tg1223 mice (tg1223, 40.3 ± 
11.4 TUNEL+ cells/mm2 liver section; C57BL/6, 3.9 ± 6.2 TUNEL+ cells/mm2 liver section; 
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p=0.0005), but rarely in tg1222 and virtually absent in C57BL/6 mouse livers from the age of 6 
months on (Figure 80).  
Figure 80: Chronic liver injury in 
tg1223 mice. Analysis of 
transaminase levels (ALT and AST) 
in sera of transgenic and control 
mice. Standard deviation is 
indicated by error bars (left panel). 
Increased hepatocyte cell death in 
tg1223 livers shown by H&E 
staining and TUNEL/DAPI assay. Black arrowheads indicate apoptotic hepatocytes. TUNEL, green TUNEL+ 
hepatocyte nuclei indicate apoptosis (white arrowheads; scale bars, 50 m; right panel). 
 
Hepatitis persisted in both transgenic lines for ≥18 months. Phenotypes were much milder in 
tg1222 mice, implying that the LT expression level determined the severity of inflammation and 
liver injury. Therefore, tg1223 mice were selected for additional experiments and further key 
results were obtained from this mouse line. 
Microarray and real-time PCR analyses that I performed together with Johannes Haybäck 
revealed elevated mRNA expression of genes involved in embryogenesis (e.g., Dmrta1), liver 
inflammation (e.g., Pbfe1), carcinogenesis (e.g. Phlda3 and Thrsp 209), glucose homeostasis 
and insulin sensitivity (e.g. Fgf21), and reduced mRNA expression of genes responsible for cell-
cycle control (Gadd45g) and protease inhibition (SerpinA9) in 9-month-old tg1223 livers 
compared with C57BL/6 livers (Figure 81).  
 
 
Figure 81: Analysis of mRNA expression in 9 month-old tg1223 compared to age-matched C57BL/6 livers. 
Based on a non-supervised DNA-microarray analysis, the expression of candidate genes was assessed by real-time 
PCR. Differences are reported as fold change. Standard deviation (+/- SD) is indicated by error bars. Strong up-
regulation of various genes involved in inflammatory processes and carcinogenesis (e.g. Spl1, Dmrta1, Phlda3), cell 
adhesion and metastasis (e.g. P-Selectin), fibrogenesis (e.g. Fgf21), or carcinogenesis (Nrtk2, Tmem45b) were 
detected (left). Genes responsible for cell cycle control (e.g. Gadd45g) were significantly down-regulated in tg1223 
livers compared to C57BL/6 livers (right). 
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Several genes strongly up- or down-regulated in 3-month-old tg1223 livers (Figure 76) returned 
to normal levels at 9 months of age. However, as expected, expression of Lt and Lt mRNAs 
remained at high levels at that time-point. 
On the other hand, genes involved in cell division, liver inflammation, lipid metabolism, wound 
healing, and tumorigenesis were significantly up-regulated (p<0.001), whereas genes involved 
in growth arrest and apoptosis were significantly down-regulated (p<0.001) in 9-month-old 
compared with 3-month-old tg1223 livers (Figure 82). 
 
 
 
Figure 82: Real-time PCR analysis 
of C57BL/6 and tg1223 livers at 3 
and 9 months of age. Indicated are 
the 100 highest up- and down-
regulated genes in 9 month-old 
tg1223 livers, when compared to 9 
and 3 month-old C57BL/6 as well as 
3-month-old tg1223 livers. Rows 
represent particular genes, columns 
indicate individual mice;. Data are 
presented in a log2 scale (blue: up-
regulated; red: down-regulated). 
 
 
 
6.4.8 LT and LT over-expression induces HCC development 
At 12 months of age, about 20% (6/34) of tg1223 mice developed macroscopically visible 
nodules (Figure 83). Tumor frequency increased in tg1223 mice with age, reaching ~35% 
(18/51) by 18 months, whereas C57BL/6 mice did not develop any tumors (0/35; p<0.0001).  
 
Figure 83: Over-expression of LT in 
the liver leads to HCC development. 
Macroscopy of C57BL/6 (left panel) and 
tg1223 livers at the age of 12 (middle panel) 
and 18 months (right panel). White arrows 
indicate tumor nodules. White arrowhead 
indicates a liver lobe completely affected by 
HCC. Scale bar size is indicated. 
 
The following scheme summarizes tumor development observed in tg1223 mice at 12 and 18 
months of age (Figure 84). 
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Figure 84: Chronic hepatitis and HCC incidence 
in tg1223 mice. Chronic hepatitis and HCC 
incidence in 12-month-old tg1223 and C57BL/6 
mice (left) and in 18-month-old tg1223 and 
C57BL/6 mice (right).  
 
 
 
With the help of Prof. Dr. Achim Weber - liver pathologist at the Department of Pathology, 
University Hospital Zurich - tumor nodules were classified histologically as HCC, including 
broadening of liver cell cords, loss of collagen IV networks, and increased proliferative activity. 
In contrast, age-matched C57BL/6 livers lacked HCC (0/20; p=0.05; Figure 85). 
 
Figure 85: Histological analysis of livers from 
tg1223 and C57BL/6 mice. Dashed line depicts 
the HCC border. Collagen IV staining shows the 
broadening of the liver cell cords and loss of 
collagen IV networks indicative of HCC in tg1223 
mice (scale bar, 200m). High numbers of Ki67+ 
proliferating hepatocytes (arrows) are only found 
in tg1223 HCC (right column; scale bar, 100m). 
 
 
Tumors varied in size (1-25mm) and histology. Interestingly males and females were affected 
with similar frequencies (males: females=13:11; p=0.3). A6+ oval cells 210 were focally (8/24) or 
diffusely (2/24) distributed within some tg1223 HCC. The remaining HCC from tg1223 mice 
(14/24) lacked A6+ cells but were surrounded by them at the border zone of HCC (Figure 86).  
 
 
Figure 86: Immunohistochemical analysis of A6+ cells in 
HCC in 12 or 18 month-old tg1223 livers. Approximately 
45% of tg1223 HCC were composed of A6+ cells (presumably 
oval cells), which were either focally or diffusely distributed. 
Other tg1223 HCC lacked A6+ cells within the tumor (very 
right panel) but were surrounded by these cells at the border 
zone of the tumor (second right panel). The tumor border is 
marked by dashed line (scale bar: 200μm; insert: higher 
magnification). 
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6.4.9 Expression of tumor markers in HCC from tg1223 mice 
I then evaluated expression of human liver tumor markers golgi protein 73 (GP73), glutamine 
synthetase (GS), and -fetoprotein (AFP) in tg1223 livers on protein levels 211-213. GP73, GS, 
and AFP expression was elevated in most tg1223 HCC, as detected by immunohistochemistry 
and immuno-blot analysis, compared with C57BL/6 livers or unaffected liver regions adjacent to 
HCC (Figure 87).  
 
 
Figure 87: Expression of tumor markers in HCC from tg1223 mice. (A) Immuno-blot analysis of C57BL/6 and 
tg1223 HCC homogenates for GP73. Strong to moderate signal intensities were detected in all tg1223 HCC, but not 
in C57BL/6 livers. (B) Immuno-blot analysis of C57BL/6 and tg1223 HCC homogenates for AFP. -actin served as a 
loading control (kDa, kilo Dalton). (C) Immunohistochemistry for GP73 and GS in a representative tg1223 HCC and 
age-matched C57BL/6 control (scale bar, 100m). 
 
 
6.4.10 Mechanisms driving LT-induced chronic hepatitis and liver cancer 
To identify other receptors and molecular mediators potentially involved in LT-induced chronic 
hepatitis and HCC development, tg1223 were intercrossed with Tnfr1-/- and Ikkhep mice. The 
requirement of lymphocytes in chronic hepatitis and HCC formation was investigated by 
intercrossing with Rag1-/- mice, which lack mature lymphocytes. 
The absence of IKK, TNFR1 or lymphocytes per se did not appear to influence transgenic Lt 
and Lt mRNA expression. Initially, at 3 months of age, tg1223/Ikkhep, tg1223/Tnfr1-/- and 
tg1223/Rag1-/- mice lacked histological evidence of hepatitis similar to tg1223 mice (data not 
shown). The aberrant hepatic gene expression pattern described for 3-month-old tg1223 mice 
developed only partially in tg1223/Ikkhep and tg1223/Rag1-/- mice, whereas tg1223/Tnfr1-/- 
livers displayed an expression profile similar to that of tg1223 mice (Figure 76 & Figure 88).  
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Figure 88: Real-time PCR mRNA 
expression analysis in livers of 
tg1223/Ikkhep tg1223/Tnfr1-/- and 
tg1223/Rag1-/- mice. Data (blue: up-
regulated; red: down-regulated) are 
presented on a log2 scale. Columns 
represent particular genes, rows 
indicate individual mice. Each data 
point shows the median expression 
of a particular gene resulting from 
three to four technical replicates, 
normalized to the mean expression 
value of the respective gene in 
C57BL/6 livers. 
 
At 9 months of age, tg1223/Rag1-/- (n=26) and tg1223/Ikkhep (n=18) livers lacked hepatitis, 
hepatocyte or oval-cell proliferation, while tg1223/Tnfr1-/- (n=8) livers were indistinguishable 
from those of tg1223 mice (Figure 89, left).  
At the age of 18 months, tg1223/Rag1-/- (n=26) and tg1223/Ikkhep (n=25) mice were devoid of 
hepatitis and HCC (p<0.0001) (Figure 89, right), suggesting that both lymphocytes and 
hepatocyte-specific IKK expression are required for LT-induced chronic hepatitis and HCC 
development. 
 
 
Figure 89: Histological and immunohistochemical analysis of livers of tg1223/Ikkhep, tg1223/Rag1-/- and 
tg1223/Tnfr1-/- mice at 9 months age (left) and 18 months (right). A6 staining for oval cells, CD3 for T cells, B220 
for B-cells (scale bar, 500m; left panel). Dashed line depicts the HCC border (upper row; scale bar, 200m). 
Collagen IV staining highlights the broadening of liver cell cords and loss of collagen IV networks in tg1223/Tnfr1-/- 
HCC. Ki67+-proliferating hepatocytes are indicated by arrowheads (lower row; scale bar, 50m; right). 
LYMPHOTOXIN’S ROLE IN INFLAMMATION-INDUCED CARCINOGENESIS 
 
105
Notably, tg1223/Tnfr1-/- mice displayed HCC (4/12) with an incidence similar to that among 
tg1223 mice indicating that TNFR1 signaling is not essential for LT-induced HCC formation in 
tg1223 mice. 
 
 
6.4.11 Hepatocytes are the major responsive liver cells to agonistic LTR antibody 
treatment 
To investigate whether hepatocytes represent the major LT responsive liver cells and to 
investigate LTR signaling in Tnfr1-/- and Ikkhep livers, TNF (positive control), agonistic LTR 
antibody (3C8), and appropriate negative controls (PBS or rat IgG) were administered 
intravenously to C57BL/6 and various knockout mice. Nuclear p65 (RelA) translocation in 
hepatocytes and non-parenchymal cells (NPC, e.g. Kupffer cells and lymphocytes), alterations 
in the hepatic transcriptome, and protein expression of selected chemokines were examined. 
 
 
Figure 90: Hepatocytes respond to 
TNF injection.  
Immunohistochemical analysis of 
nuclear translocation of p65 (RelA) 
and real-time PCR for mRNA 
expression of selected NFB target 
genes in livers of C57BL/6 and 
various knockout mice treated with 
TNF. Real-time PCR data are 
presented on a log2 scale (blue, up-
regulated; red, down-regulated). 
Rows indicate individual mice; 
columns represent particular genes. 
Each data point reflects the median 
expression value of a particular gene 
resulting from 3-4 technical 
replicates 45min after TNF 
administration, normalized to the 
mean expression value of the 
respective gene in C57BL/6 livers. 
Statistical significance was evaluated 
by t-test: *p≤0.05; **p<0.001; 
***p<0.0001 (scale bar, 50m). 
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As expected, intravenous administration of TNF but not PBS treatment caused a strong 
response in the livers of C57BL/6 and Ltr-/- mice with nuclear translocation of p65 in 
hepatocytes and NPCs. Moreover, transcription levels of selected NFB target genes were 
elevated in these mice similar to livers from 3 month-old tg1223 mice. In Ikkhep mice, TNF 
administration did not induce p65 translocation in hepatocytes but did in NPC. However this 
induction sufficed to an up-regulation of the examined NFB target genes (Figure 90).  
Tnfr1-/- mice served as a negative control with hardly any change in the transcription profile. No 
increase in p65 translocation was found in livers of Tnfr1-/- mice compared to the PBS-treated 
control group. Acute administration of TNF in Tnfr2-/- livers caused nuclear p65 translocation in 
hepatocytes and NPC, as well as elevated expression of selected NFκB target genes. In 
contrast, administration of TNF in Tnfr1/2-/- mice failed to induce nuclear p65 translocation in 
hepatocytes and NPC, as well as up-regulation of selected NFB target genes except Ccl2. 
 
Administration of 3C8 induced nuclear p65 translocation, primarily in hepatocytes and some 
NPC of C57BL/6 livers (Figure 91), as well as transcriptional changes and up-regulation of 
selected chemokines reminiscent of those observed in 3-month-old tg1223 livers.  
 
Figure 91: Hepatocytes can integrate LTR 
signaling. Immunohistochemical analysis of 
nuclear p65 translocation and real-time PCR 
for mRNA expression of selected NFB target 
genes in livers of C57BL/6 and various 
knockout mice treated with 3C8. Data are 
presented on a log2 scale (blue: up-
regulated; red: down-regulated). Columns 
represent particular genes, rows indicate 
individual mice. Each data point reflects the 
median expression value of a particular gene 
resulting from three to four technical 
replicates, normalized to the mean 
expression value of the respective gene in 
C57BL/6 livers. Statistical significance was 
evaluated by t test: *p≤0.05; **p<0.001; 
***p<0.0001; (scale bar, 50m). 
 
Similar results were obtained after 3C8 treatment of Tnfr1-/- mice, in contrast to Ikkhep livers, 
which were devoid of nuclear p65 translocation in hepatocytes and NPC. Furthermore, up-
regulation of selected NFB target genes could not be detected. Control Ltr-/- mice treated with 
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3C8 lacked nuclear p65 translocation in hepatocytes or NPC, as well as up-regulation of 
selected NFB target genes. 
To examine whether lack of functional IKK on hepatocytes and NPC would suppress LTR-
induced up-regulation of selected NFB responsive genes, I also investigated livers of mice 
expressing a non-phosphorylatable IKKAA knock-in allele that we had received from the group 
of Prof. Dr. Michael Karin (IkkAA/AA 196). Upon 3C8 treatment IkkAA/AA mice up-regulated 
selected NFB responsive genes (Figure 92).  
Figure 92: Real-time PCR for 
mRNA expression of selected 
NFB target genes in livers of 
C57BL/6 and IkkAA/AA mice treated 
with 3C8. Data are presented on a 
log2 scale (blue: up-regulated; red: 
down-regulated). Rows indicate 
individual mice; columns represent 
particular genes. Each data point reflects the median expression value of a particular gene resulting from 3-4 
technical replicates, normalized to the mean expression value of the respective gene in C57BL/6 livers. Statistical 
significance was evaluated by t test: *p≤0.05; **p<0.001; ***p<0.0001. 
 
The degree of mRNA up-regulation in liver was similar to that in 3C8-treated C57BL/6 mice. In 
contrast, control treated (rat IgG) IkkAA/AA mice lacked up-regulation of selected NFB 
responsive genes. This finding suggests that 3C8-mediated hepatic LTR signaling is mainly 
integrated by hepatocytes involving canonical NFB pathway. 
 
 
6.4.12 Inhibition of LTR signaling reduces chronic hepatitis and carcinogenesis 
Together with Johannes Haybäck, I further investigated and analyzed the involvement of LTR 
signaling in the transition of chronic hepatitis to HCC by long-term LTR-Ig administration in 
tg1223 mice. Nine-month-old tg1223 mice with chronic hepatitis (n=31) or age-matched 
C57BL/6 mice (n=23) were treated with LTR-Ig for 2 months, remained untreated for another 4 
weeks, and were then sacrificed. 
LTR-Ig treatment significantly reduced chronic hepatitis incidence in tg1223 mice, compared 
with that in untreated tg1223 mice (treated: 4/31; untreated: 34/34; p<0.0001). Furthermore, 
LTR-Ig treatment suppressed chronic hepatitis-driven HCC formation (treated: 0/31; untreated: 
6/34; p<0.05) (Figure 93). LTR-Ig treatment did not lead to overt histopathological alterations in 
C57BL/6 livers or overt changes in lymphocyte (B- and T-cells) or macrophage populations 
within spleens of C57BL/6 or tg1223 mice (data not shown). 
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Figure 93: Histological analysis (left panel) and immunohistochemical analysis (right panel) of livers derived 
from 12 months-old LTR-Ig treated mice. Left: Representative sections show no hepatitis or HCC in untreated or 
LTR-Ig-treated C57BL/6 livers (upper row). Untreated tg1223 livers display hepatitis in 34/34 (middle panel, left 
column) and HCC in 6/34 cases (lower panel, left column). LTR-Ig treatment reduces the incidence of hepatitis (4/31 
mice) (middle and lower panel, right column) and prevents HCC formation in LTR-Ig treated tg1223 mice. 
Arrowheads indicate inflammatory foci. Tumor border is indicted by a dashed line (scale bar, 200m). Right: 
Immunohistological analysis of livers derived from LTβR-Ig-treated mice. Liver sections were stained with antibodies 
detecting T- (CD3), and B-cells (B220), macrophages and Kupffer cells (F4/80) as well as A6+ oval cells. In the case 
of persistent inflammation in livers of LTβR-Ig treated mice we found B- (B220), T-cell (CD3) infiltrates, macrophages 
and Kupffer cells (F4/80), as well as oval cell proliferation (scale bar: 50μm). 
 
Efficiency of LTR-Ig treatment was ascertained by the loss of LTR-dependent follicular 
dendritic cells (FDCs) as stained by MfgE8 within C57BL/6 and tg1223 spleens (Figure 94).  
 
Figure 94: Successful application of LTR-Ig leads 
to loss of FDCs. Immunohistological analysis for the 
presence of FDC networks in spleens of LTβR-Ig 
treated C57BL/6 or tg1223 mice. MFGE8 (FDC-M1) 
staining reveals a complete dedifferentiation of FDC 
networks in LTβR-Ig-treated C57BL/6 or tg1223 
spleens. Arrowheads indicate FDC networks in 
spleens of untreated mice (scale bar: 200μm). 
 
 
 
Thus, our results imply that long-term suppression of LTR reduces chronic hepatitis incidence 
and can prevent the transition from chronic hepatitis to HCC in tg1223 mice. In the future, it will 
be investigated whether our results can be also translated to other models or even the human 
situation.  
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6.5 Discussion 
6.5.1 Lymphotoxin in viral hepatitis and HCV replication 
The first part of this study uncovered drastic and robust mRNA up-regulation of LTR, LT, and 
LT in biopsies from patients with HBV- or HCV-induced hepatitis and HCC. LT and LIGHT 
transcripts were mainly expressed by CD3+ T-cells and CD20+ B-cells; a significant proportion of 
LT and LT expression was also attributable to hepatocytes. Notably, up-regulation of LTR, 
LT, and LT transcripts was also detected in non-virus related HCC, which could stem from 
activated, tumor-infiltrating lymphocytes and/or from neoplastic hepatocytes that have up-
regulated LT, possibly in response to IL6. It was demonstrated that HCC-derived cell lines 
express IL6 214 and that LT levels can be increased in response to IL6 and IL1 in hepatic and 
oval cell lines 215. 
In a siRNA library screen, nine host genes related to LTR and NFB signaling were identified 
to influence HCV replication with the level of silencing of the host genes corresponding to the 
residual HCV replication activity 182. Using similar HCV replicon cells containing a subgenomic 
construct derived from HCV genotype 1b, I could reproduce the findings for LT. However, I did 
not obtain the same efficient decrease in HCV replication, which could on the one hand be 
caused by less efficient silencing of LT, as in the study by Ng et al., it was found that the 
decrease in HCV replication depends on the efficient silencing of at least one of the host genes 
identified. On the other hand, which appears to be more likely the reason, our HCV construct 
did not show additional mutations as in the case of the study by Ng et al., which increases HCV 
replication, thus probably also leading to larger effects, when HCV replication is modified. 
Moreover, silencing of LTR decreased HCV replication levels significantly – and it appears to 
be even more efficient than silencing its ligand. However, it remains to determine whether this 
also works with infectious HCV. The decrease in HCV replication is by far not as efficient as it is 
the case after treatment IFN, however for patients that are not responding to IFN and 
ribavirin therapy, who make up approximately 50% of all patients 216 217, blocking of LTR 
signaling might be beneficial for decreasing viral load and thereby potentially curing hepatitis.  
Surprisingly, the opposed approach – triggering of LTR signaling – increased HCV replication 
levels using replicon cells approximately 6 fold. More interestingly, also in an infectious setting, 
HCV replication levels were increased approximately 3 fold, which is a tremendous increase, as 
the replication capacity almost reached its limit in infectious cell culture systems. These results 
indicate that there is a strong link between LTR signaling and HCV replication, making it more 
and more likely that interfering with LTR signaling might be an effective therapeutic approach 
to decrease viral replication in HCV-infected patients. However, considering the studies, in 
which HCV core protein was shown to interact with the cytoplasmic tail of LTR 183, 185, it is not 
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clear whether this interaction is sufficient to trigger signaling downstream of LTR, which might 
enhance HCV’s replicative potential. Therefore, it remains to be determined whether blocking of 
LTR signaling with LTR-Fc, a fusion protein of the LTR and the Fc-portion of the constant 
IgG immunoglobulin molecule, binding efficiently to LT12 and LIGHT, would indeed prevent 
replication of HCV.  
 
 
6.5.2 LTR and NFB signaling in viral hepatitis and HCC development 
Recent publications have clearly indicated an important role of NFB signaling in hepato-
carcinogenesis. LT signaling induces both canonical and non-canonical NFB pathways, whose 
role in controlling liver cancer formation remains controversial 166. There is a big difference 
whether the role of NFB signaling in liver cancer is investigated in the context of chronic 
hepatitis or DNA-damage induced by a chemical carcinogen. Our data indicate that in the 
context of chronic hepatitis NFB signaling is a liver cancer promoting factor. In a mouse model 
with acute DEN exposure, depletion of functional NFB signaling (Ikkhep mice) increased 
hepatocyte cell death, enhanced Kupffer cell activation, and elevated HCC incidence 171. In 
contrast, NFB signaling promotes HCC development in mdr2-/- mice 169, and hepatocyte-
specific depletion of IKK prevents HCC formation in tg1223 mice. How can this contradictory 
role of IKK signaling in HCC formation be reconciled? On the one hand, IKK signaling might 
be required for hepatocytes to appropriately respond to and survive carcinogenic stimuli and 
acute liver injury (e.g. DEN exposure). On the other hand, IKK signaling might enable 
chemokine expression by hepatocytes, leading to hepatitis and HCC.  
Consistent with this hypothesis, tg1223/Rag1-/- mice were devoid of chronic hepatitis, 
hepatocyte or oval-cell proliferation and failed to develop HCC. 
But how can a contribution of immune cells to liver tumorigenesis be explained? One 
explanation might be that CD4+ or CD8+ T-cells expressing inflammatory cytokines (e.g. IL1, 
TNF, and IFN), as well as cytolytic proteins (e.g. Granzyme B), contribute to hepatocyte cell 
death, tissue remodeling, and transformation, finally resulting in HCC 191, 218. Intrahepatic 
lymphocytes may also influence the production of inflammatory mediators, because 3-month-old 
tg1223/Rag1-/- livers displayed markedly reduced cytokine and chemokine levels. We propose 
that, rather than directly acting as a cell-autonomous oncogene on hepatocytes or A6+ oval 
cells, hepatic LT expression induces local up-regulation of chemokines (e.g., CCL2, CXCL10, 
CXCL1, and CCL7) by hepatocytes.  
This potentially leads to the attraction of circulating inflammatory cells and a hyperproliferative, 
hepatotoxic environment stochastically leading to HCC formation. It is worth mentioning that 
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some chemokines which I have found to be strongly up-regulated in this study (e.g., CXCL10) 
have been reported to be mainly expressed by human hepatocytes in chronic hepatitis C 219. 
Ablation of TNFR1 signaling did not prevent chronic hepatitis and HCC formation in tg1223 
mice, although anti-TNF antibody treatment prevents HCC development in mdr2-/- mice 169. We 
investigated the mode of LT signaling in Tnfr1-/- livers upon 3C8 treatment. This treatment 
induced analogous hepatic changes seen in tg1223 mice at 3 months of age. Similar to our 
results with tg1223/Tnfr1-/- mice, this finding suggests that heterotrimeric LT causes p65 
translocation in hepatocytes and induces a TNFR1-independent signaling cascade via LTR, 
presumably contributing to chronic hepatitis and HCC. Most probably, HCC formation in mdr2-/- 
mice depends on pathways involving TNFR1 distinct from the LTR-dependent pathways 
described in our study. 
Intravenous administration of TNF into Ikkhep mice did not cause p65 translocation in 
hepatocytes but up-regulated NFB target genes, presumably through TNF-activated NPC. In 
contrast, 3C8 treatment in Ikkhep mice had no effect. Therefore, hepatocytes but not NPC are 
likely to be the major liver cells integrating LT signaling. Interestingly, upon 3C8 treatment 
IkkAA/AA livers up-regulated selected NFB target genes, similar to C57BL/6 mice. Therefore, 
the absence of IKK in hepatocytes and NPC allows NFB target gene expression upon 3C8 
treatment, suggesting the involvement of the classical NFB pathway in LTR-induced hepatic 
signaling. 
LTR signaling was reported to induce oval-cell proliferation 220, which is thought to contribute to 
the development of liver tumors 221. We observed proliferation of A6+ oval cells in chronically 
inflamed tg1223 livers at the age of 9 months and found A6+ cells within and at the border of 
tg1223 HCC. Whether those A6+ cells represent transformed oval cells contributing to liver 
carcinogenesis or whether A6 is up-regulated on aberrant hepatocytes within HCC remains to 
be determined. 
Lack of lymphocytes or chronic hepatitis prevented oval-cell proliferation, although LT and  
transgene expression was unaltered. Therefore, it is conceivable that activated, infiltrating 
lymphocytes or Kupffer cells may contribute to oval cell proliferation by providing further LT or 
other cytokines in tg1223 livers. 
On the basis of the presented data, Johannes Haybäck and I created a model that describes 
the sequence of events leading to chronic hepatitis and HCC in tg1223 mice can be proposed 
(Figure 95). 
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Figure 95: Scheme of chronic inflammation-induced liver carcinogenesis in tg1223 mice. Transgenic 
hepatocytes (brown) express LT and induce chemokine production (e.g., CXCL1, CXCL10, CCL2, and CCL7) in 
the presence of IKK and intrahepatic lymphocytes. Chemo-attraction and activation of myeloid cells and 
lymphocytes expressing particular chemokine receptors (e.g., CXCR3, CXCR2, CCR2, and CCR1) cause hepatitis: 
CXCL10 attracts CXCR3+ T- and NK-cells, CXCL1 CXCR2+ T-cells, B-cells, neutrophils, and CCL2 CCR2+ 
macrophages, and CCL7 attracts CCR1+ monocytes. Activated, infiltrating immune cells secrete cytotoxic cytokines 
(e.g., IL6, IL1b, TNF, IFN, and LT) that cause tissue destruction, hepatocyte proliferation, cell death, and tissue 
remodeling. In such an environment, hepatocytes are susceptible to chromosomal aberrations leading to HCC. 
Tissue destruction and remodeling supports the infiltration of activated inflammatory cells (e.g., myeloid cells), 
leading to a feed-forward loop toward chronic aggressive hepatitis. Asterisks indicate that genetic depletion of those 
components (IKK; T and B cells) blocks chronic hepatitis development and HCC. Blocking LTR signaling with 
LTR-Ig in 9-month-old tg1223 mice reduces chronic hepatitis incidence and prevents HCC. (+) indicates the 
fortification of a described process. (┴) indicates the suppression of a described process. The transcription factor 
RelA is schematically depicted as a green circle, inducing transcription of NFB target genes (e.g., chemokines) 
(arrow). B, B cells; T, T cells; MØ, macrophages; N, neutrophils; NK, NK cells. 
 
What are the potential clinical implications of our findings? It has recently been demonstrated 
that pharmacological inhibition of LTR signaling reduces virus-, bacteria-, and concavalin A–
induced liver injury 188-190, whereas triggering LTR signaling on hepatocytes appears to be 
beneficial during liver regeneration 158. Moreover, siRNA knock-down of various components of 
the LTR signaling pathway (e.g., LT and RelA) were shown to interfere with HCV replication 
in vitro 182. Therefore, inhibition of LTR signaling might also impede the efficiency of HCV 
replication. 
What are the possible side effects of blocking LTR signaling? The reported effects include 
alterations in the micro-architecture of white pulp follicles and disappearance of FDC networks 
in non-human primates 222. Despite the loss of FDCs and a reduced capacity to trap immune 
complexes, the primary antibody response to keyhole limpet-hemocyanin was not significantly 
altered 222. 
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Accordingly, together with Johannes Haybäck, I have investigated a possible beneficial effect of 
blocking LTR signaling in tg1223 mice with chronic hepatitis. This partially reverted 
inflammation and prevented HCC formation, suggesting that LTR-Ig treatment might be 
beneficial in liver pathologies with sustained LT signaling. Our results show that LT signaling is 
critically involved in hepatitis and subsequent HCC development and imply that blocking LTR 
signaling might become a beneficial therapeutic approach in the context of HBV- or HCV-
induced chronic hepatitis and other liver diseases displaying sustained hepatic LTR signaling. 
 
 
6.5.3 Interference with lymphotoxin signaling in other types of cancer 
However, the concept that blocking LTR signaling might interfere with cancer progression, as 
we could show with LTR-Ig treatment in a mouse model of HCC is not entirely new.  
Treatment with LTβR-Ig in a prostate cancer model (TRAMP; mice develop spontaneously 
prostate cancer with 100% penetrance and metastases) interrupted clonal T-cell deletion, 
reduced the size of the primary cancer, and completely prevented further metastasis - 
suggesting an important role of LT in controlling anti-tumor T-cell selection, showing the value of 
non-antigen based immune prevention for individuals with genetic predisposition to cancer 223. 
Other studies have focused on the activation of LTR signaling pathways in various cancer 
types. Bergsagel et al., have reported a constitutive activation of NFB signaling in multiple 
myeloma as a result of mutations in the LTR gene 224, emphasizing a critical role for the NFB 
pathway in its pathogenesis. Furthermore, constitutive NFB activity was detected in diffuse 
large B-cell lymphoma, indicating a role for this signaling pathway as a primary pathogenic 
event in lymphomagenesis 170. 
In addition, LTR-mediated signaling - most likely through the non-canonical NFB pathway - is 
also involved in tumor angiogenesis. Activation of LTR on fibrosarcoma cells by activated host 
lymphocytes is capable of initiating a novel, pro-angiogenic pathway leading to organized tumor 
tissue development. Conversely, in this model, inhibition of LTR signaling prevented tumor 
angiogenesis and neovascularization, resulting in tumor growth arrest 225. 
Data by Lukashev et al., clearly indicate that in a syngeneic colon tumor model, agonistic LTβR 
antibody treatment induces lymphocyte infiltration and tumor necrosis by enhancing tumor 
chemosensitivity 226. One proposed mechanism might be the induction of pro-inflammatory 
chemokines functioning as chemo-attractants for T, NK, and dendritic cells, contributing to 
tumor destruction. However, extensive studies revealed that there are human cell lines resistant 
to agonistic LTR treatment, indicating that treatment success may depend on the cancer cell 
type. Moreover, this treatment decreased tumor size and/or improved long-term animal survival 
in two out of six orthotopic xenografts derived from independent surgical colorectal carcinoma 
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samples. Therefore, it is questionable whether the results gained indeed point to the fact that in 
some cases or tumor entities activation of LTR signaling might be anti-tumorigenic. Further 
studies are needed to reveal the details of this concept. 
In addition to the previously described TRAMP model, subcutaneous allografts of mouse 
androgen-dependent AD-CaP cell line myc-CaP were used to facilitate better mechanistic 
analysis of CR-CaP development. To determine whether inflammation-responsive IKK 
participates in development of CR-CaP, IKK was knocked-out in prostate epithelial cells of 
TRAMP mice. This neither affected primary tumor growth nor CR-CaP emergence after 
castration 227. In contrast, specific deletion of IKK in bone marrow-derived cells delayed 
development of CR-CaP emergence, although lacking effects on primary tumor development. 
These results suggested an involvement of immune cells promoting tumor emergence after 
castration. Indeed, after androgen ablation the regressing tumors were infiltrated with T- and B-
cells, NK-cells and myeloid cell types. 
Furthermore, inflammatory cytokines, for example, IL6, IL12, TNF and LT, were up-regulated 
in the regressing myc-CaP allografts. Notably, LT ablation on B-cells, but not on T-cells delayed 
CRCaP growth. Accordingly, in addition to mediators released by dying CaP cells, critical 
participants in tumor emergence are tumor-infiltrating B-cells, producing LT that signals through 
LTR on CaP cells to induce IKK nuclear translocation and STAT3 activation. 
Interventions preventing LT production or ablating LT signaling could delay regressing tumors in 
patients with androgen ablation therapy. 
In a study on nasopharyngeal carcinoma (NPC), a distinct type of head and neck cancer, LTR 
was shown to be frequently over-expressed in primary NPC tumors, concomitant with an 
amplification of chromosome 12p13.3 228. In vitro studies in nasopharyngeal epithelial cells 
revealed increased NFB activity and cell proliferation due to LTR over-expression. Addition of 
LT12 led to increased proliferation of nasopharyngeal epithelial cells and siRNA knockdown of 
LTR expression inhibited growth of the NPC tumors with 12p13.3 amplification 228, further 
strengthening a tumor-promoting role of LTR signaling in this type of carcinoma. 
Interestingly, LT signaling may also be involved in the maturation and recruitment of NK-cells 
and may have an important role in anti-tumor surveillance. It was shown that LT deficiency 
leads to defects in NK maturation and recruitment and that formation of experimental pulmonary 
metastases upon injection of B16F10 melanoma cells was enhanced in LT-/- mice 229.  
Therefore, LT signaling may be involved in NK-cell maturation, recruitment and anti-tumor 
surveillance. 
Figure 96 summarizes the previously discussed studies in which inhibition or activation of LTR 
signaling had shown a beneficial effect on cancer progression. 
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Figure 96: Scheme summarizing in vivo studies showing pro- and anti-tumorigenic effects of LTR activation 
or inhibition. Experiments describing the pro- or anti-carcinogenic effects (depicted with + or -) of activated LTR 
signaling in vivo [(1) 163; (2) 227; (3) 228; (4) 223; (5) 225; (6) 226; colored sectors]. The gray sector indicates that also lack 
of LT signaling can influence anti-tumor surveillance causing significant enhancement of experimental pulmonary 
metastases upon injection of B16F10 melanoma (7) 229). (Right column) Depicts various studies indicating that block 
of LTR signaling might work as an anti-tumor strategy. CaP: prostate cancer; CRCaP: castration-resistant prostate 
cancer; FSC: fibrosarcoma; NPC: nasopharyngeal carcinoma. 
 
The above-described results convincingly demonstrate a participation of LTR signaling in 
carcinogenesis, however, involving various mechanisms and biological functions in the diverse 
in vivo paradigms tested. It will be an important future task to investigate and reveal in detail the 
mechanisms underlying the different effects of induced LTR signaling in the various cancer 
models. What could be the reason(s) for the fact that increased LTR signaling could in some 
instances generate a pro-carcinogenic environment 163 and in other paradigms lead to tumor 
reduction 226? Apparently, this might have something to do with the tumor type investigated as 
well as the organ in which the tumor has developed. In this regard, it is also important to note 
that, e.g., transgenic mice expressing LT in other organs than liver have so far not been 
reported to display inflammation-induced carcinogenesis, although most of these models show 
strong signs of inflammation. It is very possible that tumorigenesis develops with low frequency 
at late stage of life in these animals (similar to tg1223 mice) and that this has escaped the 
attention of the experimentators. However, it is also possible that a highly regenerative, 
proliferative environment (e.g., like in liver) is needed to induce inflammation-induced 
carcinogenesis in the context of deregulated LTR signaling. 
However, LT’s involvement is very unlikely to be universal to all cancer types or signaling 
pathways contributing to or enabling carcinogenesis: In an illuminating study, it was shown that 
neither lack of TNF nor LT reduced tumor burden on a p53-deficient background, suggesting 
that in the context of p53-deficiency LT signaling does not aggravate carcinogenesis 230. 
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Recent data of various laboratories indicate that there is still much more to be learned about the 
link between LT signaling and cancer, at the site of carcinogenesis as well as at the site where 
the host’s adaptive immune response is triggered against cancer. Exciting times are ahead of 
us, verifying the utility of LTR antagonists and agonists in the various different clinical settings 
and hopefully revealing the detailed mechanisms of LTR signaling in the context of 
inflammation and cancer. 
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